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Abstract 
Treatment options for ovarian cancer patients remain limited and overall survival is less 
than 50 percent despite recent clinical advances. The lipid phosphatase inositol 
polyphosphate 4-phosphatase type II (INPP4B) has been described as a tumour 
suppressor in the PI3K/Akt pathway with loss of expression found most pronounced in 
breast, ovarian cancer and melanoma. Using microarray technology a DNA repair 
defect was identified in INPP4B-deficient MCF-10A cells. After validation of the 
microarray data, I further characterised the DNA repair defect by comet assays and 
quantification of γH2AX, RAD51 and 53BP1 foci formation through 
immunofluorescence studies. Mechanistically, with collaborative efforts I discovered 
that INPP4B forms a protein complex with the key players of DNA repair, ATR and 
BRCA1, in GST pulldown and 293T overexpression assays. Finally, I assessed whether 
or not INPP4B loss resulted in synthetically lethal interaction with PARP inhibition, as 
evidenced with tumours harbouring BRCA1/2 mutations. INPP4B loss resulted in 
significantly increased sensitivity towards PARP inhibition, in vitro and in vivo. Given 
that INPP4B loss has been found in 40% of ovarian cancer patients, this study provides 
the rationale for establishing INPP4B as a biomarker of PARP inhibitor response, and 
consequently offers novel therapeutic options for a significant subset of patients. 
  
 4 
Table of Contents 
Declaration	 2	
Abstract	 3	
Acknowledgements	 8	
Abbreviations	 9	
CHAPTER	1.	 Literature	Review	 15	
1.1	 Ovarian	cancer	 15	1.1.1	 The	biology	of	ovarian	cancer	 15	1.1.2	 Diagnosis,	staging,	and	clinical	management	 24	
1.2	 PI3K/Akt	pathway	 27	1.2.1	 Phosphoinositides	 29	1.2.2	 Activation	of	the	PI3K	pathway	 34	1.2.3	 Termination	of	the	PI3K/Akt	pathway	 49	
1.3	 DNA	damage	response	 63	1.3.1	 Sources	of	DNA	damage	 66	1.3.2	 Base	excision	repair	 66	1.3.3	 Nucleotide	excision	repair	 69	1.3.4	 Mismatch	repair	 71	1.3.5	 Double	strand	break	repair	 73	1.3.6	 DNA	damage	sensing	 79	1.3.7	 Cancer	therapy	 100	
1.4	 Aims	and	objectives	 124	
CHAPTER	2.	 Materials	and	methods	 125	
2.1	 General	materials	and	methods	 125	2.1.1	 Tissue	culture	 125	2.1.2	 Cloning	 134	
 5 
2.1.3	 Western	blot	 135	
2.2	 Chapter	3	materials	and	methods	 141	2.2.1	 Microarray	 141	2.2.2	 RT-PCR	 142	2.2.3	 Comet	assay	 144	2.2.4	 Immunofluorescence	assay	 145	2.2.5	 Cell	cycle	analysis	 148	
2.3	 Chapter	4	materials	and	methods	 150	2.3.1	 Immunoprecipitation	 150	2.3.2	 MEF	experiments	 151	2.3.3	 GST	pull	down	assay	 151	
2.4	 Chapter	5	materials	and	methods	 159	2.4.1	 Drug	handling	and	storage	 159	2.4.2	 Cell	proliferation	assay	 159	2.4.3	 Clonogenic	survival	assay	 160	2.4.4	 Xenograft	experiments	 161	
CHAPTER	3.	 Establishment	of	a	DNA	repair	defect	in	ovarian	cancer	cells	 162	
3.1	 Introduction	 162	
3.2	 Results	 174	3.2.1	 Validation	of	BRCA1	mutant	gene	signature	 174	3.2.2	 Loss	of	INPP4B	results	in	a	DNA	repair	defect	in	Ovca429	cells	upon	comet	assay	analysis	 177	3.2.3	 Loss	of	INPP4B	results	in	γH2AX	foci	retention	upon	treatment	with	etoposide	in	Ovca429	and	Ovca433	knockdown	cell	pools	 181	3.2.4	 Loss	of	INPP4B	results	in	RAD51	and	53BP1	foci	retention	upon	treatment	with	etoposide	in	Ovca429	knockdown	cell	pools	 188	
 6 
3.2.5	 Loss	of	INPP4B	results	in	RAD51	foci	retention	upon	irradiation	in	Ovca433	knockdown	cell	pools	 193	3.2.6	 Loss	of	INPP4B	in	Ovca429	and	Ovca433	cancer	cell	lines	has	no	impact	on	BRCA1	foci	formation	upon	irradiation	 196	3.2.7	 INPP4B-deficient	Ovca433	knockdown	cell	pools	undergo	aberrant	cell	cycle	progression	 201	
3.3	 Discussion	 205	
CHAPTER	4.	 Biological	function	of	INPP4B	 215	
4.1	 Introduction	 215	
Results	 216	4.1.1	 Reduced	ATR	expression	observed	in	INPP4B	deficient	Ovca429	knockdown	cells.	 216	4.1.2	 Loss	of	INPP4B	in	mouse	embryonic	fibroblasts	results	in	concomitant	loss	of	BRCA1,	ATR	and	ATM	protein	levels	 219	4.1.3	 INPP4B,	BRCA1,	and	ATR	interact	in	a	protein	complex	 222	
4.2	 Discussion	 226	
CHAPTER	5.	 Treatment	of	INPP4B	deficient	cells	with	DNA	repair	inhibitors	 230	
5.1	 Introduction	 230	
5.2	 Results	 235	5.2.1	 Loss	of	INPP4B	results	in	increased	sensitivity	towards	olaparib	 235	5.2.2	 Loss	of	INPP4B	results	in	increase	in	cisplatin	sensitivity	and	dual	treatment	of	INPP4B-deficient	cells	with	cisplatin	and	olaparib	results	in	an	additive	effect	 241	5.2.3	 INPP4B	knockdown	in	Ovca429	cells	sensitises	tumour	growth	to	olaparib	in	
vivo	 243	5.2.4	 Treatment	of	INPP4B	deficient	Ovca429	knockdown	cells	with	Chk1	inhibitor	LY2940930	results	in	resistance	in	cell	proliferation	assays	 246	
5.3	 Discussion	 252	
 7 
CHAPTER	6.	 Final	Discussion	 257	
CHAPTER	7.	 Appendix	 266	
References	 280	
 
 
  
 8 
Acknowledgements  
I would like to thank my PhD supervisors Christina Gewinner, Daniel Hochhauser and 
John Hartley for their support and guidance over the last four years. In particular, I am 
extremely thankful for my primary supervisor Christina for her unwavering efforts to 
teach me, challenge my weaknesses and always encourage me, and for being an 
excellent supervisor, life mentor and friend. My thanks also go to Felipe Cia Viciano, 
Victoria Spanswick and Su-kit Chew for their assistance with experimental procedures 
and to Julie Olszewski for her support throughout my programme. I am beyond grateful 
for the support of my family who have been cheering me on so patiently and for funding 
this degree. Finally, words cannot express my gratitude to God for providing me with 
strength and perseverance, as well as a revelation of His love and goodness over the last 
four years.  
  
 9 
Abbreviations 
53BP1 p53-binding protein 1 
AP apurinic/apyrimidinic 
APE1 apurinic/apyrimidinic endonuclease 1 
APLF aprataxin and PNKP like factor 
APS ammonium persulphate 
AT ataxia telangiectasia 
ATM ataxia telangiectasia mutated  
ATR ATM and Rad3-Related  
ATRIP ATR-interacting protein  
BAD Bcl-2 associated death promoter 
BER base excision repair 
BH BCR homology  
BH3 Bcl-2 homology 3 
BL BRCA-like  
BRAF homologv-raf murine sarcoma viral oncogene homolog B 
BRCA1 breast cancer 1, early onset 
BRCA2 breast cancer 2, early onset 
BSA bovine serum albumin 
CA125 cancer antigen 125 
cAMP cyclic adenosine monophosphate  
CDC25 cell division cycle 25 
CDK cyclin-dependent kinase 
Chk1 checkpoint kinase 1 
Chk2 checkpoint kinase 2 
 10 
CT computed tomographic 
CtIP CtBP-interacting protein 
DBB DNA binding complex  
DDR DNA damage response 
dHJ double Holliday junction 
DNA-PK DNA-dependent protein kinase  
DNA-PKcs catalytic subunit of DNA dependent protein kinase  
dNTP deoxyribonucleotide triphosphate 
DSB double-strand break  
dsDNA double stranded DNA  
DTT dithiothreitol  
E. coli escherichia coli 
EDGR epidermal growth factor receptor 
EDTA ethylenediaminetetraacetic acid 
EOC epithelial ovarian cancer 
ER oestrogen receptor  
ERCC1-XPF excision repair cross complementation group 1/xeroderma 
pigmentosum group F complex  
ERK extracellular signal-regulated kinase 
EXO1 exonuclease 1 
FANC Fanconi Anemia, complementation 
FCS foetal calf serum 
FHA forkhead-associated 
FOXO forkhead box O 
Glut glucose transporter  
 11 
GPCR G-protein coupled receptor 
GSEA gene set enrichment analysis  
GSK3 glycogen synthase kinase 3  
GST glutathione S-transferase 
H2AX histone family H2A, member X  
HER2 human epidermal growth factor receptor 2 
HGEC high grade endometrioid carcinoma 
HGSC high grade serous carcinoma 
HIF1α hypoxia-inducible factor-1 α  
hMSH2 human mutS homolog 2  
HR homologous recombination 
ICL interstrand crosslinks 
INPP4A inositol polyphosphate 4-phosphatase type I 
INPP4B inositol polyphosphate 4-phosphatase type II 
Ins(1,3,4)P3 inositol 1,3,4-trisphosphate  
Ins(3,4)P2 inositol 3,4-bisphosphate  
IPTG isopropyl β – D – 1 – thiogalactopyranoside 
IR ionising radiation 
KEGG Kyoto encyclopedia of genes and genomes 
KRAS Kirsten rat sarcoma viral oncogene and mutations. 
LB Luria-Bertani 
LGEC low grade endometrioid carcinoma 
LGSC low grade serous carcinoma 
LIG ligase 
LOH loss of heterozygosity 
 12 
MAPK mitogen-activated protein kinase  
MDC1 mediator of DNA-damage checkpoint 1 
MDM2 mouse double minute 2 
MGMT O6 methylguanine DNA methyltransferase 
MMR mismatch repair  
MRN MRE11-Rad50-NBS1  
MSI microsatellite instability 
mTOR mammalian target of rapamycin  
mTORC1 mammalian target of rapamycin complex 1 
mTORC2 mammalian  target of rapamycin complex 2 
NBL non-BRCA-like 
NBS1 nibrin 
NER nucleotide excision repair 
NHEJ non-homologous end joining 
NO nitric oxide 
OS overall survival 
PALB2 partner and localiser of BRCA2  
PAR poly(ADP-ribose) 
PARP poly(ADP-ribose) polymerase 
PBS phosphate buffered saline 
PBST 1 X PBS containing 0.1% Tween20 
PCNA proliferating cell nuclear antigen  
PCR polymerase chain reaction 
PDGF plate derived growth factor 
PDK1 phosphoinositide-dependent kinase- 
 13 
PEI polyethylenimine 
PH pleckstrin homology 
PI phosphoinositide 
PI4K phosphoinositol-4-kinase  
PIK phosphatidylinositol kinase homology  
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha  
PIKK phosphatidylinositol 3-kinase related kinases 
PIP5K phosphatidylinositol-4-phosphate 5-kinase  
PNK polynucleotide kinases  
pol DNA polymerase  
PRAS40 proline-rich Akt substrate of 40 kDa 
PtdIns phosphatidylinositols 
PTEN phosphatase and tensin homolog 
qPCR real-time polymerase chain reaction 
RAD51AP1 RAD51 associated protein 1 
RB1 Retinoblastoma 1 
Rheb ras homolog enriched in brain 
RNF ring finger protein 
ROS reactive oxygen species 
RPA replication protein A  
RTK receptor tyrosine kinase 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
SDSA ynthesis dependent strand annealing  
 14 
  
SH2 Src homology 2 
SH3 Src homology 3  
SHIP1/2 SH2 domain-containing inositol-5’-phosphatase 1/2 
SSB single-strand break 
ssDNA single-stranded DNA 
TAE tris acetate EDTA  
TBS tris-buffered saline 
TBST 1 X TBS containing 0.1% Tween20  
TE tris-EDTA 
TEMED tetramethylethylenediamine 
TMZ temozolomide 
TOP tomoisomerase 
TOPBP1 topoisomerase (DNA) II binding protein 1 
TSC tuberous sclerosis complex 
UV ultraviolet 
VEGF vascular endothelial growth factor 
Vsp34 vacuolar protein-sorting defective-34  
XP xeroderma pigmentosum  
XRCC x-ray repair cross-complementing protein 
 15 
CHAPTER 1.   Literature Review 
1.1 Ovarian cancer 
1.1.1 The biology of ovarian cancer 
1.1.1.1 The female reproductive system 
The human female reproductive system consists of network of organs that co-ordinate 
together and gives rise the ability to produce and bear offspring. The principal organs 
that make up the female reproductive system are the ovaries, fallopian tubes, uterus, 
vagina, and components of the external genitalia, as shown in figure 1.1. The ovaries 
are paired female pelvic reproductive organs, which house the female egg cells (also 
known as ovum/ova) and are responsible for the production of sex hormones oestrogen 
and progesterone. The paired organs are located on either side of the uterus relative to 
the lateral wall of the pelvis and attached to the back of the broad ligament of the uterus. 
The ovary consists of four types of cells: the surface epithelium, the stroma, germ cells 
and granulosa cells. The surface epithelium of the ovary is composed of a single layer 
of cells and lines the external surface of the ovaries. The bulk of the internal substance 
consists of the stroma, a dense, fibrous tissue. Germ cells, or oocytes, are located near 
the periphery of the stroma. Granulosa cells are specialised cells that surround the germ 
cells to form ovarian follicles, essential cellular structures released during ovulation. 
The fallopian tubes extend from the left and right of the uterus to the edge of the 
ovaries, ending in a funnel shaped structure covered with small finger-like projections 
called fimbriae. The function of the fimbriae is to sweep over the outside of the ovaries 
to pick up the released ova and carry them for transport into the uterus. The internal 
lining of the fallopian tubes is covered in cilia which work with the smooth muscle of 
the tube to move the ovum to the uterus. The uterus is a hollow, muscular organ which 
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is connected to the two fallopian tubes on its superior end, and to the vagina, via the 
cervix, on its inferior end. The uterus houses the developing foetus during pregnancy 
and the inner lining of the uterus, known as the endometrium, provides support to the 
embryo during early development. The vagina is an elastic, muscular tube that connects 
the cervix of the uterus to the exterior of the body, and is located inferior of the uterus. 
The vagina functions as a receptacle of the penis during sexual intercourse and carries 
sperm to the uterus and fallopian tubes. It also serves as the birth canal to allow delivery 
of the foetus during childbirth. During menstruation the menstrual flow exits the body 
via the vagina. 
 
 
Figure 1.1 Anatomy of the female reproductive system. The principal organs of the 
female reproductive system are the ovaries, uterine tubes, uterus, vagina, and 
components of the external genitalia. The ovaries, uterine tubes, and uterus are enclosed 
within an extensive mesentery known as the broad ligament. The uterine tubes run 
along the superior border of the broad ligament and open into the pelvic cavity lateral to 
the ovaries. A segment of the broad ligament, known as the mesovarium, supports and 
stabilises the position of each ovary. Image source: 
http://healthcare.utah.edu/healthlibrary/related/doc.php?type=34&id=17114-1 
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1.1.1.2 Incidence, epidemiology and risk factors of ovarian cancer 
Ovarian cancer is the leading cause of death from gynaecological cancers and the fourth 
most common cause of death in women in the UK (Jemal et al., 2007; Zhang et al., 
2009c). In 2011, there were 225,000 new cases of ovarian cancer and 140,000 deaths 
due to ovarian cancer worldwide, accounting for approximately 4% of all cancers 
diagnosed in women (Jemal et al., 2011). Incidence rates vary considerably across the 
globe, with more developed countries possessing an incidence rate of almost twice that 
of less developed countries. The highest ovarian cancer incidence rates are found in 
northern, central and eastern Europe and the lowest rates in Africa and parts of Asia 
(Ferlay J, 2010). The 5-year survival rate of ovarian cancer ranges from 94% for 
localised disease, 73% for regional disease, and 28% for distant disease with an overall 
survival of 46% across all stages (Jemal et al., 2010). While the 5-year survival has 
increased over the last three decades, the overall cure rate has not improved and remains 
at less than 40%.  The cure rate for the most common and most aggressive form of 
ovarian cancer, high grade serous ovarian carcinoma, is even worse. Furthermore, 
approximately 80% of patients present with disease spread beyond the ovaries, giving 
rise to poor prognosis and poor overall survival (Jemal et al., 2010). 
 
Risk factors for developing ovarian cancer include increasing age, positive family 
history of ovarian, breast, uterine, or colon cancer, and high numbers of ovulatory 
cycles. Ovarian cancer is predominantly a disease of older, post-menopausal women 
with over 80% of cases being diagnosed in women over 50 years (ONS, 2010). The life-
time risk of developing ovarian cancer is 1 in 54 for women in the UK (Sasieni et al., 
2011), and this risk increases by three to four fold in women who have a first-degree 
relative diagnosed with ovarian cancer compared with women with no family cancer 
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history. Consequently, positive family cancer history plays a significant role in 
developing ovarian cancer, and approximately 13 – 15% of ovarian cancers are 
associated with germline mutations in members of the BRCA breast and ovarian cancer 
susceptibility family of genes, BRCA1 and BRCA2 (breast cancer 1, early onset; breast 
cancer 2, early onset). Other non-inherited risk factors that increase the likelihood of 
developing ovarian cancer include high ovulatory cycle numbers, infertility as well 
exposure to talc in the genital areas. Conversely, factors that decrease the number of 
ovulatory cycles reduce this risk; these include multiple pregnancies, the use of oral 
contraceptives, and prolonged lactation. Tubal ligation and hysterectomy have also been 
found to reduce the risk of developing ovarian cancer. 
 
1.1.1.3 Types of ovarian cancer 
One of the problems in understanding the pathogenesis of ovarian cancer is the diverse 
histological, clinicopathological and behavioural nature of the disease. Ovarian cancer 
is a heterogeneous disease that is composed of a collection of molecularly and 
aetiologically distinct tumours that share a common anatomical location. Both benign 
and malignant tumours can arise from three cell types: germ cell tumours, sex cord-
stromal tumours and surface epithelial tumours.  (Romero and Bast, 2012). 
 
Surface epithelial ovarian tumours usually develop after the age of 40 and account for 
approximately 90% of malignant ovarian tumours (Chen et al., 2003). Due to the 
majority of malignant ovarian tumours being epithelial in origin, the focus of this study 
will be on this particular subtype. Epithelial ovarian cancer (EOC) was initially thought 
to originate from the ovarian epithelium. In recent years, it has become apparent that 
some ovarian cancers and primary peritoneal carcinomas can also arise from 
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endometriosis, epithelial rests in the normal peritoneum, or the fimbriae of fallopian 
tubes (Romero and Bast, 2012). EOCs are now believed to be derived from flattened 
nondescript epithelial cells that resemble the epithelium of the fallopian tube and/or 
ovaries, endometrium, mucin-secreting endocervical glands, glycogen-filled vaginal 
rests and internal lining of the urinary bladder. These sites of origins define the five 
EOC subtypes, serous, endometrioid, mucinous, clear cell and transitional cell 
carcinomas, respectively, as depicted in figure 1.2. In agreement, a recent finding from 
Perets et al. demonstrated in animal models that some EOC serous carcinomas can 
originate from fallopian tubal secretory epithelial cells (Perets et al., 2013). Carcinomas 
are malignancies that have an epithelial origin. Serous and endometrioid carcinomas can 
further be subdivided into low and high aggressive states, termed low grade and high 
grade cancers respectively. Epithelial tumours that lack any specific differentiation are 
classified as undifferentiated. The distribution of histological subtypes is as follows: 
60% serous, 10 – 20% endometrioid, <10% clear cell, 6% transitional, <5% mucinous 
and <1% undifferentiated tumours. High grade serous carcinomas (HGSCs) are by far 
the most common subtype and account for 90% of all serous tumours, representing over 
50% of all ovarian carcinomas.  
 
Identification of the spread of ovarian cancer involves the use of the International 
Federation of Obstetricians and Gynaecologists staging system, also known as the FIGO 
system. In brief, ovarian cancer staging is stratified into four stages: I, II, III and IV. 
Stage I tumours are confined to the ovaries and stage II tumours involve the ovaries and 
an extension into the pelvis. Once the tumour has spread to the peritoneum the cancer is 
classified as stage III, with stage IV tumours involving metastasis beyond the 
peritoneum. Grading of ovarian cancer indicates how active or aggressive the cancer is. 
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There are three grades, grade I, II and III, which represent low, moderate and high grade 
tumours, respectively. Low grade tumours are typically well differentiated, and are less 
likely to spread than high grade cancers. High grade tumours are usually represented by 
poorly differentiated cells with a higher likelihood of invasion. Moderate grade 
carcinomas represent an intermediate state between low and high grade. 
 
A two-tier system has been derived to recognise this complexity and stratify tumours 
into two designated types, type I and type II, based on histological grade, molecular 
phenotype and genotype (Shih Ie and Kurman, 2004).  Type I cancers include low grade 
serous carcinomas (LGSCs), mucinous carcinomas, low grade endometrioid carcinoma  
(LGECs), and clear cell carcinoma, and these tumours are often large and diagnosed at 
an early stage. They are slow growing, and are less sensitive to standard chemotherapy 
but may be responsive towards hormonal treatment. The more prevalent type II subtype 
includes HGSCs, high grade endometrioid carcinomas (HGECs) and undifferentiated 
carcinoma, all of which typically present at late stage. They evolve rapidly, undergo 
metastasis early in their course, and are clinically aggressive. Type II cancers are 
responsive towards conventional chemotherapy but do not respond as well towards 
hormonal strategies.  
 
The other two less prevalent ovarian cancer subtypes are the germ cell tumours and sex 
cord stromal tumours. Germ cell tumours are ovarian tumours formed by cells that are 
presumably derived from primordial germ cells. Germ cell tumours arise most 
frequently in women in their twenties and thirties and account for 3% of ovarian cancers 
(Smith et al., 2006). Sex cord stromal tumours are believed to be derived from theca 
cells, stromal cells, granulosa cells and their testicular sex cord counterparts, Sertoli and 
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Leydig cells. Sex cord stromal tumours can occur in women of all ages, comprising 
approximately 7% of all ovarian malignancies. 
 
 
Figure 1.2 Origin and histological epithelial ovarian cancer subtypes associated 
with type I and type II molecular classification. LGSC – low grade serous carcinoma; 
HGSC – high grade serious carcinoma. Image source: (Romero and Bast, 2012) 
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1.1.1.4 Molecular alterations in epithelial ovarian cancer 
The different subtypes of EOC can be also distinguished by their molecular alterations. 
Type I epithelial carcinomas are characterised by Kirsten rat sarcoma viral oncogene 
homolog (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), 
phosphatase and tensin homolog (PTEN) and phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA) mutations. KRAS and BRAF encode for 
upstream components of the mitogen-activated protein kinase (MAPK) pathway, which 
coordinate diverse cellular activities like gene expression, cell cycle control, cellular 
metabolism, motility, survival, apoptosis, and differentiation (Krishna and Narang, 
2008). PTEN and PIK3CA encode for components of the phosphatidylinositol-3-kinase 
(PI3K)/Akt signalling pathway, which promote cell proliferation, invasion/migration 
and survival. Approximately one third of low grade serous tumours have a mutation in 
one of these genes (Singer et al., 2003a; Singer et al., 2003b). Similarly, KRAS and 
BRAF are found frequently mutated (50 – 75%) in mucinous and endometrioid tumours 
(Garrett et al., 2001; Gemignani et al., 2003). Endometrioid, mucinous and LGSCs 
exhibit frequent inactivating mutations and epigenetic silencing of PTEN, as well as 
activating mutations of PI3KCA (Campbell et al., 2004; Landen et al., 2008; Nakayama 
et al., 2006; Willner et al., 2007). LGSCs tend to have normal karyotype and wild-type 
TP53 and BRCA1/2 (Press et al., 2008).  
 
Of the type II cancers, TP53 mutations has been found in over 90% of HGSCs and 
display high levels of genomic instability (Bell D, 2011; Landen et al., 2008). 
Approximately 13 – 15% of HGSCs are associated with germline mutations of BRCA1 
and BRCA2 (Alsop et al., 2012; Pal et al., 2005; Zhang et al., 2011). 18% of HGSCs 
have gene amplification of AKT2, a component of the PI3K/Akt pathway (Nakayama et 
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al., 2006). Additionally, genomic analysis of HGSCs revealed a deregulation of the 
retinoblastoma 1 (RB1) pathway, a pathway involved in cell cycle suppression, and 
PI3K/RAS pathways in 67% and 45% of cases, respectively. However, somatic 
mutations were rare and gene amplifications were more commonly found (CGARN, 
2011). In table 1.1 the frequency of somatic gene mutations in EOCs is summarised. 
 
Table 1.1 Frequency of somatic gene mutations in epithelial ovarian cancer 
Gene 
Mutation 
Type I Type II 
Low Grade 
Serous Clear Cell Endometrioid Mucinous 
High Grade 
Serous 
BRAF 24 – 33%1,2 1%3 24%2 50 – 75%4 <1%5 
      
KRAS 33%1,2 <1 – 7%2,3 <1%2 50 – 75%4 <1%5 
      
PIK3CA 5%1 20 – 33%3,6 20%6 rare <1%5 
      
PTEN 20%7 <1 – 5%3,8 20 – 31%8,9 rare <1%5 
 
1Nakayama et al., 2006; 2Singer et al., 2003a; 3Kuo et al.,. 2009; 4Gemignani et al., 
2003; 5CGARN, 2001; 6Campbell et al., 2004; 7Landen et al., 2008; 8Winner et al., 
2007; 9Kurman and Shih Ie, 2011 
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1.1.2 Diagnosis, staging, and clinical management  
Ovarian cancer remains the leading gynaecological cancer killer in part due to non-
specific symptoms and lack of reliable biomarkers. The symptoms of early ovarian 
cancer are minimal, and progression of the disease leads to development of 
gastrointestinal symptoms such as abdominal pain, swelling and bloating. Patients and 
their health care providers often attribute these changes to menopause, aging, dietary 
indiscretions, stress, depression, or functional bowel problems. Frequently, women are 
medically managed without having a pelvic examination. As a result, early detection of 
ovarian cancer fails. 
 
When abnormal ovarian pathology is suspected an ultrasound is conducted followed by 
cancer antigen 125 (CA125) tumour marker assessment. CA125 is a high molecular 
weight glycoprotein discovered in 1981 by Bast et al. and is important for adhesion, 
motility, and invasion of ovarian cancer (Bast et al., 1981; Bast and Spriggs, 2011). 
Elevated CA125 levels are observed in the majority of ovarian cancer sub-types, as well 
as 50% of stage I, 90% of stage II and over 90% of stages III/IV ovarian cancer patients 
(Carlson et al., 1994). However, CA125 is also found increased in several other cancers 
such as endometrial, pancreatic and lung cancer and consequently has limited 
specificity for detecting ovarian cancer. A study conducted in 2010 revealed that 
treatment of patients with recurrent ovarian cancer based on elevated CA125 did not 
increase overall survival (OS) compared to patients with delayed treatment. On the 
contrary, early treatment was associated with an early deterioration of quality of life 
(Rustin et al., 2010). While there have been numerous novel biomarkers discovered for 
ovarian cancer, an evaluation conducted by Cramer et al. concluded that CA125 
remains the single best biomarker amongst the ovarian cancer specimens tested (Cramer 
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et al., 2011). Despite the limitations of the biomarker, assessing CA125 levels is 
currently considered standard of care for ovarian cancer screening, as well as for 
monitoring response to treatment and detecting disease recurrence (Lutz et al., 2011). 
 
To detect any disease spread beyond the ovaries, a computed tomographic (CT) scan of 
the pelvis, abdomen and chest is conducted. Ovarian cancer is one of the few 
malignancies where surgeons will undertake cytoreductive operations, even if all 
macroscopic tumours cannot be removed. If the disease is limited to the ovary, the 
ovary is removed surgically. For women who wish to retain their fertility, the 
contralateral ovary and uterus is preserved upon normal imaging presentation and at 
surgery. If the cancer is found to have spread beyond the ovaries, debulking surgery is 
conducted in late-stage disease to achieve no residual visible disease, which has been 
found to improve prognosis (Schorge et al., 2010). Residual tumour size of over 2 cm is 
associated with reduced survival of 12 – 16 months, compared to a survival of 40 – 45 
months if the tumour is less than 2 cm (Mutch, 2002). 
 
1.1.2.1 Conventional chemotherapy and drug resistance 
Administration of a combination of carboplatin and paclitaxel is currently considered 
the standard of care for ovarian cancer. Chemotherapy treatment and numerous 
randomised clinical trials have yielded a total of over 80% response rates, of which 40 – 
60% were complete responses (du Bois et al., 2003; Neijt et al., 2000; Ozols et al., 
2003; Sandercock et al., 2002). Carboplatin interacts with DNA to interfere with DNA 
repair and paclitaxel stabilises microtubules to inhibit cell division. Despite the high 
response rate, the majority of patients eventually relapse with a median progression-free 
survival of 18 months (Greenlee et al., 2001). The addition of other chemotherapeutic 
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agents, such as gemcitabine, liposomal doxorubicin and topotecan, to standard treatment 
has not resulted in any survival advantage (Bookman et al., 2009). Gemcitabine 
interferes with DNA replication, liposomal doxorubicin intercalates with DNA and 
topotecan/etoposide administration results in irreversible DNA damage. At relapse, if 
the patients are treated with the same drugs, their response rates reflect the treatment-
free interval (Gore et al., 1990). This treatment response can be categorised into 
platinum-sensitive, platinum-resistant and platinum-refractory disease which indicates 
recurrence of disease after more than six months, less than six months, during or on 
completion of platinum chemotherapy, respectively. While the response rate of 
platinum-sensitive disease to carboplatin is greater than 50%, the response rate of 
platinum-resistant disease is 10 – 20% and even less for platinum-refractory disease. If 
the patient displays poor response towards carboplatin, alternative treatments such as 
liposomal doxorubicin, gemcitabine, topotecan, etoposide and hormonal therapies are 
implemented. However, with each subsequent relapse follows a decrease in response 
rate due to the development of drug resistance. Efforts to circumvent this resistance 
have been made by the use of different chemotherapy agents in varying combinations, 
doses and schedules, but have only led to marginal improvements in survival of patients 
with recurrent disease compared to mono-therapy (Bolis et al., 1999; Bookman et al., 
2003; Buda et al., 2004; De Placido et al., 2004; Gonzalez-Martin, 2013; Monk et al., 
2010; Sehouli et al., 2008). 
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1.2 PI3K/Akt pathway 
The activation of the PI3K/Akt pathway has been found in several human cancers and is 
crucial for tumour progression and resistance development against chemotherapy and 
targeted therapies. This pathway regulates cell metabolism, growth, proliferation, 
migration and survival via regulation of a multitude of components in a signalling 
cascade driven manner, as depicted in figure 1.3. The next sections will discuss in depth 
the various components of PI3K signalling responsible for the activation and 
termination of this pathway, as well as the mutations of these components that exist in 
human cancers.  
 
 
Figure 1.3 PI3K/Akt signalling. Growth factors and hormones activate receptor 
tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs), which in turn 
activate PI3K. Activated Ras protein can also activate PI3K directly. Upon activation, 
class I PI3K gives rise to phosphatidylinositol-3,4,5-trisphosphate (PIP3). Akt, along 
with other proteins carrying a phosphoinositide binding domain, is recruited to the 
plasma membrane with binding affinity for both PIP3 and PI(3,4)P2 where it is activated 
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and subsequently initiates responses that regulate cell growth, proliferation, survival and 
motility. The pathway can be terminated by three phosphatases: phosphatase and tensin 
homologue (PTEN), SH2 domain-containing inositol-5'-phosphatase 1/2 (SHIP1/2) and 
inositol polyphosphate 4-phosphatase type II (INPP4B). PTEN hydrolyses PIP3 to 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), SHIP1/2 dephosphorylates PIP3 to 
PI(3,4)P2 and INPP4B fully terminates the signalling pathway by the hydrolysis of 
PI(3,4)P2 to phosphatidylinositol-3-phosphate (PI(3)P). PI(3)P can also be produced 
from phosphatidylinositol (PtdIns) by class III PI3K, Vsp34. Image source: (Engelman 
et al., 2006) 
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1.2.1 Phosphoinositides 
Phosphatidylinositol (PtdIns) and its phosphorylated derivatives are lipid molecules 
which reside in cellular membranes. Once phosphorylated, the phosphorylated PtdIns, 
otherwise known as phosphoinositides (PIs), attract specific proteins with a binding 
domain for PIs. PIs initiate various responses that result in cellular growth, cell cycle 
entry, cell migration and cell survival.  
 
PtdIns consists of a myo-inositol ring that contains six hydroxyl groups configured with 
five of its six hydroxyl groups being equatorial and one at position D2 being axial, as 
shown in figure 1.4. PtdIns has a glycerol backbone esteriﬁed to two fatty acid chains 
and a phosphate, and attached to a polar myo-inositol head group that extends into the 
cytoplasm. The inositol head group has free hydroxyl groups at positions D2 through 
D6, and those at positions D3, D4 and D5 are readily phosphorylated by cytoplasmic 
lipid kinases. The combination of phosphorylated products gives rise to seven known 
PIs (figure 1.4): PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(4,5)P2, PI(3,5)P2, PIP3. The 
amounts of PIs within cells have been estimated in different cells and tissues, and 
significant variance has been found in human tissue type distribution, as well as 
between yeast and plants (Nasuhoglu et al., 2002; Wenk et al., 2003).  
  
 30 
 
Figure 1.4. Phosphatidylinositol structure and metabolic reactions generating 
phosphoinositides. Here, INPP4B dephosphorylates PI(3,4)P2 to PI(3)P. Image source: 
(Di Paolo and De Camilli, 2006) 
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PtdIns is synthesised in the endoplasmic reticulum from cytidine diphosphate 
diacylglycerol and myo-inositol by PtdIns synthase (Agranoff et al., 1958) and 
distributed throughout the cell via several PtdIns transfer proteins (Cockcroft and 
Carvou, 2007; Ile et al., 2006). PIs affect cellular functions by interacting with 
molecules that either reside in the membrane or are recruited to the membrane through 
interaction with PIs via inositide binding protein domains, such as the pleckstrin 
homology (PH) domain that has lipid binding selectivity for PI(3)P, PI(4)P, PI(3,4)P2, 
PI(4,5)P2, PIP3. Table 1.2 lists the PI-binding modules, their binding preferences and 
examples of proteins that contain them. PI metabolism is strictly controlled in cells by 
the action of specific lipid kinases and lipid phosphatases. In general, phosphorylation 
occurs in two sites within the cell. Mono-phosphorylations of most PIs by Class II 
phosphoinositol-4-kinase (PI4K) and Class III PI3K occur in endomembranes, such as 
the endosomes and the Golgi network. Phosphorylation of PI(4)P to PI(4,5)P2 by 
phosphatidylinositol-4-phosphate 5-kinase (PIP5K) and further phosphorylation to PIP3 
by class I PI3Ks occurs primarily at the plasma membrane. PIs have also been found in 
the nucleus and their functions encompass many aspects of transcription, chromatin 
remodeling, and mRNA maturation; however, defined mechanisms have yet to be 
established (Shah et al., 2013). The phosphorylation status of PIs can be changed by 
phosphoinositide phosphatases and hydrolysis by phosphoinositide-specific 
phospholipase C enzymes (PLCs). While some of the phosphoinositide phosphatases 
remove phosphate groups located in a specific position on the inositol ring, others, 
mainly the ones that dephosphorylate mono-phosphorylated PIs, possess functional 
specificity related to PI localisation. The localisation and site of phosphorylation and 
dephosphorylation of PIs is depicted in figure 1.5. 
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Table 1.2. Phosphoinositide binding modules, binding preferences and examples of 
proteins that contain them. Image source: (Di Paolo and De Camilli, 2006) 
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Figure 1.5 Predominant subcellular localisation of phosphoinositides and locations 
of phosphorylation/dephosphorylation events. PI(4,5)P2 and PIP3 are primarily 
located at the plasma membrane. PI(3,4)P2 is predominantly found in the plasma 
membrane and early endosome. PI(4)P is found concentrated at the Golgi complex, but 
also found in the plasma membrane as well. PI(3)P is mostly found in the early 
endosomes and PI(3,5)P2 on the late compartments of the endosomal pathway. Image 
source: (Di Paolo and De Camilli, 2006) 
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1.2.2 Activation of the PI3K pathway 
1.2.2.1 Phosphatidylinositol-3-kinases 
PI3Ks are a family of intracellular signalling enzymes that phosphorylate the 3’-
hydroxyl group of the inositol ring of lipid second messenger phosphoinositides (Toker 
and Cantley, 1997). PI3Ks can be divided into three classes, based on lipid substrate 
preference and sequence homology: class I, class II, and class III (Domin and 
Waterfield, 1997; Vanhaesebroeck et al., 1997). The domain structures of the PI3K 
isoforms are shown in figure 1.6. All PI3K isoforms are widely expressed across tissue 
types, with the exception of class IA p55γ and p110δ subunits, which are predominately 
expressed in the brain/testes, and in lymphocytes, respectively. Several growth factors 
and signalling compounds can initiate activation of PI3K, including fibroblast growth 
factor, vascular endothelial growth factor (VEGF), angiopoietin I, and insulin. All of 
these molecules activate RTKs and lead to autophosphorylation of the receptors, which 
subsequently provide a docking site for PI3K. Other receptors and proteins such as 
GPCRs and the GTPase Ras are also able to activate PI3K. 
 
1.2.2.1.1 Class I PI3Ks 
Class I PI3Ks can utilise PtdIns, PI(4)P, and PI(4,5)P2 as a substrate in vitro, whereas in 
vivo, Class I PI3Ks primarily generate PIP3 from PI(4,5)P2. Class I PI3Ks can further be 
subdivided into class IA and class IB.  
 
Class IA PI3Ks are the most widely implicated class in human cancer and consist of a 
regulatory subunit (p85α, p85β, p50α p55α and p55γ) and a catalytic subunit (p110α, 
p110β and p110δ). PIK3R1, PIK3R2 and PIK3R3 encode p85α, p85β and p55γ, 
respectively. Through alternative transcription initiation sites, the PIK3R1 gene also 
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gives rise to two shorter isoforms, p50α and p55α.  A common core structure is shared 
between the p85 isoforms consisting of a p110-binding domain flanked by two Src-
homology 2 (SH2) domains, as depicted in figure 1.6.  The p85 regulatory subunit plays 
an essential role in maintaining the p110 catalytic subunit in a low activity state in 
quiescent cells and mediating activation through binding of the SH2 domains of p85 to 
phospho-tyrosine residues containing the motif pYxxM located on RTKs or adaptor 
molecules, where x represents any amino acid (Songyang et al., 1993). The p110 
subunit is only stable in complex with a p85 subunit and no evidence for free p85 or 
p110 subunits has been obtained (Geering et al., 2007). Class IA PI3K catalytic subunits 
p110α, p110β and p110δ are expressed by genes PIK3CA, PIK3CB, and PIK3CD, 
respectively (Fruman et al., 1998). The p110 isoforms contain an N-terminal p85-
binding domain, a Ras-binding domain, a phosphatidylinositol kinase homology (PIK) 
domain, and a C-terminal catalytic domain. Mutations in the PIK3CA genes encoding 
the catalytic subunit p110α are found frequently across a variety of cancer tissue types. 
PIK3CA mutations occur most commonly in hepatocellular (36%), breast (26%), colon 
(26%), ovarian (10%), glioma (8%), and gastric (7%) cancers (Bunney and Katan, 
2010). Over 80% of the mutations have been observed around two hotspots: E545 in the 
helical phosphatidylinositol kinase homology domain, and H1047 near the end of the 
catalytic domain. The resulting effect of the mutations promotes constitutive PI3K 
signalling. Recent data have suggested that glioblastomas, ovarian cancers and colon 
carcinomas also harbour activating mutations in PIK3R1, which encodes p85α, however 
the mechanism and the broader implications of these mutations have yet to be defined 
(CGARN, 2008; Philp et al., 2001).  	
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Class IB PI3Ks have a p110γ catalytic subunit and a two part regulatory subunit, 
consisting of p101 and p87. Class IB PI3Ks do not have a p85 regulatory subunit and 
are therefore not regulated by RTKs. Instead, class IB PI3Ks are activated by GPCRs 
via interaction with the Gβγ subunit of trimeric G proteins (Stephens et al., 1997). Other 
p110 regulatory subunit homologues include p84 and p87PIKAP which also mediate 
activation of p110γ (Suire et al., 2005; Voigt et al., 2006).  	
1.2.2.1.2 Class II PI3Ks 
Class II PI3Ks consist of a p110-like catalytic subunit only, with no regulatory subunit. 
The three isoforms of class II PI3Ks, PIK3C2α, PIK3C2β and PIK3C2γ are encoded by 
three distinct genes. The structure of class II PI3Ks includes a divergent N-terminus, a 
PI binding PX domain and an additional C2 domain at the C-terminus. These enzymes 
preferentially phosphorylate PI, as well as PI(4)P, although to a lesser extent (Engelman 
et al., 2006). Class II PI3Ks play a role in regulating membrane trafficking and receptor 
internalisation by binding to clathrin, a protein involved in formation of coated vesicles 
(Gaidarov et al., 2001). Activation of class II PI3Ks can be mediated by RTKs, cytokine 
receptors and integrins; however, downstream functions in response to activation are 
less well defined (Katso et al., 2001).  
 
1.2.2.1.3 Class III PI3Ks  
Class III PI3Ks consist of the catalytic subunit vacuolar protein-sorting defective-34 
(Vsp34). Originally identified in budding yeast as the gene product required for 
trafficking vesicles from the Golgi apparatus to the vacuole (Odorizzi et al., 2000), 
Vps34 has also been found to have mammalian functions. Vps34 has been implicated in 
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controlling cell growth through regulation of mammalian target of rapamycin (mTOR) 
activity in response to amino acid availability (Byfield et al., 2005; Nobukuni et al., 
2005), as well as in autophagy, a cellular response to nutrient starvation (Kihara et al., 
2001; Wurmser and Emr, 2002).  
 
 
 
 
Figure 1.6 The domain structures of PI3K isoforms. PI3Ks can be divided into three 
classes based on lipid substrate preference and sequence homology. Class IA PI3K is a 
heterodimer that consists of a regulatory subunit (p85α/p55α/p50α/p85β/p55γ) and a 
catalytic subunit (p110α/p110β/p110∂). The p85 regulatory subunit consists of a p110-
binding domain flanked by two Src-homology 2 (SH2) domains. The longer isoforms 
p85α and p85β also have an extended N-terminal region containing an Src-homology 3 
(SH3) domain, and a BCR homology (BH) domain flanked by two proline-rich (P) 
regions as indicated by the dotted lines (Fruman et al., 1998). Class IA catalytic 
subunits, as with the rest of the PI3K isoforms, contain a C2 domain, 
phosphatidylinositol kinase homology (PIK) domain, as well as a C-terminal catalytic 
domain. The class IA p110 subunit also shares a Ras binding domain with class IB, and 
Class II PI3K. A p85 binding domain at the N-terminus of class IA p110 interacts with 
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the p85 regulatory subunit. Class IB PI3Ks are heterodimers consisting of regulatory 
subunits (p101, p84, p87PIKAP) and the p110γ catalytic subunit. Although P110γ share 
extensive homology with class IA p110 proteins, class IB p110 regulatory subunit is 
distinct from p85 proteins. Class II PI3Ks contain only a p110-like catalytic subunit 
(PIK3C2α, PIK3C2β, PIK3C2γ), which contain an extended divergent N-terminus and 
a PX domain at the C-terminus. Class III PI3K consists of a single member, Vsp34. As 
described above, class IB, class II and class III catalytic subunits shares significant 
sequence homology with class IA p110 subunits. Image source: (Engelman et al., 2006) 
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1.2.2.2 Akt 
Akt, also known as protein kinase B, is a serine-threonine kinase that is activated 
downstream of PI3K. There are three mammalian isoforms of Akt: Akt1, Akt2 and 
Akt3 (Brodbeck et al., 1999; Cheng et al., 1992; Jones et al., 1991). The isoforms share 
approximately 80% amino acid homology and are thought to have similar primary 
substrate specificity (Vanhaesebroeck and Alessi, 2000). In addition, a splice variant of 
the Akt3 isoform has been found which contains a truncated C-terminus hydrophobic 
domain (Brodbeck et al., 2001). Akt is widely expressed across various tissue types. 
Akt1 is primarily expressed in the brain, heart and lung (Coffer and Woodgett, 1991); 
Akt2 is mainly expressed in skeletal muscles and embryonic brown fats (Altomare et 
al., 1995; Altomare et al., 1998); Akt3 is predominantly expressed in the lung, brain and 
kidney (Brodbeck et al., 1999). The three Akt isoforms share a conserved N-terminal 
PH domain, a central kinase domain and a C-terminal regulatory domain, which 
contains a hydrophobic motif, characteristic of the cyclic adenosine monophosphate 
(cAMP) dependent protein kinase A/protein kinase G/protein kinase C super family of 
protein kinases, as depicted in figure 1.7 (Song et al., 2005). The N-terminal PH domain 
of Akt interacts with PIP3 and PI(3,4)P2 (Franke et al., 1997).  
 
In vivo, knockout of the different Akt isoforms in mice has revealed distinct biological 
roles: Akt1 knockout mice were found to be smaller than the control mice and showed 
increased rates of apoptosis in some tissues, reflecting the role of Akt1 in cell survival 
(Chen et al., 2001; Cho et al., 2001b). Akt2 null mice developed type II diabetes and had 
impaired glucose utilisation revealing a role of Akt2 in the insulin receptor signalling 
pathway (Cho et al., 2001a; Garofalo et al., 2003). In a separate study, point mutations 
in the kinase domain of Akt2 were identified in a familial form of severe insulin 
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resistance, supporting the role of Akt2 in glucose metabolism (George et al., 2004). Akt3 
knockout mice display impairments in brain development, however the exact functional 
role of Akt3 has been less well defined (Yang et al., 2004). 
 
 
Figure 1.7 Domain structures of the Akt isoforms. Three human isoforms of Akt 
have been identified that share approximately 80% amino acid sequence homology. In 
addition, a splice variant of Akt3 has been found with a truncated hydrophobic domain. 
PH – pleckstrin homology domain; HD – hydrophobic domain. Image source: (Matheny 
and Adamo, 2009) 
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1.2.2.2.1 Akt regulation 
The coordinated activation of Class I PI3K and SHIP1/2 gives rise to PIP3 and PI(3,4)P2 
accumulation at the plasma membrane to which Akt can bind via its PH domain. Akt is 
activated by site-specific phosphorylation at residues Thr308 and Ser473, by 
phosphoinositide-dependent kinase-1 (PDK1) and mTOR complex 2 (mTORC2)/DNA-
dependent protein kinase (DNA-PK), respectively (Alessi et al., 1996; Feng et al., 2004; 
Sarbassov et al., 2005). Other molecules, including integrin-linked kinase and mitogen-
activated protein kinase-activated protein kinase-2 have also been reported to 
phosphorylate the Ser473 residue of Akt (Balendran et al., 1999; Delcommenne et al., 
1998). Activation of Akt can also be PI3K-independent: cAMP elevating agents have 
been shown to activate Akt through protein kinase A (Filippa et al., 1999; Sable et al., 
1997) and non-kinase interactors such as heat shock protein 90, heat shock protein 27, T 
cell leukaemia/lymphoma 1, and fucosyltransferase 1 have also been found to positively 
regulate Akt catalytic activity (Song et al., 2005).  
 
Genetic alterations of all three Akt isoforms have been found in various cancer types. A 
somatic mutation in the PH-domain of Akt1 was discovered in breast (8%), colorectal 
(6%) and ovarian (1%) cancers (Carpten et al., 2007). The PH domain mutation allows 
promiscuous binding to the plasma membrane in the absence of 3’ PIs. In the absence of 
serum, constitutive phosphorylation of S473 was observed in these mutants. However, 
T308 phosphorylation required serum, suggesting that cancers harbouring this mutation 
may still require some PI3K activity for full activation of Akt. Mutations in Akt2 and 
Akt3 were identified in melanoma samples as well as colorectal cancer, albeit 
infrequently occurring (Davies et al., 2008; Parsons et al., 2005).  
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1.2.2.2.2 Akt and cell survival 
The substrates of Akt are involved in crucial processes that promote cell survival, 
metabolism, cell proliferation, cell growth, angiogenesis and glucose uptake; these are 
all important functions in the development and maintenance of cancer cells.  
 
Akt enhances cell survival by blocking the function of the Bcl-2 homology domain 3 
(BH3)-only proapoptotic proteins, which exert their effects by binding and sequestering 
pro-survival Bcl-2 family members. Akt directly phosphorylates BH3-only protein Bcl-
2 associated death promoter (BAD) on S136, which creates a binding site for 14-3-3 
regulatory proteins and triggers the release of BAD from their target proteins (Datta et 
al., 1997; Datta et al., 2000; del Peso et al., 1997). Akt also inhibits expression of BH3-
only proteins by phosphorylation of forkhead box O (FOXO) proteins in the nucleus, 
which results in FOXO transcription factors being displaced from target genes that 
promote apoptosis, cell-cycle arrest and metabolic processes, as well as being exported 
out of the nucleus (Tran et al., 2003). Other targets of Akt involved in cell survival 
include the multi-site phosphorylation of E3 ubiquitin ligase mouse double minute 2 
(MDM2) homolog by Akt, which in turn inhibits p53 function and transcription of the 
BH3-only proapoptotic proteins Puma and Noxa. Akt also phosphorylates glycogen 
synthase kinase (GSK) family member 3 (GSK3) isoforms, which inhibit anti-apoptotic 
family member MCL-1. However, it is unclear what importance these targets play in 
cell survival. Finally, Akt indirectly promotes cell survival through its roles in nutrient 
uptake, metabolism, and maintenance of mitochondrial membrane potential.  
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1.2.2.2.3 Akt and cell growth 
In addition to cell survival, Akt also plays a role in a well conserved function of cell 
growth through activation of mTOR complex 1 (mTORC1), a critical regulator of 
translation initiation and ribosome biogenesis (Wullschleger et al., 2006). mTORC1, a 
complex composed of the protein kinase mTOR, Raptor and mammalian lethal with 
SEC13 protein 8, promotes cell growth in response to nutrients and growth factors. 
Upon activation, mTORC1 alters metabolism from catabolic metabolism to growth-
promoting anabolic metabolism, stimulating the synthesis of proteins, lipids, and 
nucleotides (Howell et al., 2013). Due to the resource demanding cellular processes 
downstream of mTORC1, cells have evolved mechanisms whereby the activation state 
of mTORC1 is influenced by the intracellular availability of nutrients and energy 
(Dibble and Manning, 2013). mTORC1 is regulated by a variety of secreted factors 
including growth factors, cytokines, and hormones, such as insulin and insulin-like 
growth factor 1. Insulin activates mTORC1, which inhibits the TSC1-TSC2-TBC1D7 
complex (the tuberous sclerosis complex (TSC) complex) to turn on Ras homolog 
enriched in brain (Rheb), an essential activator of mTORC1 (Menon et al., 2014). Loss 
of the PTEN tumour suppressor results in constitutive activation of mTORC1 (Menon et 
al., 2014). While the mechanism of mTORC1 activation of downstream substrates by 
Akt is unclear, it has been suggested that Akt directly phosphorylates mTORC1 at 
S2448 and activates it, but the effects of this stimulation has failed to demonstrate 
functional significance (Scott et al., 1998; Sekulic et al., 2000) and S6K1 rather than 
Akt has been shown to be responsible for phosphorylation of the S2448 site (Chiang 
and Abraham, 2005; Holz and Blenis, 2005). A second Akt substrate that regulates 
mTORC1 is proline-rich Akt substrate of 40 kDa (PRAS40). Overexpression of the 
mutant homologue of PRAS40 blocked Akt activation of S6K1, suggesting that Akt-
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mediated phosphorylation of PRAS40 stimulates mTORC1 signalling (Sancak et al., 
2007; Vander Haar et al., 2007).  
 
1.2.2.2.4 Akt and cell proliferation 
Cell proliferation is another key process that Akt promotes through regulation of 
downstream targets involved in cell cycle progression. In brief, progression of the cell 
cycle can be divided into four stages: S phase, M phase, G1 phase, and G2 phase 
(discussed in detail in section 1.3.6.4). After mitosis occurs in the M phase, the cells 
undergo cell growth in the G1 phase. DNA replication follows in the S phase, and the 
cell prepares for entry into mitosis in the G2 phase. The phosphorylation of the p27Kip1 
cyclin-dependent kinase inhibitor by Akt (Liang et al., 2002; Shin et al., 2002; Viglietto 
et al., 2002) results in cytosolic sequestering of p27Kip1 through 14-3-3 protein binding 
(Sekimoto et al., 2004). Preventing nuclear localisation of p27Kip1 results G1 cell cycle 
progression through cyclin E and cyclin A. Akt also regulates p27 by phosphorylating 
FOXO transcription factors, thus inhibiting p27 transcription. Akt dependent 
phosphorylation of targets such as GSK3, tuberous sclerosis 2, and PRAS40, is also 
likely to drive cell proliferation by regulating the stability and synthesis of proteins 
involved in G1 cell cycle progression. GSK3 mediates phosphorylation of the G1 
cyclins, cyclin D and cyclin E, and the transcription factors c-jun and c-myc, which all 
play a central role in the G1/S phase cell cycle transition. Phosphorylation of these 
molecules targets them for proteasomal degradation (Diehl et al., 1998; Wei et al., 2005; 
Welcker et al., 2003; Yeh et al., 2004). The importance of Akt in the transition through 
other phases of the cell cycle remains unclear. Elevated Akt activity has been shown 
during the G2/M phase of the cell cycle, and Akt activation promotes mitosis 
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progression even upon DNA damage (Kandel et al., 2002; Shtivelman et al., 2002). 
Constitutively active Akt has been found to directly phosphorylate the DNA damage 
checkpoint kinase Chk1 on S280 (King et al., 2004), stimulating Chk1 translocation to 
the cytosol, where it is sequestered by DNA damage sensors ataxia telangiectasia 
mutated (ATM) and ATM and Rad3-Related (ATR) (Puc et al., 2005).  
 
1.2.2.2.5 Akt and angiogenesis 
PI3K/Akt pathway activation by VEGF and phosphorylation of Akt substrates is likely 
to contribute to angiogenesis though endothelial cell survival, growth and proliferation. 
Furthermore, Akt directly phosphorylates and activates endothelial nitric oxide (NO) 
synthase, which stimulates vasodilation, vascular remodelling and angiogenesis 
(Morbidelli et al., 2003). The Akt1 isoform exerts an essential role in blood flow 
control, cellular migration, and NO synthesis during postnatal angiogenesis (Ackah et 
al., 2005). Through PI3K/Akt signalling, mTORC1 mediated translation of hypoxia-
inducible factor-1/2 α (HIF1α and HIF2α) leads to expression and secretion of VEGF 
and other angiogenic factors, stimulating angiogenesis in a dual autocrine and paracrine 
fashion (Gordan and Simon, 2007; Semenza, 2003).  
 
1.2.2.2.6 Akt and cell metabolism 
Akt signalling also regulates nutrient uptake and cell metabolism through a variety of 
downstream targets, the more prominent function of Akt being its ability to stimulate 
glucose uptake in response to insulin (figure 1.8). Akt2 associates with glucose 
transporter (Glut) family member 4 (Glut4)-containing vesicles upon insulin stimulation 
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of adipocytes (Calera et al., 1998) and Akt activation results in the translocation of 
Glut4 to the plasma membrane. Activation of mTORC1 promotes the transcription of 
Glut1, the main glucose transporter in most cell types, in a HIF1α dependent manner 
(Taha et al., 1999; Zelzer et al., 1998). Akt has also been found to regulate amino acid 
uptake, through mTORC1 driven signalling (Edinger and Thompson, 2002), however, 
the mechanism of this effect remains unclear. Glucose and lipid metabolism is regulated 
by Akt activation through stimulation of hexokinases, which aid in converting glucose 
to its glucose 6-phosphate active form, but the direct target involved in this regulation is 
currently unknown (Robey and Hay, 2006). Glucose 6-phosphate can be processed for 
storage by conversion to glycogen or catabolised to produce cellular energy through 
glycolysis and Akt can regulate both of these mechanisms. As a result, Akt activation 
significantly contributes to the highly glycolytic nature of tumour cells by increasing the 
rate of glycolysis (Elstrom et al., 2004). Akt-mediated inhibition of GSK3 by 
phosphorylation inhibits phosphorylation and inhibition of glycogen synthase, thereby 
stimulating glycogen synthesis. Expression of glycolytic enzymes is promoted through 
the activity of HIF1α and FOXO1 inhibition contributes to glucose homeostasis (Accili 
and Arden, 2004).  Lipid metabolism is regulated by Akt through phosphorylation and 
inhibition of GSK3, which targets promoting transcription factors involved the 
biosynthesis of cholesterol and fatty acids (Sundqvist et al., 2005).  
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Figure 1.8. Signalling pathway of Akt in cell metabolism. Activation of RTK 
activates Akt and mTOR, which stimulate glycolysis in part by Akt-induced localisation 
of glucose transporters to the cell surface. Image source: (Hennessy et al., 2005) 
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1.2.2.2.7 Akt and cellular migration and invasion 
Over the last few years, the role of Akt in cellular migration and invasion has been 
better defined. Activation of Akt1 decreases mammary epithelial cell migration, and 
promotes an epithelial to mesenchymal transition that resembles events required for 
metastasis (Irie et al., 2005; Yoeli-Lerner et al., 2005). Akt1 has an inhibitory effect on 
the in vitro migration and leads to the degradation of nuclear factor of activated T cells 
transcription factors (Yoeli-Lerner et al., 2005). Small interfering RNA knockdown of 
Akt1, but not Akt2, led to an increase in the migration of mammary epithelial cells, and 
also increases activation of extracellular signal-regulated kinases (ERK) family 
members 1 and 2 (ERK1 and ERK2), a signalling event required for the enhanced 
migration. The mechanism for these two effects remains unknown. Studies of Akt 
isoforms in mouse tumour models have the same effect, with one study suggesting Akt1 
inhibits metastases, whereas Akt2 promotes it, and vice versa in another study 
(Arboleda et al., 2003; Hutchinson et al., 2004; Zhou et al., 2006). These studies 
demonstrate that Akt has significant cross talk with other signalling pathways and also 
emphasises the differing roles of Akt isoforms.  
 
1.2.2.3 Akt and autophagy 
Class I PI3K can regulate autophagy indirectly via Akt and mTORC1. Once activated, 
Akt phosphorylates and inhibits TSC2, which allows GTP-bound Rheb to activate the 
mTORC1 complex. This results in inhibition of autophagy by phosphorylation and 
regulation of proteins involved in autophagosome formation. When there is an 
abundance of nutrients, active mTORC1 inhibits autophagosome formation by 
associating with the ULK1-ATG13-FIP200 complex and phosphorylating ULK1 (the 
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mammalian homologue of the autophagy yeast protein Atg1) and Atg13. (Hosokawa et 
al., 2009; Jung et al., 2009). The activity of downstream target of mTORC1, S6 kinase, 
has also been associated with autophagy suppression, however other studies suggest that 
S6 kinase promote autophagy instead (Armour et al., 2009; Blommaart et al., 1995; 
Zeng and Kinsella, 2008). A study of another downstream target of mTORC1, death-
associated protein-1 (DAP1), revealed that under amino acid deprivation, decrease in 
DAP1 phosphorylation restores the anti-autophagic function of DAP1 (Koren et al., 
2010). mTORC2 can negatively regulate autophagy indirectly through Akt. Akt 
activation results in the inactivation of FoxO3, which prevents expression of its target 
genes, such as autophagy-related genes, such as LC3 and Bnip3 (Brunet et al., 1999).  
 
1.2.3 Termination of the PI3K/Akt pathway 
Negative regulation of the PI3K/Akt pathway can be initiated by several components, 
namely by the phosphatase activity of PTEN, SH2-containing inositol 5’-phosphatase 
1/2 (SHIP 1/2) and inositol polyphosphate 4-phosphatase type I and II 
(INPP4A/INPP4B). 
 
1.2.3.1 PTEN 
Negative regulation of the PI3K/Akt signalling pathway is conducted in part by the 
catalytic function of tumour suppressor PTEN, which dephosphorylates PIP3 to 
PI(4,5)P2. This prevents PIP3-dependent recruitment of Akt and PDK1 to the plasma 
membrane and activation of AKT. The domain structure of PTEN is a 403 amino acid 
protein that is composed of five functional domains: a P(4,5)P2 binding domain , a 
phosphatase domain, a C2 domain, a carboxyl-terminal tail and a post synaptic density 
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protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-
1 protein (zo-1) (PDZ) binding domain. 
 
Cytogenetic and molecular studies in the 1980s were the first to reveal partial or 
complete loss of chromosome 10 in brain, bladder and prostate cancer (Bigner et al., 
1984). It was not until 1997 that the tumour suppressor gene PTEN was identified at the 
10q23 locus and found to be disrupted in multiple sporadic tumour types (Li et al., 
1997; Steck et al., 1997). Germline mutations of PTEN were also linked with Cowden 
syndrome (Liaw et al., 1997), a rare disorder characterised by multiple tumour-like 
growths as well as a predisposition to develop certain forms of cancer.  
 
Inactivation of PTEN leads to loss of its lipid phosphatase activity, resulting in an 
accumulation of PIP3 and consequently increased PIP3-dependent activation of Akt and 
activation of its downstream targets. The majority of somatic mutations in PTEN result 
in protein truncation. Missense mutations have also been found in central nervous 
system (20%), endometrial (39%), colorectal (9%), skin (17%), prostate (14%), breast 
(6%) and ovarian (4%) cancers, as documented by the Sanger Institute Catalogue of 
Somatic Mutations in Cancer (COSMIC) website 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=gene&ln=PTEN). PTEN 
inactivation has also been found to be due to epigenetic silencing, through promoter 
hypermethylation in a variety of cancers (Alvarez-Nunez et al., 2006; Garcia et al., 
2004; Goel et al., 2004; Ho et al., 2009; Salvesen et al., 2001). PTEN protein levels 
correlate with disease severity, suggesting that PTEN is functionally haploinsufficient 
(Alimonti et al., 2010; Salmena et al., 2008). A graphical representation of the 
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correlation between gradual PTEN loss, Akt signalling and disease phenotype in mice is 
depicted in figure 1.9. 
 
 
Figure 1.9. Correlation between PTEN loss, Akt signal intensity and incidence of 
the indicated phenotypes. Through the generation and characterisation of a PTENhy/+ 
mouse model, even a negligible decrease in PTEN expression is sufficient to promote 
cancer susceptibility in mice. Image and method source: (Alimonti et al., 2010)  
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 Heterozygous loss of PTEN in mice results in neoplasia of multiple epithelia, including 
the intestine, prostate, endometrium and mammary glands (Podsypanina et al., 1999) 
and homozygous deletion of PTEN leads to aggressive prostate carcinoma (Trotman et 
al., 2003; Wang et al., 2003). Furthermore, loss of PTEN expression in primary tumours 
is associated with higher Gleason scores, a measure of prognosis evaluation in men with 
prostate cancer, and an accumulation of PTEN mutations have been found in metastatic 
disease as well (Sansal and Sellers, 2004). Interestingly, while loss of PTEN is 
tumorigenic, it has not been clearly established if PTEN loss alone is sufficient to 
activate Akt. Studies have shown that RTK inhibitors can downregulate Akt, even when 
PTEN expression is lost, suggesting that loss of PTEN might not preclude the capacity 
of RTK inhibitors to shut down PI3K signalling (Stommel et al., 2007). However, it 
seems to reduce to likelihood of cancers responding to these inhibitors as single agent 
therapies (Berns et al., 2007; Bianco et al., 2003; Mellinghoff et al., 2005; Nagata et al., 
2004).  Lastly, PTEN also possesses protein phosphatase activity and plays a key role in 
autodephosphorylation-mediated regulation of its lipid phosphatase activity (Tibarewal 
et al., 2012). 
 
1.2.3.2 SHIP1/2 
SRC homology 2 (SH2)-containing inositol 5'-phosphatase 1 (SHIP1) and SHIP2 
proteins are negative regulators of the PI3K/Akt pathway. SHIP1/2 consists of an N-
terminal SH2 domain which binds to specific phosphotyrosine-containing sequences 
found in proteins such as SRC homology 2 domain-containing protein, a central 
catalytic phosphatase domain and a C-terminal proline-rich domain which is recognised 
by SH3-domain containing proteins. SHIP2 contain an additional C-terminal sterile α-
domain. The haematopoietic-restricted SHIP1 hydrolyses PIP3 to PI(3,4)P2. The SHIP1 
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homologue, SHIP2, is found more widely expressed in tissues, such as the heart, liver, 
skeletal muscles, and brain (Hamilton et al., 2011), and like SHIP1, dephosphorylates 
PIP3 to PI(3,4)P2 in vitro and in vivo (Kagawa et al., 2008; Pesesse et al., 1997; Wada et 
al., 2001). While PI(3,4)P2 can still act as a second messenger through affinity of Akt 
for PI(3,4)P2 (Klippel et al., 1997), SHIP1 dampens the PIP3 – mediated Akt signalling, 
and thus acts as a negative regulator of the PI3K pathway. SHIP1 is mutated or 
markedly reduced in many leukemias and lymphomas; cells from acute myeloid 
leukemia patients display down regulation of SHIP1 expression (Luo et al., 2003) and 
SHIP1 is also found truncated, or totally absent in T cells from patients with T acute 
lymphoblastic leukemia (Lo et al., 2009). Considering that SHIP1 inhibition promotes 
cancer cell growth, it has been described that oncogenic proteins, such as leukemia 
associated oncogene breakpoint cluster region-C-Abl oncogene, induce SHIP1 down-
regulation (Ruschmann et al., 2010; Sattler et al., 1999). The role of SHIP2 in tumour 
initiation is more ambiguous and laboratories have failed to identify SHIP2 as a tumour 
suppressor; however, the phosphatase may play a role in tumour progression (Prasad et 
al., 2008; Yamanaka et al., 2009).  
 
Knockout mouse models have revealed greater insight into the functional role of 
SHIP1/2. SHIP1 knockout mice remained viable and fertile, but with reduced lifespan 
due to myeloid infiltration (Liu et al., 1999), suggesting that modulation of PIP3 levels 
by SHIP1 negatively regulates cytokine-induced myeloid cells proliferation. SHIP1 
knockout also affected a variety of lymphocytes, including impaired B cell development 
and function (Helgason et al., 1998), defective natural killer cells (Wang et al., 2002) 
and reduced T-cells, along with their precursors (Collazo et al., 2009; Kashiwada et al., 
2006). While SHIP1 knockout results in impaired haematopoietic development, SHIP2 
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transgenic mice display markedly differing phenotypes due to different tissue-specific 
expression levels. Overexpression of SHIP2 in mice resulted in a reduction of Akt 
phosphorylation in liver, adipose tissue and skeletal muscles and as a consequence the 
mice developed insulin sensitivity and impaired glucose homeostasis (Kagawa et al., 
2008). By reducing the pool of PIP3, SHIP2 decreased Akt activation, glycogen 
synthesis (Sasaoka et al., 2001) and glucose uptake (Wada et al., 2001). SHIP2 is 
therefore considered a crucial negative regulator of glucose homeostasis. On the other 
hand, SHIP2 knockout mice generated in several studies have resulted in contradicting 
characteristics (Clement et al., 2001; Sleeman et al., 2005). Further studies will need to 
be conducted to clarify the role of SHIP2 in glucose homeostasis. 
 
1.2.3.3 Inositol polyphosphate 4-phosphatases  
Inositol polyphosphate 4-phosphatases are the only known PI(3,4)P2 phosphatases in 
mammalian cells and consists of two types: type I (INPP4A) and type II (INPP4B). 
Apart from PI(3,4)P2, INPP4A and INPP4B also hydrolyse the soluble inositol 
phosphates, inositol 1,3,4-trisphosphate (Ins(1,3,4)P3) and inositol 3,4-bisphosphate 
(Ins(3,4)P2), however the rate of hydrolysis is over 100-fold slower than hydrolysis of 
PIs (Norris and Majerus, 1994). Mammalian INPP4A and INPP4B share 37% amino 
acid sequence homology, as well as a core domain structure consisting of an N-terminal 
C2 lipid-binding domain, a largely uncharacterised central domain and a C-terminal 
dual phosphatase domain. The C2 lipid-binding domains of the 4-phosphatases are 
calcium-independent and interact with the membrane through electrostatic and PI 
interactions (Murray and Honig, 2002; Norris et al., 1997a; Norris and Majerus, 1994). 
While not much is known about the central domains of the 4-phosphatases, it has been 
proposed that these domains contain predicted PEST sequences, polypeptide sequences 
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enriched in amino acids proline (P), glutamic acid (E), serine (S), and threonine (T) 
which target proteins for rapid intracellular proteolysis (Norris et al., 1997b; 
Rechsteiner and Rogers, 1996). The greatest sequence similarity between the INPP4A 
and INPP4B is exhibited within their lipid phosphatase domain. This region contains 
the C(X)5R catalytic region, where X represents any amino acid. This domain is also 
found in PTEN, as well as other dual specificity protein phosphatases, which are 
capable of dephosphorylating both lipids and proteins. Splice variants of INPP4A and 
INPP4B have been identified consisting of an α and β form. INPP4Aα and INPP4Bα 
consist of a hydrophilic C-terminal region, whereas INPP4Aβ and INPP4Bβ consist of a 
hydrophobic C-terminal region (Norris et al., 1997a; Norris et al., 1995a); however, 
their individual functions remain unknown.  
 
INPP4A is predominantly expressed in brain, whereas INPP4B is found highly 
expressed in skeletal muscle, heart, brain, and pancreas, epithelial cells of the breast, 
and prostate glands. INPP4A is critical for neuronal function, and its loss results in 
neurodegeneration and early postnatal mortality (Nystuen et al., 2001; Sasaki et al., 
2010). However, limited evidence points to INPP4A and its role as a tumour suppressor. 
INPP4B, on the other hand, has been found to play a role in cancer development in a 
variety of different tissues and is the protein of interest for this study. 
 
INPP4B was initially isolated from rat brain and shown to be an enzyme that accounts 
for 4-phosphate activity present in rat tissue (Norris et al., 1997a; Norris et al., 1995b). 
The murine INPP4B locus was mapped on chromosome 8 in a synthetic synthesised 
region of the human 4q27-31 interval between the cytokine interleukin 15 gene and the 
ubiquitin specific peptidase 38 gene. The two murine isoforms of INPP4B, INPP4Bα 
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and INPP4Bβ, are encoded by this locus and are highly conserved; consensus 
phosphatase catalytic sites and conserved C2 domains share vast similarity with human 
and rat homologues with INPP4B C2 lipid-binding domains sharing more that 91% 
sequence homology (Ferron and Vacher, 2006). A novel shorter isoform of INPP4Bα 
has also been characterised resulting from an alternative translation initiation site and 
exon 5 skipping (Ferron and Vacher, 2006). The two isoforms have different expression 
patterns and cell localisations; INPP4Bα exhibits relatively ubiquitous expression with 
a wide tissue distribution and mainly a cytosolic subcellular localisation. In contrast, 
INPP4Bβ is mainly expressed in brain, heart, intestine, skeletal muscles and spleen 
tissue and is associated with the Golgi apparatus (Ferron and Vacher, 2006).  
 
1.2.3.3.1 INPP4B substrates 
The main substrate of INPP4B is PI(3,4)P2, which it dephosphorylates on the D4 
position generating PI(3)P. The murine C2 domain of INPP4B preferentially binds to 
phosphatidic acid and PIP3; however, INPP4B has been found to be able to 
dephosphorylate PIP3 in the context of bone morphogenesis (Ferron and Vacher, 2006). 
Gewinner et al. reported that INPP4B is solely able to dephosphorylate PI(3,4)P2 in 
vitro in mammary epithelial cells and overexpression of INPP4B depletes this 
phospholipid pool (Gewinner et al., 2009). The substrates of INPP4B also include the 
soluble inositol phosphates, Ins(1,3,4)P3 and inositol 3,4-bisphosphate; however, the 
rate of hydrolysis is over 120-fold and 900-fold slower than for the PI(3,4)P2, 
respectively (Norris et al., 1997a; Norris and Majerus, 1994). In osteoclasts, INPP4B 
was found to also dephosphorylate PI(4,5)P2 and the rate of hydrolysis for Ins(1,3,4)P3 
was approximately five times higher than for the PIs (Mathieu Ferron, 2011). 
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1.2.3.3.2 INPP4B in human diseases 
Studies conducted over the last few years have provided evidence linking INPP4B as a 
tumour suppressor gene in several epithelial cancers, including breast cancer, prostate 
cancer and melanoma (Agoulnik et al., 2011; Fedele et al., 2010; Gewinner et al., 2009; 
Hodgson et al., 2011; Kim et al., 2012; Perez-Lorenzo et al., 2013a). INPP4B has also 
been implicated as a tumour biomarker for radioresistance in laryngeal cancer (Kim et 
al., 2012) and loss of INPP4B is associated with squamous cell lung carcinoma 
(Magnussen A., 2011). Table 1.3 summarises INPP4B loss across several epithelial 
human cancers.  
 
The role of INPP4B in breast cancer is the most well established study amongst all the 
cancer sub-types. INPP4B expression in normal breast tissue correlates with oestrogen 
receptor (ER) expression. The protein is mostly located in the ducts and lobule 
epithelium, and primarily in ER positive and mostly non-proliferative cells (Fedele et 
al., 2010). INPP4B is frequently lost in the more aggressive subtypes of breast cancer, 
such as triple negative (ER negative, progesterone receptor negative and epidermal 
growth factor receptor ErbB/HER negative) and basal-like breast cancer (Fedele et al., 
2010). Genomic studies of INPP4B in breast cancer cell lines revealed over half of 
basal-like breast cancers exhibit loss of heterozygosity (LOH) of INPP4B, whilst only a 
small fraction of non-basal like cancers carry the same allelic loss. Furthermore, 
INPP4B LOH is detected in the 60% of BRCA1 mutant breast cancers (Gewinner et al., 
2009). Expression of INPP4B may therefore represent a breast cancer prognostic 
marker, since it is expressed in the luminal A ER-positive and low grade carcinomas, 
and correlates to better patient survival, while loss of expression is frequently found in 
the more aggressive breast cancer subtypes (Fedele et al., 2010; Gewinner et al., 2009). 
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Evidence for the role of ER in the regulation of INPP4B, however, remain rudimentary 
and contradictory; Transcription levels of INPP4B are not altered in response to 
oestradiol stimulation, nor does INPP4B expression affect ER levels in ER-positive and 
INPP4B-positive MCF-7 breast cancer cells (Fedele et al., 2010). In contrast, a gene 
array study of breast tumour xenografts has shown INPP4B transcription is enhanced 
following oestrogen receptor stimulation (Harvell et al., 2006). Further investigation 
will be required to clearly define the role of ER in INPP4B regulation. Loss of INPP4B 
in conjunction with loss of PTEN has also been observed in breast cancer; Gewinner et 
al. reported that loss of both INPP4B and PTEN resulted in cellular senescence in 
human mammary epithelial cells (HMECs) and Fedele et al. observed that INPP4B loss 
occurred more in PTEN-null breast cancers (Fedele et al., 2010; Gewinner et al., 2009).  
 
INPP4B has also been discovered as a tumour suppressor in prostate cancer. Analysis of 
the genome and transcriptome of 218 prostate cancer tumours revealed that 42% of 
primary prostate cancers and all metastatic prostate cancers exhibit aberrations in the 
PI3K/Akt pathway (Taylor et al., 2010). Interestingly, in the metastatic prostate cancer 
samples almost half of the samples had reduced INPP4B expression, to a similar extent 
as reduced of PTEN expression (Taylor et al., 2010). Hodgson et al. found that INPP4B 
is an androgen responsive gene, and androgen receptor (AR) activation results in an 
increase in INPP4B transcription in the LNCaP prostate cancer cell line (Hodgson et al., 
2011). In addition, PTEN did not demonstrate androgen-regulated expression. 
Androgen ablation therapies in the treatment of advanced prostate cancers are 
associated with increased Akt signalling (Wang et al., 2007). Since INPP4B is an 
androgen regulated tumour suppressor gene in prostate epithelium, INPP4B expression 
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levels should be assessed when considering androgen ablation therapies for advanced 
prostate cancer patients. 
 
INPP4B has also been implicated in other diseases. Kim et al. identified INPP4B as a 
novel tumour resistance biomarker in the Hep-2 human laryngeal cancer cell line. 
INPP4B was highly expressed in radioresistant Hep-2 cells and induced by treatment 
with radiation or other anti-cancer drugs in lung, colon and breast cancer cell lines (Kim 
et al., 2012). Furthermore, INPP4B induced expression by radiation was blocked by 
ERK inhibition, suggesting that ERK-dependent induction of INPP4B expression 
triggers development of a tumour-resistance phenotype via Akt signalling (Kim et al., 
2012). Thus, INPP4B is an important target molecule for the resolution of radio-
resistance in cancer cells. INPP4B has also been associated with lung squamous cell 
carcinoma, with one-fifth of 180 samples analysed showing a LOH of INPP4B, as well 
as almost half showing reduced levels or INPP4B protein expression (Magnussen A., 
2011; Stjernstrom et al., 2014). In addition, a decrease in INPP4B expression has been 
found to correlate with tumour progression in melanocytic neoplasm (Perez-Lorenzo et 
al., 2013b). Ferron et al. identified INPP4B as a major modulator of osteoclast 
differentiation and as a gene linked to variability of bone mineral density in mice and 
humans, providing evidence for INPP4B as a potential therapeutic target and biomarker 
for osteoclast defects and osteoporosis (Ferron et al., 2011). Finally, INPP4B 
aberrations have also been identified in ovarian cancer. High rates of copy number loss 
at the 4q31.1-3 locus was found in 39.8% of ovarian cancers (Etemadmoghadam et al., 
2009). Gewinner et al. observed that loss of INPP4B expression in ovarian cancer 
tissues correlated with decreased patient survival as well as increased lymph node 
metastasis (Figure 1.10). It is clear that loss of INPP4B plays an important role in 
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cancer through its association with tumourigenesis, poor survival, therapeutic resistance 
and aggressive sub-types across a broad spectrum of tissue types. Further investigation 
is warranted to address using INPP4B as a marker for designation of therapeutic 
strategies.   
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Table 1.3. INPP4B loss in different tumour types 
 
  
 
Tumour Type 
 
INPP4B Loss 
Breast, total (Richardson et al., 2006) 
Breast, BRCA1 mutant (Gewinner et al., 2009) 
Breast, basal-like (Fedele et al., 2010) 
Breast, basal-like (Weigman et al., 2011) 
32.6% - loss of heterozygosity 
60.0% - loss of heterozygosity 
8.0% - loss of expression 
40% - copy number variation 
Ovarian (Etemadmoghadam et al., 2009) 39.8% - copy number variation 
Melanoma (Lin et al., 2008) 21.6% - loss of heterozygosity 
Prostate, primary (Agoulnik et al., 2011; 
Taylor et al., 2010) 
Prostate, metastatic (Taylor et al., 2010) 
8.0% - loss of expression or mutation 
 
47.0%  - loss of expression or mutation 
Nasopharyngeal carcinoma (Yuen et al., 
2014) 
49.2% - loss of expression 
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Figure 1.10. INPP4B expression levels correlate with patient survival and 
metastasis in ovarian cancer. (A) Survival graph over time (in months) for ovarian 
cancer tissue stained for INPP4B expression. Black, blue and red lines indicate no, low 
and high INPP4B expression, respectively. Ovarian cancer patients with no INPP4B 
expression had poor overall survival compared to patients with low or high INPP4B 
expression (p<0.00001).  (B) INPP4B expression levels were investigated to assess 
correlation of lymph node metastasis in ovarian cancer tissues. Tissues that had no 
INPP4B expression exhibited more lymph node metastasis (9 samples, n=13), compared 
to tissues exhibiting low or high INPP4B expression (2 samples, n=6; 9 samples, n=31). 
Image source: (Gewinner et al., 2009)  
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1.3 DNA damage response 
Recently, more research on the PI3K/Akt pathway components and their relevance to 
genomic stability has been conducted. Hyperactivation of Akt was found to lead to cell 
cycle checkpoint progression aberrations and overexpression of Akt1 was found to 
promote genome instability through repression of HR (Plo et al., 2008b; Puc et al., 
2005). Genomic instability is recognised as a characteristic of most solid tumours and 
adult onset leukaemias, and ranges from obvious chromosomal changes of DNA copy 
number and structure alterations, to the more conspicuous DNA structure aberrations, 
such as nucleotide substitutions, insertions and deletions. These genetic mutations have 
a resulting effect on tumourigenesis, tumour development and cellular behaviour. 
Importantly, these mutations also influence how the tumour will respond to therapy.  
 
Genomic integrity maintenance is controlled by the DNA damage response (DDR) 
network, an elaborate signal transduction system which senses DNA damage and 
recruits the appropriate repair factors. With the integrity of DNA being continually 
challenged both endogenously and exogenously, this extensive signalling network has 
evolved to sense different types of damage and co-ordinate a response that includes 
activation of transcription, cell cycle control, apoptosis, senescence, and DNA repair 
processes (Figure 1.11). ‘Sensor proteins’ respond to genotoxic stress and activate a 
collection of protein kinases, which co-ordinate a signalling cascade by targeting 
several substrates that regulate the function of downstream effectors. At the core of the 
DDR pathway abide the related protein kinases, ATM and ATR, which act as DNA 
damage sensors and are activated by DNA damage. ATM and its regulator, the MRE11-
Rad50-NBS1 (MRN) complex, sense double-strand breaks (DSBs). ATR and its 
regulator ATR-interacting protein (ATRIP) sense single-strand breaks (SSBs), which 
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can be generated by the processing of DSBs, as well as SSBs present at stalled 
replication forks. Both kinases then phosphorylate a plethora of downstream proteins to 
initiate a signalling cascade that includes many common substrates and further amplify 
the signal. Two key proteins involved in the downstream signalling cascade are 
checkpoint kinase 1 and 2 (Chk1 and Chk2), two important kinases which when 
activated, delay cell cycle progression to facilitate DNA repair or eliminate hazardous 
damaged cells depending on the extent of the DNA damage. The next sections will 
discuss sources of DNA damage and the variety of DNA mechanisms established to 
counter genetic insults.  
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Figure 1.11. Forms of DNA damage and associated DNA damage response (DDR) 
pathways. Through both endogenous and exogenous sources, DNA is constantly being 
damaged resulting in a variety of lesions being formed, including SSBs, DSBs, bulky 
adducts, base mismatches/insertions/deletions and base alkylation. Upon DNA damage, 
various DNA repair mechanisms are implemented according to the particular insult 
encountered. The cell cycle stage also determines what type of DNA repair mechanism 
is used. Key proteins involved in each DDR mechanism are shown above, as well as the 
tumour types associated with DDR defects and the drugs that target these defects. BER 
– base excision repair; NER – nucleotide excision repair; NHEJ – non homologous end 
joining. Image source: (Lord and Ashworth, 2012). 
  
 66 
1.3.1 Sources of DNA damage 
In order to maintain genomic integrity, DNA must be protected from DNA damage 
induced by environmental agents or spontaneously generated. Spontaneous DNA 
alterations can occur due to deoxyribonucleotide triphosphates (dNTP) 
misincorporation during DNA replication, interconversion between DNA bases caused 
by deamination, loss of DNA bases following DNA depurination and modification of 
DNA bases by alkylation. In addition, oxidation of DNA bases and DNA breaks by 
reactive oxygen species (ROS) can be generated by normal cellular metabolism. In 
total, it has been estimated that a cell may experience up to 105 spontaneous DNA 
lesions per day (Hoeijmakers, 2009). DNA damage can also be generated by 
environmental agents and can be produced by physical or chemical sources. Ionising 
radiation (IR) and ultraviolet (UV) light from sunlight can induce up to 105 DNA 
lesions per cell per day. IR from cosmic radiation or medical equipment generating X-
ray or radiotherapy can induce oxidation of DNA bases and DNA breaks.  
 
1.3.2 Base excision repair  
Subtle base changes to DNA through oxidative lesions, alkylation products, and 
deamination are repaired by base excision repair (BER). The essence of core base 
excision repair requires the function of four proteins: a DNA glycosylase, an AP 
endonuclease, a DNA polymerase, and a DNA ligase. All of these proteins co-operate 
together to remove a damaged DNA base and replace it with the correct base. Two 
forms of BER have been found, short-patch BER and long-patch BER, and varying 
combinations of enzymes work in concert to repair DNA damage, depending on the 
type of BER implemented. The decision to proceed via the long-patch or short-patch 
BER mechanism, however, is poorly understood. Usually, the damaged base is 
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recognised by a DNA glycosylase. After recognition this glycosylase catalyses the 
cleavage of an N-glycosidic bond, effectively removing the damaged base and creating 
an apurinic or apyrimidinic site (AP site). The AP endonuclease creates a single-
stranded DNA nick 5’ to the AP site. In short-patch BER, X-ray repair cross-
complementing protein (XRCC) family member 1 (XRCC1) is recruited to the nick 
generated by the action of a glycosylase and/or AP endonuclease, functioning as a 
scaffolding protein. The AP endonuclease further processes the nick, creating a single-
nucleotide gap in the DNA and DNA polymerase fills in the gap with the correct 
nucleotide. Finally, a DNA ligase seals the nick and completes the repair process. BER 
is depicted in figure 1.12. 
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Figure 1.12. Base excision repair. DNA damage results in several proteins being 
recruited for base excision repair. The grey, blue, yellow and pink proteins represent 
DNA glycosylases, endonucleases, DNA polymerases and DNA ligases, respectively. 
Proteins indicated in purple font represent protein interactions involved in long patch 
BER. Image source: (Robertson et al., 2009) 
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1.3.3 Nucleotide excision repair  
Nucleotide excision repair (NER) recognises and repairs DNA lesions that are caused 
by chemicals, which covalently bind to a DNA base and form a bulky adduct and distort 
the DNA helix. Compounds which produce such lesions include chemicals typically 
present in the environment in a relatively harmless form, such as nitrosamine found in 
latex and food and benzopyrenes from cigarette smoke (Wogan et al., 2004) and cross-
linking agents, which have the ability to form two distinct covalent bonds with DNA, by 
intrastrand or interstrand crosslinks (Trimmer and Essigmann, 1999). The latter 
crosslink tends to be the more toxic lesion due to both strands being damaged. 
Detection of the structure distortion of DNA caused by the bulky adducts is conducted 
by sensor complex xeroderma pigmentosum (XP) group C (XPC) protein complex 
(XPC-HR23B-Cen2). Smaller distortions are recognised by the damaged DNA binding 
complex (DBB). Transcription factor II human opens a denaturation bubble of 
approximately thirty nucleotides around the lesion. The resulting exposed single strand 
DNA is then bound by replication protein A (RPA). XPG incises the damaged strand 3’ 
of the lesion and the excision repair cross complementation group 1/xeroderma 
pigmentosum group F complex (ERCC1-XPF) incises the damaged strand at the 5’ end. 
The resulting gap is filled by DNA polymerase delta/epsilon (pol δ/ε). Finally, the nick 
is sealed by ligase (LIG) family member 3 (LIG3), with the minority of nicks sealed by 
LIG1 in replicating cells (Nouspikel, 2009). Since NER requires an intact strand to 
serve as a template to repair the other, interstrand crosslinks repair requires a 
combination of NER with other DNA repair mechanisms, such as HR. NER is depicted 
in figure 1.13. 
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Figure 1.13. Nucleotide excision repair. (A) DNA distortion is detected by protein 
sensor complex XPC-HR23B-Cen2. (B) DNA lesions with small distortions are 
detected by the DDB complex, which results in ubiquitination of XPC and XPE. (C) 
Ubiquitation of XPC leads to increased affinity for DNA, whereas ubiquitation of XPE 
results in its degradation. (D) Transcription factor II human (TFIIH) opens up a 
nucleotide bubble of approximately 30 nucleotides around the lesion. (E) The XPA-
RPA complex displaces the XPC complex and RPA binds to the single stranded DNA. 
(F) XPG removes the damaged strand 3’ of the lesion; ERCC1-XPF removes the 
damaged strand 5’  of the lesion. (G) The resulting gap is replaced by DNA 
polymerase ∂ or ε. (H) The nick is sealed by LIG3 or LIG1 in replicating cells. Image 
source: (Nouspikel, 2009) 
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1.3.4 Mismatch repair  
Mismatch repair (MMR) substitutes bases that are incorrectly incorporated during DNA 
replication, thereby preventing mutations from becoming permanent in dividing cells. 
Defects in MMR result in a higher spontaneous mutation rate and inactivation of MMR 
is associated with hereditary and spontaneous cancers (Modrich and Lahue, 1996). 
Initially studied in Escherichia coli (E. coli), understanding of MMR in eukaryotes has 
been built upon the framework derived from prokaryotic observations. Key to the 
process of MMR are proteins encoded by the human homologues of E. coli proteins, 
mutS and mutL. Human mutS homolog 2 (hMSH2) heterodimerises with hMSH6 or 
hMSH3 to form hMutSα or hMutSβ, respectively, and initiates repair. hMutSα 
preferentially recognises mismatches of 1 or 2 nucleotides, while hMutSβ preferentially 
recognises larger insertion/deletion mispairs. Proliferating cell nuclear antigen (PCNA) 
and exonuclease 1 (EXO1) remove a patch of nascent DNA, including the 
misincorporated nucleotide, in a bi-directional manner. The excision gap is filled by 
high-fidelity DNA synthesis by pol δ and PCNA and LIG1 subsequently restores strand 
continuity. Defects in MMR have been associated with resistance to many DNA 
damaging anticancer therapeutic agents, such as cisplatin and the antimetabolite 6-
thioguanine (Karran and Marinus, 1982). MMR is depicted in figure 1.14. 
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Figure 1.14. Mismatch repair. Depending on where a nick is made relative to the 
mismatch determines what kind of repair is conducted. A nick introduced at the outer 
strand either the 3’ (A) or 5’ (B) end of the mismatch results in a G/T to A/T repair. An 
inner strand nick, however, results in the repair of G/T to G/C. (A) A nick in the 3’ end 
of the mismatch on the outer ring results in the MutSα/MutLα heterodimer complex 
binding to the mismatch and translocating along the DNA strand until it encounters 
PCNA bound at the 3’ end of the nick. Additional nicks are introduced by the ternary 
structure, where EXO1 is loaded, generating a long single stranded gap. The gap is 
filled by the PCNA/pol δ complex and the nick is sealed by a DNA ligase. (B) A 5’ nick 
relative to the mismatch allows the MutSα/MulLα complex to load EXO1 directly at 
the nick. The strand is degraded and the gap filled by the PCNA/pol δ complex. Image 
source: (Pena-Diaz and Jiricny, 2012) 
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1.3.5 Double strand break repair 
DSBs are the most dangerous and life-threatening lesions whose repair is initiated by 
several DNA repair pathway mechanisms. Two main pathways are used for DSB repair: 
homologous recombination (HR) and non-homologous end joining (NHEJ). HR is 
primarily induced in the S and G2 phases of the cell cycle, when sister chromatids can 
be used as a template for HR (You and Bailis, 2010) resulting in error-free repair. On 
the other hand, NHEJ does not require the presence of a homologous DNA strand and is 
therefore more error prone. Failure to repair DSBs can result in chromosome loss, 
chromosomal rearrangements, apoptosis, or carcinogenesis (Hoeijmakers, 2001). 
 
1.3.5.1 Classical Non homologous end joining 
NHEJ repairs DSBs by rejoining the DNA ends without requiring sequence homologies, 
and thus is recognized as having a high potential for error. The repair mechanism 
proceeds by three steps: recognition of the break, DNA processing to remove non-
ligatable ends and damaged DNA ends, and ligation of the DNA ends. DSBs are rapidly 
bound by the Ku heterodimer Ku70/Ku80, which loads onto the DSB ends by its 
toroidal structure (Mahaney et al., 2009). The Ku heterodimer acts as a scaffold for the 
association of the catalytic subunit of DNA dependent protein kinase (DNA-PKcs), 
recruiting the kinase to the DNA ends and activating it (Meek et al., 2008). While 
DNA-PKcs has several targets, the most extensively studied target is DNA-PKcs itself. 
There are currently 16 amino acid residues identified within the DNA-PKcs protein that 
can be autophosphorylated, and mutations of several of these autophosphorylation sites 
have resulted in diminished DNA repair and sensitivity of cells to IR (Chan et al., 
2002a; Ding et al., 2003). Once bound to the DSB, autophosphorylation of DNA-PKcs 
on the six residue ABCDE cluster results in the destabilisation of the DNA-PKcs 
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interaction with the DNA ends, providing access for processing enzymes. ATM can also 
induce ABCDE DNA-PKcs autophosphorylation, which has been shown to facilitate 
access of DNA ends to DSB resecting enzymes in order to promote HR when NHEJ 
fails (Shrivastav et al., 2008). Excessive processing is prevented by DNA-PKcs 
autophosphorylation, on the five-residue PQR cluster, which helps protect DNA ends 
(Meek et al., 2008). After DNA-PKcs is loaded, the XRCC4/LIG4 DNA repair complex 
is recruited and promotes the religation of the broken ends with the help of stimulatory 
factor XRCC4-like factor (XLF) (Mahaney et al., 2009). Nucleases ARTEMIS and 
aprataxin and PNKP like factor (APLF), as well as polynucleotide kinases (PNK), 
process DNA termini that contain non-ligatable end groups prior to DNA ligation 
(Mahaney et al., 2009). ARTEMIS and APLF are phosphorylated in an ATM-dependent 
manner (Macrae et al., 2008; Zhang et al., 2004). NHEJ is depicted in figure 1.15. 
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Figure 1.15. Non homologous end joining repair. The Ku 70/80 heterodimer rapidly 
binds to the DSB and recruits DNA-PKcs to the site of damage, where it provides 
access for enzymes to process DNA ends. The XRCC4/LIG4 complex ligates the DNA 
ends. Image source: (Weterings and Chen, 2008) 
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1.3.5.2 Homologous Recombination  
HR comprises a series of events that use DNA strand invasion and template-directed 
DNA repair synthesis, culminating in high fidelity, error-free repair. Due to HR 
requiring a sister chromatid, this mechanism of repair is restricted to the S and G2 
phases of the cell cycle, where chromatids exist in duplicate. Recognition of the DSBs 
by the MRN complex promotes activation of ATM and preparation of DNA for HR, 
through a process known as DNA resection. Resection is mediated in part by direct 
phosphorylation of CtBP-interacting protein (CtIP), which promotes resection in 
collaboration with the MRN complex (Yun and Hiom, 2009). Nucleolytic degradation 
of the 5’ strand leaves a long 3’ single-stranded DNA (ssDNA) overhang. The ssDNA 
is initially bound by RPA, which displays higher affinity and specificity for ssDNA than 
Rad51 (Wold, 1997). RAD51, the key protein in HR which catalyses homology search 
and DNA strand exchange, displaces RPA to yield the presynaptic filament. 
Recombination mediators such as BRCA2, human homologue of RAD52 XRCC2, and 
XRCC3 interact with RAD51 to aid in this process. Purification of full-length BRCA2 
by Jensen et al. shows that BRCA2 both binds RAD51 and potentiates recombinational 
DNA repair by promoting assembly of RAD51 onto ssDNA (Jensen et al., 2010). 
RAD51 associated protein 1 (RAD51AP1) and partner and localiser of BRCA2 
(PALB2) promotes the invasion of the presynaptic filament to pair with the homologous 
double stranded DNA (dsDNA), forming the D-loop. DNA synthesis extends the D-
loop. BRCA1 is an important protein involved in DNA repair and a large body of 
evidence supports a direct role of BRCA1 in HR. In mouse embryonic stem cell lines, 
BRCA1 has been found to associate and co-localise with RAD51 in nuclear foci, and, 
accordingly, BRCA1 is required for their formation (Bhattacharyya et al., 2000; Scully 
et al., 1997). Furthermore, recruitment of BRCA1 has been found at sites of DNA 
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damage induced by IR, and is required for efficient generation of ssDNA (Schlegel et 
al., 2006). BRCA1 has also been shown to be required for the activation of cell cycle 
arrest after DNA damage (Xu et al., 2001). It has been suggested that part of the 
function of BRCA1 is recruitment of BRCA2 and the HR machinery through its 
interaction with PALB2 (Zhang et al., 2009a; Zhang et al., 2009b). From here HR can 
be split into 3 distinct sub-pathways: Synthesis dependent strand annealing (SDSA), 
double-strand break repair (DSBR), and double Holliday junction (dHJ) dissolution. In 
SDSA, the structure can be dismantled by Fanconi Anemia, Complementation (FANC) 
Group M (FANCM), leading to a non-crossover repair outcome. Alternatively, a second 
event of invasion occurs by engaging the second end of the DSB to the template strand, 
forming a dHJ. DSBR resolves the dHJ by specialised nucleases termed resolvases, 
yielding crossover and non-crossover products. In dHJ dissolution, these junctions are 
dissolved by the helicase-topoisomerase complex BLM-Topo IIIα-RMI1-RMI2 to yield 
non-crossover products. The pathway is depicted in figure 1.16. 
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Figure 1.16. Homologous recombination pathways. Three distinct HR pathways are 
depicted: Synthesis dependent strand annealing (SDSA), double-strand break repair 
(DSBR), and double Holliday junction (dHJ) dissolution. Saccharomyces cerevisiae and 
human proteins (underlined) involved are indicated above. Source: (Daley et al., 2013; 
Wold, 1997)  
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1.3.6 DNA damage sensing 
The DDR pathway consists of a complex interwoven signalling network, and at the core 
of DDR are the ATM and ATR kinases. Signal sensors recognise aberrant DNA 
structures associated with DNA damage as well as replication stress and activate 
transducers which include ATM, ATR and their downstream kinases. The effectors of 
these kinases then regulate a number of cellular processes required to maintain genomic 
integrity. This DDR framework is depicted in figure 1.17. ATM and ATR, as well as 
DNA-PKcs, belong to a family of phosphatidylinositol 3-kinase related kinases 
(PIKKs). While ATM and ATR phosphorylate hundreds of proteins in response to DNA 
damage, DNA-PKcs regulate a smaller number of targets and chiefly plays a role in 
NHEJ. Studies have shown that ATM and ATR responses have distinct functions. 
ATM, in conjunction with the MRN sensor complex, primarily responds to DSBs 
generated by radiation and genotoxins, but only weakly by agents that block DNA 
replication without inducing damage (Matsuoka et al., 2000). ATR, on the other hand, is 
activated when DNA replication is impeded, such as through replication fork stalling or 
damage through UV and other replication-associated genotoxins. In addition, ATR is 
activated through processing of DSBs, as well as in NER.   
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Figure 1.17. The DNA damage response network. Upon DNA damage, kinases ATM 
and ATR are recruited to the site of damage via sensor proteins, where they 
phosphorylate downstream kinases, scaffolding proteins and regulatory proteins. This 
leads to further activation of effector proteins which regulate cell cycle components, 
transcription factors and DNA repair proteins, resulting in a response of cellular 
apoptosis, cell cycle arrest, of DNA repair, depending on the extent of DNA damage. 
Image source: (Furgason and Bahassi el, 2013) 
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1.3.6.1 ATM and DNA damage sensing  
In undamaged cells, ATM is thought to exist as an inactive homodimer. Upon DNA 
damage, inactive ATM homodimers are induced to autophosphorylate in trans, and 
result in the dissociation of the dimers to partially active monomers (Bakkenist and 
Kastan, 2003). While the primary signal that induces autophosphorylation of ATM is 
unknown, it does not appear to be linked to the vicinity of the damage and may be 
linked to long range alterations in the chromatin structure (Bakkenist and Kastan, 2003). 
Autophosphorylation sites S1981, S367 and S1893 have been linked with the activation 
of ATM, as well as the acetylation by TIP60 acetyl-transferase (Lavin and Kozlov, 
2007). Upon DNA damage, the MRN complex is recruited to sites of damage and binds 
to the DSB ends. While the mechanism of the MRN complex in ATM activation in a 
DSB – dependent manner is not fully understood, MRN is required for localisation and 
activation of ATM to DSBs and MRN is therefore suggested to play the role as a sensor 
protein for ATM activation (Lee and Paull, 2005; Uziel et al., 2003). Once activated, 
ATM regulates a number of events on the chromatin flanking the DSB, the key event 
being phosphorylation of histone family H2A, member X (H2AX). Phosphorylation of 
H2AX (known as γH2AX) takes place minutes after DNA damage and spans chromatin 
domains larger than 500 kb which flank the site of damage. This allows for an 
accumulation of DNA repair proteins and chromatin-remodeling complexes to form 
around the DSBs. ATM also aids in the propagation of the H2AX phosphorylation via 
its interaction with mediator of DNA-damage checkpoint 1 (MDC1). MDC1 binds to 
γH2AX via its BRCA1 C-terminus domain, as this binding is required for full-sized 
γH2AX foci formation (Stewart et al., 2003). MDC1 can also directly bind to ATM via 
its forkhead-associated (FHA) domain, and indirectly through binding to nibrin (NBS1), 
which is part of the MRN complex, and this binding enables MDC1 to recruit ATM to 
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the nucleosomes containing γH2AX and propagate H2AX phosphorylation along 
chromatin. Interestingly, whereas MDC1 is important for the spreading of ATM on 
chromatin near DSBs, studies with mouse cells suggest that ATM is also able to 
phosphorylate H2AX on chromatin distal to DSBs in the absence of MDC1 (Savic et 
al., 2009). How ATM reaches and acts on chromatin distal from DSBs remains to be 
elucidated. Recruitment of ATM to γH2AX has also been associated with Tip60 
acetyltransferase, although in depth studies have yet to be conducted (Sun et al., 2009). 
Phosphorylation of H2AX by ATM results in a series of ubiquitination and 
SUMOylation reactions which promote the recruitment of BRCA1 and p53-binding 
protein 1 (53BP1). ATM activation is depicted in figure 1.18.  
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Figure 1.18. Activation of ATM by DSBs. (A) ATM recognises DNA ends, and is 
recruited to the site of damage. MRN functions as a sensor of strand breaks and 
activated ATM via phosphorylation. ATM in turn activates substrates such as H2AX in 
flanking nucleosomes, as well as p53 and Chk2. MDC1 recognises γH2AX and further 
activates ATM, propagating H2AX phosphorylation along large chromatin domains. 
(B) Phosphorylated MDC1 also recruits E3 ligase ring finger protein (RNF) family 
member 8 (RNF8) to the DSB, which in turn promotes another E3 ligate RNF168 to 
ubiquitinate substrates including H2A and H2AX. RNF168 extends the ubiquitin chains 
on the substrate and RAP80 recognises the ubiquitin chains, and forms a complex with 
BRCA1 through Abraxas. RNF168 also promotes the recruitment of 53BP1, which bind 
to the dimethylated lysine 20 of histone H4 exposed around the DSBs. The co-
ordination of the recruitment of BRCA1 and 53BP1, which act to promote and 
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antagonise HR respectively, remains unknown. Dashed green and black lines represent 
phosphorylation and ubiquitination events, respectively. Image source: (Marechal and 
Zou, 2013) 
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1.3.6.2 ATM to ATR switch at DNA breaks 
A study conducted by Shiotani and Zou found that ATR activation results in an 
attenuation of ATM activation and subsequently revealed an ATM-ATR switch in 
response to DSB (Shiotani and Zou, 2009). Processing of DSBs in HR results in the 
generation of RPA-coated ssDNA strands by DNA resection, to which ATRIP binds to 
in a complex containing ATR and ATRIP, leading to a series of processes that activate 
ATR fully (figure 1.19). As ssDNA lengthens, the DDR response to DSB ends changes 
from an ATM-driven response to ATR activation. This suggests the ssDNA is the key 
structure that recruits ATR and elicits a response upon DNA damage. The RPA and 
ssDNA binding also promotes the recruitment of the Rad17-Rfc2-5 complex which act 
as clamp loaders in the junction between ssDNA and dsDNA, and the loading of the 9-
1-1 checkpoint clamps onto the dsDNA. Topoisomerase (DNA) II binding protein 1 
(TOPBP1) is recruited to the dsDNA by way of the association of phosphorylated Rad9 
and Rhino with the 9-1-1 complex, and stimulates ATR-ATRIP to its full capacity, 
leading to phosphorylation of other targets by ATR (Delacroix et al., 2007). CtIP has 
also been implicated in this process by promoting DNA end resection, and the ensuing 
ATR activation (Sartori et al., 2007). 
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Figure 1.19. ATR activation via DSB resection. (1) RPA binding to ssDNA promotes 
ATR-ATRIP binding to RPA. (2) ATR is auto-transphosphorylated. (3) The rad17-rfc2-
5 complex binds as a clamp loader to junctions between ssDNA and dsDNA. The 9-1-1 
complex acts as a clamp and binds onto the dsDNA. (4) TOPBP1 interacts with 
phosphorylated rad9 and rhino, which binds to the 9-1-1 complex. (5) TOPBP1 engages 
with the ATR-ATRIP complex via autophosphorylation of ATR and enables TOPBP1 
to stimulate ATR-ATRIP to its full capacity, resulting in the phosphorylation of targets 
downstream of ATR. Image source: (Marechal and Zou, 2013) 
  
 87 
1.3.6.3 Activation of the ATM-Chk2 and ATR-Chk1 DNA pathways  
One of the key substrates of ATM and ATR are the serine-threonine checkpoint kinases, 
Chk1 and Chk2, which are selectively phosphorylated and activated to trigger a wide 
range of downstream responses to DNA damage (figure 1.20.). ATM phosphorylates 
Chk2, whereas ATR phosphorylates Chk1. ATM phosphorylates Chk2 on T68 located 
within an N-terminal serine/threonine-glutamine (SQ/TQ) rich motif (Ahn et al., 2000). 
The SQ/TQ motif of Chk2 is then recognised by the FHA domain of another Chk2 
molecule and transient homodimerisation occurs followed by intermolecular activation 
loop autophosphorylation and full activation of Chk2 (Ahn et al., 2002; Oliver et al., 
2006). Chk2 is then thought to dissociate from sites of DNA damage and disperse 
throughout the nucleus to act on substrates involved in cell cycle progression, apoptosis 
and gene transcription (Lukas et al., 2003). Substrates of Chk2 include p53, double 
minute 4 protein, cell division cycle 25 (CDC25) family phosphatases, BRCA1 and 
transcription factors forkhead box M1 and E2F1 (Smith et al., 2010).  
 
The phosphorylation of Chk1 by ATR is dependent on the claspin mediator protein. 
Claspin is subjected to ATR-dependent phosphorylation, and once modified, binds 
Chk1 (Kumagai and Dunphy, 2003). Two additional mediators, timeless and timeless-
interacting protein have been associated with normal replication as well as ATR-Chk1 
activation in response to replication stress (Kondratov and Antoch, 2007). 
Phosphorylated claspin recruits Chk1 to ssDNA bringing it into close proximity with 
ATR, thus enabling ATR to phosphorylate Chk1 directly at multiple SQ/TQ sites within 
the C-regulatory domain, such as S317 and S345 (Kumagai and Dunphy, 2003). 
Phosphorylation of these sites plays an essential role in Chk1 activity, although the 
mechanisms for this regulation remain poorly understood (Niida et al., 2007; Walker et 
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al., 2009). Chk1 has been reported to also undergo autophosphorylation during 
activation, however the significance of this modification has yet to be clearly 
established (Kumagai et al., 2004). Once activated, Chk1 is thought to dissociate from 
claspin to act on nuclear and cytoplasmic substrates (Lukas et al., 2003). Chk1-mediated 
regulation includes degradation of CDC25A and CDC25C phosphatases, stimulation of 
wee1 kinase activity, modulation of RAD51 and BRCA2, and repression of gene 
transcription through phosphorylation of histone H3 (Bahassi et al., 2008; Blasina et al., 
1999; Falck et al., 2002; Lee et al., 2001; Shimada et al., 2008; Sorensen et al., 2005).  
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Figure 1.20. Activation of ATM-Chk2 and ATR-Chk1 pathways. ATM and ATR 
are activated by DSBs and RPA bound ssDNA, respectively. ATM, along with the 
MRN sensor complex, activates numerous proteins in response to DSBs, including 
Chk2. Activation of ATR results in the phosphorylation of Chk1, among other 
substrates. The two checkpoint kinases then activate multiple DNA damage and 
replication checkpoint responses. Phosphorylation events are depicted by ‘P’ in orange 
and acetylation events by ‘Ac’ in yellow. Image source: (Smith et al., 2010) 
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1.3.6.4 ATM/ATR activation and the cell cycle 
One of the downstream signalling events that occur upon ATM/ATR activation due to 
DNA damage is the inhibition of cell cycle progression, to permit time for DNA repair 
or eliminate damaged cells through apoptosis. Deregulation of signals that regulate cell 
cycle progression can lead to constitutive mitogenic signalling as well as a resistance 
towards anti-mitogenic signalling, and consequently cells acquire sustained proliferative 
signalling, a hallmark of cancer (Hanahan and Weinberg, 2011). Furthermore, most 
tumour cells possess genomic instability, which further contributes to the accumulation 
of mutations and development of more aggressive phenotypes.  
 
The cell cycle can be divided into four stages (figure 1.21). The S phase is where DNA 
replication occurs and the M phase is where the cell divides into two daughter cells in a 
process known as mitosis. Separating these two important phases are the G1 and G2 
phases. The G1 phase occurs after the M phase and is a stage where the cell is sensitive 
to positive and negative regulatory growth signals. The G2 phase occurs after the S 
phase and is a time where the cell prepares for entry into mitosis. A fifth state exists 
called the G0 phase, where the cell has reversibly withdrawn from the cell cycle due to 
mitogen deprivation or high cell density (Zetterberg and Larsson, 1985). Progression 
through the cell cycle is controlled by the cyclin-dependent kinase (CDK) family of 
serine/threonine kinases, and their cyclin regulatory subunits and is marked by sensor 
mechanisms, called checkpoints, which maintain the correct order of events. CDK 
activity requires binding of cyclins, which are synthesised and destroyed at specific 
times during the cell cycle, thus regulating kinase activity temporally. Only a certain 
subset of CDK – cyclin complexes is directly involved in regulation of the cell cycle. 
They include three interphase CDKs (CDK2, CDK4 and CDK6), a mitotic CDK 
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(CDK1) and ten cyclins that belong to four different classes (the A-, B-, D- and E-type 
cyclins). Cyclin D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 drive G1 progression 
through the restriction point, which is the point at which the cell is committed to 
complete the cycle (Planas-Silva and Weinberg, 1997). S phase is initiated by cyclin A-
CDK2, and cyclin B-CDK1 regulates progression through G2 and entry into mitosis 
(Nigg, 2001). Tumour associated mutations frequently deregulate CDK-cyclin 
complexes, resulting in either sustained proliferation or unscheduled re-entry into the 
cell cycle, two properties characteristic of cancer (Hanahan and Weinberg, 2011). 
 
If the sensor mechanisms detect aberrant cell cycle progression, such as detection of 
DNA damage, checkpoint pathways carry the signal to effectors that can trigger cell 
cycle arrest until the problem is resolved through modulation of CDK activity. CDK 
activity is regulated by two families of inhibitors: INK4 proteins, 
including INK4A, INK4B, INK4C and INK4D, and the Cip and Kip family, composed 
of p21, p27 and p57. Cell cycle arrest allows for the repair of defects or elimination of 
the defective cell, thus preventing transmission of mutations to the daughter cells. 
Accumulation of DNA mutations may promote genomic instability and lead to cellular 
transformation and oncogenesis. For example, G1 arrest can be induced through the 
action of the INK4, which inhibit CDK4 and CDK6, or, alternatively, via the Cip/Kip 
family of inhibitors, which suppress CDK2 activity.   
 92 
 
Figure 1.21. Cell cycle regulation. The cell cycle depicted here in the middle can be 
divided into four phases: G1, S, G2 and M. A fifth phase known as G0 represents cells 
in quiescence. CDKs drive the cell out of quiescence (G0), resulting in the cell being 
irreversibly committed to S phase transition. Various cyclin-dependent kinases (CDKs) 
act in concert to regulate cell cycle progression, as well as modulate the activities of 
other cell-cycle-related kinases. The DNA-damage checkpoint kinases Chk1 and Chk2 
can induce cell cycle arrest upon DNA damage in the transition between G1/S and 
G2/M, respectively. Cancers associated with genetic alteration of specific kinases are 
indicated in blue boxes. BUB1, budding uninhibited by benzimidazoles 1; BUB1B, 
BUB1 homologue beta (also known as BUBR1); MPS1, monopolar spindle 1; MVA, 
mosaic variegated aneuploidy; PCSS, premature chromatid separation syndrome; RB, 
retinoblastoma protein family members. Image source: (Lapenna and Giordano, 2009) 
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Multiple checkpoints exist to evoke multiple responses upon DNA damage (figure 
1.22). DNA damage induces cell cycle delays at the G1/S and G2/M transitions (known 
as the G1 and G2 checkpoints), as well as a reduction in the rate of DNA synthesis 
(known as the intra-S checkpoint). The G1 checkpoint is predominantly regulated by the 
tumour suppressor p53 through its activation of the cyclin-dependent kinase inhibitor 
p21CIP1 (Kastan and Bartek, 2004). The G2 checkpoint, on the other hand, is regulated 
by blocking the activation of the mitotic CDK1-cyclin B complex (O'Connell et al., 
2000). Inhibition of the CDC25 family phosphatases results in the prevention of the 
removal of inhibitory threonine 14/tyrosine 15 phosphorylation of CDK1 (Boutros et 
al., 2007). The intra-S checkpoint involves active replication fork slowing and 
suppression of replication origin firing; however, the molecular mechanism for these 
responses is less clearly defined (Grallert and Boye, 2008; Seiler et al., 2007). 
Aberrations in DNA synthesis result in a replication checkpoint response that stabilise 
stalled replication forks and prevents formation of new forks by the suppression of late 
replication origin firing (Branzei and Foiani, 2009). In addition, the S-M checkpoint is 
implemented which delays mitosis until replication is complete, most likely through 
maintenance of inhibitory phosphorylation of CDK1 (O'Connell et al., 2000). 
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Figure 1.22. DNA damage and replication checkpoints induced upon DNA damage 
and DNA synthesis inhibition. In response to DNA damage the entry to S-phase is 
delayed, DNA replication is slowed, and entry to mitosis is prevented through 
implementation of the G1, intra-S and G2 checkpoints, respectively. Inhibition of DNA 
synthesis results in the activation of replication checkpoints, which stabilise stalled 
replication forks, suppress the late replication origin firing and enable mitotic delay 
until DNA replication is complete. Image source: (Smith et al., 2010) 
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1.3.6.5 ATM-Chk2 and ATM-Chk1 pathways and cancer 
Alterations of DDR pathway components result in inherited human cancer 
predispositions syndromes as well as genomic instability through sporadic mutations. 
Homozygous inherited loss-of-function mutations of ATM result in ataxia telangiectasia 
(AT) syndrome, which is characterised by radiation hypersensitivity, 
immunodeficiency, neurodegeneration, and spontaneous predisposition to lymphoma 
(Abadir and Hakami, 1983; Morrell et al., 1986; Taylor et al., 1975). Similarly, 
knockdown of ATM in mice results in radiosensitivity, as well as a predisposition to 
lymphoma (Xu and Baltimore, 1996). Individuals who harbour heterozygous mutations 
of ATM have an increased incidence of breast cancer, and some other cancers, possibly 
due to environmental exposure to radiation (Briani et al., 2006; Thompson et al., 2005), 
and sensitivity to radiation in vitro in heterozygous cells from individuals result in a 
intermediate sensitivity between AT patients and normal individuals (Swift et al., 1991). 
Sporadic mutations of ATM have been found in lung and lymphoid malignancies, albeit 
in relatively low incidences (Ding et al., 2008; Gumy-Pause et al., 2004). ATM can 
therefore be viewed as a cancer susceptibility gene that interacts with certain 
environmental factors resulting in a heightened predisposition to cancer. Mutations in 
genes encoding the MRE11 and NBS1 proteins result in ataxia-like disorder, as well as 
Nijmegen breakage syndrome (NBS), of which both disorders share clinical similarities 
with AT (Stewart et al., 1999; Varon et al., 1998). Hypomorphic mutations of NBS1 or 
RAD50 also result in a cancer predisposition in mice (Bender et al., 2002; Kang et al., 
2002). Homozygous mutations of ATR result in the development of Seckel syndrome, 
which is associated with growth retardation and microcephaly. However, unlike AT 
patients, individuals with Seckel syndrome do not suffer from an increased incidence of 
cancer. Studies in mouse models revealed degenerative and premature aging-like 
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phenotypes in ATR knockout mice, pointing to a role of ATR in normal development, 
stem cell survival and tissue homeostasis (Ruzankina et al., 2007). Loss of function of 
ATR, however, does not result in genomic instability that promotes tumourigenesis, and 
somatic mutations of ATR have not been frequently found in human cancers, with the 
exception of stomach and endometrial tumours with microsatellite instability (MSI) 
(Heikkinen et al., 2005; Menoyo et al., 2001; Vassileva et al., 2002).  
 
Mutations further downstream of the sensor proteins also result in cancer 
predispositions. Li Fraumeni syndrome is a cancer predisposition syndrome that is 
linked to germline mutations of TP53 (Birch, 1994). Heterozygous germline mutations 
of Chk2 confer increased incidences of breast, prostate and other cancers; however, 
tumours of individuals that harbour heterozygous mutations of Chk2 do not consistently 
exhibit LOH in the remaining functional allele unlike typical tumour suppressor genes 
(Antoni et al., 2007). Germline mutations in Chk1 have not been associated with any 
human disease, and somatic mutations in Chk1 are infrequently found in cancers, with 
the exception of tumours with MSI (Vassileva et al., 2002). ATR knockout in mice 
results in chromosomal fragmentation and early embryonic lethality, and Chk1 
heterozygous mice developed tumours more rapidly upon oncogenic tumour induction 
compared to the wildtype mice (Brown and Baltimore, 2000; Liu et al., 2000). Loss of 
the remaining functional allele of Chk1 was not observed, suggestive of an important 
role of Chk1 in maintaining cell proliferation and survival (Liu et al., 2000). 
Heterozygous carriers of BRCA1/2 mutations are developmentally normal but possess a 
greater incidence of breast and ovarian cancer (King et al., 2003). Somatic loss of 
function mutations of BRCA1 and BRCA2 have been found in numerous cancer types, 
most notably the most prevalent form of ovarian cancer, high grade serous carcinoma. 
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As previously mentioned, BRCA1/2 largely play a role in HR-mediated repair of DSBs 
and heterozygous loss of BRCA1/2 in cells through LOH results in HR deficiency and 
genomic instability. In the absence of HR, the cells use alternative error-prone DNA 
repair mechanisms which lead to an accumulation of mutations, which likely promotes 
tumourigenesis (Tutt et al., 2002). While the presence of these mutations results in an 
environment that fosters carcinogenesis, the absence of efficient DNA repair 
mechanisms provides an exploitable therapeutic strategy that enables targeting of 
tumour cells defective in DNA repair. A comprehensive list of DDR aberrations and 
associated DNA repair pathways are shown in figure 1.23. 
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Figure 1.23. DDR aberrations in cancer. Abbreviations: AML, acute myeloid 
leukaemia; APE1, AP endonuclease 1; ATM, ataxia-telangiectasia mutated; ATR, 
ataxia-telangiectasia and Rad3-related; BACH1, BRCA1-associated C-terminal helicase 
1; BER, base excision repair; BRIP1, BRCA1-interacting protein C-terminal helicase 1; 
DDR, DNA damage response; DNA-PKcs, DNA-dependent protein kinase catalytic 
subunit; DSB, DNA double-strand break; FANC, Fanconi anaemia group protein; 
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HNPCC, hereditary nonpolyposis colorectal cancer; HNSCC, head and neck squamous 
cell carcinoma; HRR, homologous recombination repair; MGMT, O6-methylgyuanine 
DNA methyltransferase; MDS, myelodysplastic syndrome; miR, microRNA; MMR, 
mismatch repair; MSI, microsatellite instability; NBS1, Nijmegen breakage syndrome 
protein 1; NER, nucleotide excision repair; NHEJ, non-homologous end joining; 
OGG1, 8-oxoguanine DNA glycosylase; PARP1, poly(ADP-ribose) polymerase 1; Pol, 
DNA polymerase; SNP, single nucleotide polymorphism; TLS, translesion synthesis; 
TMZ, temozolomide; UV, ultraviolet; XP, Xeroderma pigmentosum. Image source: 
(Curtin, 2012) 
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1.3.7 Cancer therapy 
Anti-cancer therapies involve using methods to kill cancer cells more efficiently than 
normal cells. Since most cancer cells exhibit enhanced cell proliferation compared to 
their normal counterparts, several cancer drugs target the cell cycle to exploit this trait; 
targeted therapies using inhibitors of the mitotic spindle, hormonal manipulation, 
immunotherapy and drugs that inhibit growth signalling pathways can be used to target 
the cell cycle. However, the most common method of targeting the cell cycle is by the 
use of DNA damaging drugs, which result in cell cycle arrest and cell death, either 
directly or following DNA replication.  
 
1.3.7.1 DNA damaging agents in cancer therapy  
DNA damaging agents used in the clinic result in high levels of DNA damage, cell 
cycle arrest and either immediate death through apoptosis, or following DNA 
replication, thus making these drugs highly effective in killing proliferating cells. The 
agents used in cancer treatment that induce a variety of toxic DNA lesions can be 
divided into six categories of delivery mechanisms: Radiotherapy and radiomimetics, 
alkylating agents, antimetabolites, topoisomerase inhibitors and replication inhibitors.  
 
Alkylating agents result in chemical modifications of DNA bases, resulting in the 
formation of adducts through the attachment of an alkyl group to the guanine base of 
DNA. These agents can be divided into two groups, mono-functional alkylating agents 
and bi-functional alkylating agents, which have the ability to modify one and two bases, 
respectively. Bi-functional agents form two covalent adducts with DNA bases, either 
within the same DNA strand (intrastrand crosslinks) or between opposite DNA strands 
(interstrand crosslinks) (ICLs). Interstrand crosslinks are considered the more potent 
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lesion, and result usually in irreversible block to replication forks, and severe toxicity in 
cells. Examples of mono-functional alkylators include alkylsulphonates, nitrosourea 
compounds and temozolomide (TMZ). Nitrogen mustard, motomycin C and cisplatin 
are examples of bi-functional alkylating agents. DNA replication inhibitors target DNA 
synthesis directly, resulting in replication fork progression impairment and DNA lesion 
formation. Aphildocolin inhibits DNA polymerases, and hydroxyurea inhibits 
ribonucleotide reductase, an enzyme required for the production of dNTP molecules 
necessary for DNA replication. Antimetabolites, such as 5-fluorouracil and thiopurines, 
are also used in cancer therapy to induce DNA damage, by way of inhibiting the 
nucleotide metabolism pathway through depletion of dNTPs. These drugs can also 
incorporate themselves into the DNA, resulting in replication fork progression 
impairment. Topoisomerases (TOP) are critical enzymes involved in DNA replication 
which relieve torsional stress imposed by the introduction of transient strand breaks. 
Inhibitors of this enzyme prevent the re-ligation of these breaks, resulting in the 
retention of strand breaks. TOP1 is associated with controlled rotations of DNA 
supercoiling and subsequent DNA relaxation; TOP1 inhibitors, such as camptothecins, 
bind at the interface of the TOP1-DNA complex and cause replication associated DSBs. 
On the other hand, TOP2 inhibitors, such as etoposide and doxorubicin, change DNA 
topology by a “two gate” mechanism (Nitiss, 2009). IR and radiomimetics agents, such 
as bleomycin, can target non-replicating cells and therefore also target replication-
independent DSBs. The therapeutic strategy and associated DNA repair target is shown 
in figure 1.24. 
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Figure 1.24. Overview of DNA damage and the associated DNA repair pathways.  
Approximate number of the indicated type of lesion that occurs naturally in a cell each 
day is shown in parentheses in the beige box. Therapeutic DNA damaging agents that 
cause the corresponding DNA lesion are shown in orange boxes. BER, base excision 
repair; HRR, homologous recombination repair; ICL, interstrand crosslink; IR, ionising 
radiation; MMC, mitomycin C; MMR, mismatch repair; NER, nucleotide excision 
repair; NHEJ, non-homologous end joining; ROS, reactive oxygen species; SAM, S-
adenosyl methionine; SSB, single-strand break; SSBR, SSB repair; TMZ, 
temozolomide; TOPO, topoisomerase; UV, ultraviolet. Image source: (Curtin, 2012)  
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1.3.7.2 DNA repair pathways as targets for cancer therapy 
Despite the potency of DNA damaging treatment, the effects of the drugs can be 
attenuated by intact DNA repair mechanisms that remove the lesions imposed, resulting 
in cell survival. DNA repair mechanisms thus modulate the efficiency of DNA damage 
based cancer therapy. 
 
Direct reversal of a DNA lesion marks the simplest form of DNA repair. O6 
methylguanine DNA methyltransferase (MGMT) gene encodes a DNA repair protein 
that removes alkyl groups from the O6 position of guanine, an important site of DNA 
alkylation. Agents that induce alkylations at this position, such as TMZ, decarbazine 
and nitrosoureas, inhibit this repair resulting in distorted base pairing. MGMT is 
ubiquitously expressed, and high MGMT expression levels in tumour cells are 
associated with resistance to the nitrosoureas carmustine, and TMZ (Lijinsky et al., 
1994; Zaidi et al., 1996), suggesting that depletion of MGMT via pseudo-substrates 
may sensitise tumour cells to O6 alkylating agents. However, trials using O6-
benzylguanine as a pseudo-substrate in tumour tissues, including gliomas, resulted in 
marginal clinical benefit due to increased toxicities in both normal and tumour tissues 
(Rabik et al., 2006). Consequently, the drug has not entered phase III trials. Trials using 
other pseudo-substrates, such as lomeguatrib, have shown promising preclinical 
activity, but phase II trials failed to show any clinical benefit in patients with melanoma 
or colon cancer (Ranson et al., 2006; Watson et al., 2010). Epigenetic silencing of 
MGMT by promoter methylation has been associated with longer overall survival in 
patients with glioblastoma who received carmustine or TMZ, and therefore MGMT 
silencing status in patients may be useful for stratifying patients for treatment with 
alkylating agents (Hegi et al., 2005).  
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BER repairs DNA damage that is therapeutically induced by IR, DNA methylating 
agents, TOP1 poisons, and some antimetabolites. The BER pathway consists of four 
major components: glycosylates, endonucleases, DNA polymerases and DNA ligases. 
Inhibitors of DNA polymerase-β (pol β), FEN1, LIG1 and LIG3 increased sensitivity 
towards IR, TMZ and methyl methanesulphonate, respectively (Chen et al., 2008; Gao 
et al., 2008; Kumamoto-Yonezawa et al., 2010; Panda et al., 2009). AP endonuclease 1 
(APE1) inhibitors, such as methoxyamine, also target this pathway by binding to the AP 
site in DNA, as well as inhibitors of APE1 endonuclease activity. In a Phase I trial of 
methoxyamine, responses were seen in combination with pemetrexed (Eli Lilly, USA), 
and there is a study currently ongoing with TMZ. Novel and more specific APE1 
endonuclease inhibitors increased the persistence of AP sites in vitro and increased the 
cytotoxicity of alkylating agents, but they have not yet moved into advanced preclinical 
or clinical evaluation (Mohammed et al., 2011). 
 
Enzymes poly(ADP-ribose) polymerase (PARP) 1 and PARP2 also greatly facilitate 
repair by BER. Furthermore, PARP1 also has an important role in DSB repair. PARP1 
is an abundant nuclear protein and is the founding member of the PARP family. PARP1 
has several structural and regulatory roles across the genome, including roles in DNA 
repair, DNA methylation, transcription, chromatin structure and histone modification 
(Krishnakumar and Kraus, 2010). PARP1 is comprised of three functional domains: an 
amino-terminal DNA-binding domain containing three zinc fingers, an auto-
modification domain and carboxyl-terminal catalytic domain. Zinc finger 2 has the 
strongest affinity for DNA breaks whereas zinc finger 1 is responsible for DNA-
dependent PARP1 activation, in which zinc finger 3 also takes part (Langelier et al., 
2011). With respect to DNA repair, PARP1 detects DNA strand breaks through its 
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DNA-binding domain, binds to the DNA strand break and activates PARP1 to cleave 
nicotinamide adenine dinucleotide (NAD+) generating nicotinamide and ADP ribose. 
The ADP ribose units form long chains of poly (ADP)ribose (PAR), which, through 
PARylation, covalently binds to histones and several DNA repair proteins, such as 
XRCC1 (Schreiber et al., 2006). Like other nuclear proteins that play key roles in 
regulatory processes, PARP1 is subject to a variety of covalent post - translational 
modifications as endpoints of cellular signalling pathways. These include PARylation, 
acetylation, phosphorylation, ubiquitylation, and SUMOylation. PARP1 PARylation 
results in an inhibition of DNA-binding and catalytic activity (D'Amours et al., 1999). 
PAR chains are rapidly disassembled by the PAR hydrolysing enzyme PARG minutes 
after synthesis, thus providing a quick response to DNA damage lasting mere minutes 
(Schreiber et al., 2006). Therefore, inhibitors of PARP1 result in inefficient BER. 
Preclinical studies revealed that PARP inhibition through small molecule compounds or 
genetic inactivation of PARP1 enhanced the cytotoxicity and anti-tumour activity of 
TMZ, TOP1 poisons and IR (Rouleau et al., 2010). The first clinical trial of PARP 
inhibitor rucaparib in 2003 with TMZ demonstrated modest clinical response in patient 
samples, and phase II trials were accompanied by myelosuppression (Plummer et al., 
2008; R. Plummer, 2006). Eight more PARP inhibitors have undergone or are currently 
undergoing clinical evaluation in combination with alkylating agents dacarbazine and 
TMZ, as well as TOP1 inhibitors (see figure 1.24 for an extensive list of PARP 
inhibitors). Some of these combination studies have revealed no increase in anti-tumour 
activity, such as PARP inhibition in conjunction with paclitaxel treatment. PARP 
inhibitor treatment with DNA-damaging chemotherapy has generally been 
disappointing due to toxicities encountered, possibly due to using the same dose 
established for single-agent studies, in combination studies. Radiosensitisation by 
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PARP inhibition has been shown in preclinical studies, and phase I trials have revealed 
that PARP inhibitor veliparib was well tolerated with whole-brain radiotherapy in 
patients with brain metastases (Minesh P. Mehta, 2012). 
 
NER contributes to repair of ICLs and XP and ERCC1 proteins play a crucial role in 
this repair. In testis tumour cells, NER deficiency results in sensitivity to platinum-
based therapy, and a reduced capacity to repair ICL lesions (Koberle et al., 1997; 
Usanova et al., 2010). Hereditary defects of NER result in increased UV sensitivity and 
skin cancer development (Andressoo et al., 2005). Currently there are no small-
molecule inhibitors of NER. Findings of in vitro studies revealed that the 
immunosuppressant cyclosporine and epidermal growth factor receptor (EGFR) 
inhibitor cetuximab may downregulate XPG and ERCC1-XPF, respectively (Kuschal et 
al., 2011; Prewett et al., 2007).  
 
Whereas most DNA repair pathways mediate resistance to DNA damage, MMR is 
required for the toxicity of some anticancer drugs. The futile repair cycle model 
proposes that drug-induced DNA lesions in the daughter strands result in MMR 
processing without removing damage from the parental strands, which is thought to lead 
to repetitive strand breaks that may be a signal for G2-M arrest (Karran and Bignami, 
1994; Karran and Marinus, 1982). Further, the MMR system is required for cell cycle 
arrest and apoptosis (Li, 1999), which might mediate increase cytotoxicity. Defective 
MMR increased mutation rates up to 1,000-fold and the resulting MSI is associated with 
cancer development (Umar et al., 2004). Thus, MMR plays a role in the DDR pathway 
as well as prevention of short-term mutagenesis and long-term tumourigenesis. 
Inhibitors of MMR have not been developed due to evidence showing that defective 
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MMR results in tolerance to TMZ, platinum-based compounds and some nucleoside 
analogues, conferring to drug resistance (Fordham et al., 2011; Karran and Bignami, 
1994). While preclinical data have revealed chemo-sensitivity, clinical trials conducted 
using drugs to reactivate epigenetically silenced components of MMR in conjunction 
with chemotherapy resulted in adverse reactions (NCT00748527, 2008; Plumb et al., 
2000). 
 
DNA-PKcs is a critical DNA repair protein involved in NHEJ DSB repair, and 
inhibitors of this enzyme in preclinical studies have shown to slow DSB repair and 
increase cytotoxicity of IR, radiomimetics and TOP2 agents in vitro and in vivo (Munck 
et al., 2012; Zhao et al., 2006). In B cell chronic lymphocytic leukaemia cells, increased 
DNA-PKcs levels were associated with poor prognosis in patient derived samples, and 
DNA-PKcs inhibitors NU7026 and NU7441 potentiated the cytotoxicity of poor 
prognosis cells to TOP2 poisons (Willmore et al., 2004). Dual mTOR and DNA-PKcs 
inhibitor CC-115 is currently undergoing clinical evaluation in patients with advanced 
solid tumours and haematological malignancies (NCT01353625, 2011).  
 
HR is a high fidelity repair mechanism that resolves stalled and collapsed replication 
forks, as well as the processing of ICLs in cooperation with NER (Deans and West, 
2011). Tumours that harbour HR defects are more sensitive towards crosslinking 
agents, as well as antimetabolites that induce base lesions and/or replication fork 
stalling. (Evers et al., 2010). There are few HR inhibitors in clinical evaluation; one 
such inhibitor is mirin, which inhibits MRE11, although its effects are non-specific and 
target inhibition of both HR and NHEJ repair (Dupre et al., 2008). In vitro studies of 
imatinib, which inhibits RAD51 phosphorylation, resulted in the drug sensitising cells 
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to IR, as well as crosslinking agents (Choudhury et al., 2009). However, the most 
common way to target HR repair is by inhibition of the ATM-Chk2 and ATM-Chk1 
pathways. The first selective ATM inhibitor, KU55933, demonstrated inhibition of IR-
induced ATM-dependent phosphorylation events and sensitised cancer cells to IR and 
TOP poisons (Hickson et al., 2004). Treatment of cells with novel ATR inhibitors VE-
821 and NU6027 resulted in sensitisation of the cells towards DNA-damaging agents, 
however, the response was dependent on p53 status (Peasland et al., 2011; Reaper et al., 
2011). Targeting checkpoints is an attractive strategy for cancer therapy, mainly due to 
the loss of G1 checkpoint control found in cancer cells (Massague, 2004). WEE1 and 
CDC25 inhibitors have been developed, which inhibit the entry into mitosis, although 
clinical data remains limited (J. H. M. Schellens, 2011; Lavecchia et al., 2010). The 
majority of research has focused on the development of Chk1 inhibitors. While 
preclinical studies revealed a modest impact on viability, the drugs enhanced 
cytotoxicity induced by DNA-damaging agents in xenograft studies (Blasina et al., 
2008; Matthews et al., 2007; Zabludoff et al., 2008). The non-specific staurosporine 
analogue, UNC-01, was the first Chk1 inhibitor to enter clinical trials, but was 
discontinued due to poor specificity and pharmacokinetics. Phase I trials with newer 
Chk1 inhibitors, in conjunction with gemcitabine, resulted in major toxicity due to 
myelosuppression and ultimately a termination of the trial (Chen et al., 2012; Garrett 
and Collins, 2011). An extensive list of pharmacological drugs that inhibit DNA repair 
components for cancer treatment is listed in figure 1.25. 
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Figure 1.25. Inhibitors of the DDR pathway. Figure continued on the next page.  
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Figure 1.25. Inhibitors of the DDR pathway. References are indicated in the body of 
the text. Abbreviations: APE1, AP endonuclease 1; ATM, ataxia-telangiectasia mutated; 
ATR, ataxia-telangiectasia and Rad3-related; BER, base excision repair; CDC25, cell 
division cycle 25; CDK1, cyclin-dependent kinase 1; CLL, chronic lymphocytic 
leukaemia; DAC, decitabine; DDR, DNA damage response; DNA-PKcs, DNA-
dependent protein kinase catalytic subunit; DSB, DNA double-strand break; FEN1, flap 
endonuclease 1; HRR, homologous recombination repair; IR, ionising radiation; 
MGMT, O6-methylguanine DNA methyltransferase; MMC, mitomycin C; MMR, 
mismatch repair; MMS, methyl methanesulphonate; MTD, maximum tolerated dose; 
NER, nucleotide excision repair; NHEJ, non-homologous end joining; NIH, US 
National Institutes of Health; PARP, poly(ADP-ribose) polymerase; PARPi, PARP 
inhibitor; Pol, DNA polymerase; TLS, translesion synthesis; TMZ, temozolomide; XP, 
Xeroderma pigmentosum. Image source: (Curtin, 2012)  
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1.3.7.3 Synthetic lethality 
Since several cancers harbour DNA repair deficits, DNA repair mechanisms can be 
exploited for cancer treatment by specifically targeting cancer cells that possess genetic 
mutations that are not present in normal cells, a process known as synthetic lethality. 
The principle of synthetic lethality is based on the interaction between two genes that 
contribute to an essential process or processes, often nonlinearly (Guarente, 1993; 
Hartman et al., 2001). When either gene is mutated alone, the cell is viable; however, a 
combination of mutations in both results in cellular lethality as depicted in figure 1.26.  
 
In the case of BRCA1/2 mutant carriers, when cancer develops in these patients, there is 
almost always genetic or functional loss, leading to inefficient HR repair (Osorio et al., 
2002). Cells and mouse models that possess HR defects by way of BRCA1/2 mutations 
are profoundly sensitised to PARP inhibitor treatment, resulting in chromosomal 
instability, cell cycle arrest and apoptosis (Bryant et al., 2005; Farmer et al., 2005). 
Furthermore, knockdown of other genes involved in HR have also rendered the cells 
sensitive to PARP inhibition (McCabe et al., 2006). Numerous clinical trials with PARP 
inhibitors in breast and ovarian cancers have resulted in encouraging data (discussed in 
section 1.3.7.4.6). However, resistance to PARP inhibitors can be developed through 
restoration of BRCA1/2 function (Sakai et al., 2008; Swisher et al., 2008). In addition, 
PARP inhibitor resistance can be restored through inactivation of 53BP1 and DNA-
PKcs, crucial proteins involved in NHEJ (Bouwman et al., 2010; Patel et al., 2011). 
Therefore care must be taken to treat tumours which harbour deficits in NHEJ repair, 
such as in BRCA-1 mutant and triple negative breast cancers and lung cancers, where 
53BP1 is a commonly lost (Bartkova et al., 2007).  
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Other examples of synthetic lethality encompassing HR defects and PARP inhibition 
have been found. Loss of ATM in haematological malignancies or mutation of MRE11 
results in sensitivity to PARP inhibition in lymphoma and colorectal cancer cells (Vilar 
et al., 2011; Weston et al., 2010; Williamson et al., 2010). Compromised CDK1 activity 
sensitised BRCA-proficient cancers to PARP inhibition, and clinical trials for this 
combination have already commenced (Johnson et al., 2011). In short, the development 
of inhibitors of PARP has led to an increase in cytotoxicity of tumour cells in numerous 
models. Identification of suitable biomarkers paves the next step to effectively stratify 
patients that would benefit from the appropriate inhibitors, either for use as a single 
agent treatment, or in combination with other targeted therapies.  
  
 113 
 
Figure 1.26. Principles of synthetic lethality. Pathways A and B represent repair 
pathways which respond to DNA damage. When pathway B is inhibited, normal cells 
can rely on functioning pathway A to repair the damage, resulting in cell survival as 
depicted in the image on the left. In tumour cells with defective repair mechanisms 
(represented by pathway A), inhibition of pathway B can result in the erroneous 
activation of repair pathway C, which is unable to repair the damage appropriately, 
resulting in cell death. Image source: (Curtin, 2012) 
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1.3.7.4 Targeted therapies in ovarian cancer 
Improved understanding of the underlying biology of ovarian cancer has led to the 
development of molecular targeted therapies that target several hallmarks of cancer, 
including angiogenesis, survival, cell growth and metastases (Hanahan and Weinberg, 
2011; Yap et al., 2009). The majority of current research in advanced and recurrent 
ovarian cancer focuses on the inhibition of signal transduction pathways and targeting 
DNA repair mechanisms. The most successful strategies so far are employing anti-
angiogenesis and PARP inhibitors. Other approaches target aberrant pathways 
frequently upregulated in ovarian cancers such as the PI3K/Akt/mTOR network, the 
epidermal growth factor receptor, the WEE1 tyrosine kinase and the folate receptor 
alpha.  
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Table 1.4. Ovarian cancer targeted therapies and agents used in clinical trials 
Targeted therapy Agents in clinical trials 
Anti-angiogenic 
agents 
Bevacizumab is currently used in phase II and phase III trials as 
single agent therapy, as well as in combination with 
chemotherapy and other targeted therapies. Tyrosine kinase 
inhibitors that inhibit activity against tyrosine kinases inhibitors 
involved in angiogenesis are currently in phase III trials. 
Epidermal growth 
factor receptor 
inhibitors 
Gefitinib and erlotinib used with chemotherapy resulted in high 
overall response rates compared to single agent treatment. 
Monoclonal antibody pertuzumab which targets HER2 have 
reported increased response rates with gemcitabine versus 
gemcitabine monotherapy in ongoing phase III trials. 
Oestrogen receptor 
antagonists and 
aromatise inhibitors 
While anti-proliferative effects have been seen in in vitro and in 
vivo, oestrogen inhibitor tamoxifen and aromatase inhibitors 
have had modest response rates in  clinical trials.  
 
PI3K/Akt/mTOR 
pathway inhibitors 
Second generation PI3K inhibitor XL147 is in phase I trial in 
combination with paclitaxel and carboplatin. mTOR inhibitor 
everolimus and temsirolimus are currently being explored in 
phase I/II in combination with other agents with promising 
results. Akt inhibit MK02206 are in phase II trial in a biomarker 
assessed trial. 
WEE1 tyrosine 
kinases inhibitors 
Wee-1 inhibitor MK-1775 is in phase II trial in p53 mutated 
refractory and resistant ovarian cancers.  
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PARP inhibitors Phase II trials of PARP inhibitor olaparib revealed favourable 
response in ovarian cancers with BRCA1/2 mutations. Phase III 
trials have begun in BRCA mutant ovarian cancer patients. 
Other PARP inhibitors include BMN-673 (phase II), MK04827 
(niraparib), rucaparib and ABT-14699.  
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1.3.7.4.1 Anti-angiogenic therapy 
Ovarian malignancies are characterised by increasing levels of numerous pro-
angiogenic factors, including members of the VEGFs (Olson et al., 1994), and platelet 
derived growth factors (PDGFs) (Henriksen et al., 1993) family of proteins. Anti-
angiogenic agents are being evaluated in the treatment of EOCs, the most promising of 
these being bevacizumab (Genentech-Roche), a human monoclonal antibody that 
inhibits VEGF family member A, which is currently being used in phase II and phase 
III clinical trials as single agent therapy, as well in combination with chemotherapy and 
other targeted therapies (Azad et al., 2008; Burger et al., 2007; Cannistra et al., 2007; 
Garcia et al., 2008; Micha et al., 2007). Results of the trials have revealed increased 
progression-free survival in single-agent studies in recurrent ovarian cancers, as well as 
maintenance therapy with concomitant standard carboplatin-paclitaxel treatment in first 
line therapy (Burger et al., 2011; Perren et al., 2011). In another randomised phase III 
trial evaluating bevacizumab plus chemotherapy for platinum resistant recurrent ovarian 
cancer patients, combination treatment resulted in improved progression free survival 
and overall response rate compared to chemotherapy alone (Eric Pujade-Lauraine, 
2012). Other anti-angiogenic compounds under investigation are the tyrosine kinase 
inhibitors that possess potent inhibitory activity against multiple tyrosine kinases 
involved in angiogenesis. Phase III trials of tyrosine kinase inhibitors show promising 
results with good response rates alone or in conjunction with other treatments (du Bois 
et al., 2014; GlaxoSmithKline, 2010; JA Ledermann, 2013). However, since tyrosine 
kinase inhibitors are relatively new drugs, and as with most novel targeted therapies, the 
long-term side effects have yet to be clearly defined.  
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1.3.7.4.2 Epidermal growth factor receptor inhibitors 
Another targeted therapy being exploited involves EGFR, which is overexpressed in 
70% of ovarian cancers and is associated with advance disease upon diagnosis, as well 
as poor prognosis and chemo-resistance (Bartlett et al., 1996; Fischer-Colbrie et al., 
1997). While preclinical data have suggested inhibition of EGFR may have anti-tumour 
activity and reverse chemo-resistance (Ciardiello et al., 2000; Sirotnak, 2003; Sirotnak 
et al., 2000), single agent studies of EGFR inhibitors, have resulted in little or no 
success with respect to clinical response (Gordon et al., 2005; Posadas et al., 2007; 
Schilder et al., 2005; Seiden et al., 2007). However, phase II trials of EGFR inhibitor 
gefitinib and erlotinib combined with chemotherapeutic agents have resulted in higher 
overall response rates of 61.9% and 60.0% in platinum-sensitive tumours compared to 
19.2% and 7.0% in platinum-resistant tumours, respectively (Hirte et al., 2010; Pautier 
et al., 2010). Monoclonal antibody pertuzumab (Roche, Switzerland) is targeted against 
human epidermal growth factor receptor 2 (HER2) and ongoing phase III trials have 
revealed increased response rates in combination therapy with gemcitabine versus 
gemcitabine monotherapy (NCT01684878, 2012).  
 
1.3.7.4.3 Oestrogen receptor antagonists and aromatase inhibitors  
There is evidence that suggests oestrogen influences proliferation in a subset of ovarian 
cancers (Simpkins et al., 2013). Furthermore, anti-oestrogen compounds have been 
shown to inhibit proliferation of ER positive ovarian cancer cells in vitro and in vivo 
(Simpkins et al., 2012). Clinical trials have been conducted to evaluate ER antagonists 
such as tamoxifen and aromatase inhibitors, however treatment with tamoxifen and 
aromatase inhibitors for recurrent ovarian cancer resulted in a modest 13% and 8% 
overall response rate, respectively (Simpkins et al., 2013). Limitations of these studies 
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include a lack of preselecting patients based on hormone receptor or aromatase 
expression.  
 
1.3.7.4.4 PI3K/Akt/mTOR Pathway inhibitors 
Deregulation of the PI3K/Akt pathway is commonly found in ovarian cancer and 
inhibitors have been developed to target components of this pathway, as well as 
inhibitors against components of the downstream mTOR pathway, to deactivate 
aberrant signalling. mTOR is a critical target of AKT that targets proteins, such as S6 
kinases, thus regulating protein translation of different effectors in cell growth and cell 
cycle progression. First generation PI3K inhibitors, such as Wortmannin and 
LY294002, were largely unsuccessful because of high toxicity, most likely due to the 
absence of selectivity (Gharbi et al., 2007; Wipf and Halter, 2005). Second generation 
inhibitors are currently under exploration, although few have reached the phase II stage 
due to insignificant response rates. XL147 (Exelixis, USA) is a reversible, highly 
selective PI3K inhibitor which is currently in phase I trials.  
 
Single agent PI3K/Akt/mTOR inhibitors have also been largely unsuccessful, in part 
due to resistance mechanisms initiated by feedback regulation. Inhibition of mTORC1 
leads to activation of PI3K signalling through loss of a feedback loop (O'Reilly et al., 
2006), as well as activation of the growth and differentiation MAPK signalling pathway 
(Carracedo et al., 2008).  Given the extensive cross-talk and feedback loops found in 
this pathway, combination treatment of several PI3K/Akt/mTOR component inhibitors 
with chemotherapy and other tumour targeted therapies have resulted in enhanced anti-
tumour activity in vitro as well as in vivo. mTOR inhibitors such as everolimus 
(Novartis, USA) and temsirolimus (Pfizer, USA) are currently being explored in phase I 
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and phase II trials in combination with other treatments with promising results 
(NCT00886691, 2009; NCT01031381, 2009; NCT01281514, 2011; R. Morgan, 2011; 
Temkin et al., 2010). The Akt inhibitor MK-2206 (Merck & Co, USA) is in phase II 
investigation for platinum resistant ovarian, fallopian tube or primary peritoneal cancer 
in a biomarker-assessed trial (NCT01283035, 2011). 
 
1.3.7.4.5 WEE1 tyrosine kinase inhibitors 
Another DNA damage agent being used in a synthetically lethal manner is the WEE1 
tyrosine kinase inhibitor. WEE1 kinase is a crucial enzyme involved in maintaining G2-
cell cycle checkpoint arrest. Cells possessing a mutation in components involved in G1 
regulation, such as those harbouring a p53 mutation, often rely on G2 checkpoint arrest 
for DNA repair, and therefore WEE1 inhibitors are candidates for enhancing anti-
tumour activity through synthetic lethality. A phase 2 trial is currently studying whether 
p53 mutated refractory and resistance ovarian cancer patients will benefit from 
treatment with Wee-1 inhibitor MK-1775 (Merck, USA) and carboplatin 
(NCT01164995, 2010).  
 
1.3.7.4.6 PARP inhibitors 
Approximately 10% of EOCs have a germ line mutation in cancer susceptibility genes 
BRCA1 and BRCA2, rendering them deficient in HR DNA repair. The presence of a 
BRCA1 mutation in women is associated with a lifetime risk of ovarian cancer of 20-
45% (Antoniou et al., 2003). BRCA2 mutations are associated with a lifetime risk of 10-
20% for ovarian cancer.  ‘BRCAness’ is a term that describes cancers that do not 
possess mutations of BRCA1/2, but phenotypically behave like these tumours due to 
genetic and epigenetic events. Some of these aberrations may result in tumours 
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harbouring HR deficiency and with respect to ovarian cancer, up to 50% of EOCs 
harbour HR deficiency. While the progress of tumour-targeted therapies, as described in 
previous sections, has been slow in advancing in clinical trials phases, the development 
of PARP inhibitors have resulted in encouraging data. While several PARP inhibitors 
are currently being explored in clinical trials, the most advanced to date is olaparib 
(AZD2281, Astrazeneca, USA). Phase II trials with olaparib have produced response 
rates of 33% in ovarian cancers with BRCA1/2 mutations (Audeh et al., 2010), and other 
studies in recurrent serous ovarian cancer have confirmed favourable responses as well 
(Gelmon et al., 2011; J. Ang, 2010). Phase II trials evaluating the benefit of olaparib 
treatment as maintenance therapy in platinum-sensitive ovarian cancer patients with or 
without BRCA1/2 mutations have revealed clear improvements in progression free 
survival (Ledermann et al., 2012). A phase II trial is currently evaluating olaparib 
treatment in conjunction with paclitaxel and carboplatin in patients with platinum 
sensitive advanced serous ovarian cancer versus paclitaxel and carboplatin treatment 
alone (NCT01081951, 2010). Lastly, there are two phase III trials underway 
(NCT01844986 and NCT1874353) which are evaluating a new tablet formulation of 
olaparib for maintenance treatment for BRCA mutant ovarian cancers.  
 
Other PARP inhibitors are also being evaluated in clinical trials. Phase II trials of 
iniparib (BSI-201, BiPar Sciences, USA) in combination with carboplatin and 
gemcitabine in platinum sensitive and platinum resistance ovarian cancer yielded 
initially improved response rates (M. J. Birrer, 2011; R. T. Penson, 2011). Recent 
publications, however, have reported that the anti-tumour activity of iniparib is not 
consistent with PARP inhibition, and further preclinical assessment of the drug is 
required (Liu et al., 2012; Patel et al., 2012). Other PARP inhibitors currently in early 
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phase trials include MK-4827, Merck&Co, USA), ABT-14699 Pfizer, USA), and 
BMN-673 (Biomarin, USA).  
 
1.3.7.5 Ovarian cancer models  
Ovarian cancer is the seventh most common cancer diagnosed in women, and account 
for 4% of all cancers in women worldwide (Ferlay J, 2010). The majority of ovarian 
cancers are epithelial in origin; however, recent pathological and genomic findings have 
challenged the traditionally held viewpoint that EOC derives from ovarian tissues. Up 
until the early 2000s, EOC origins were believed to stem from the ovarian surface 
epithelium (Auersperg et al., 2001). However, histological and molecular analyses of 
EOCs led to the findings that suggest metastatic mucinous EOCs originate from the 
colon, and endometrioid and clear cell EOC may be derived from atypical 
endometriosis (Kelemen and Kobel, 2011; Qiu et al., 2013). The origin of HGSC, the 
most prevalent subtype of EOC, has also recently been further probed. The latest 
findings conducted by Perets et al. using de novo mouse models of HGSC suggests that 
high grade serous tumours can originate in fallopian tubal secretory epithelial cells 
(Perets et al., 2013). The study also identified the development of serous tubal 
intraepithelial carcinoma lesions as a precursor to HGSC, and advanced disease. 
Interestingly, mouse models carrying TP53 deletion and mutations, one of the genetic 
hallmarks of HGSC, did not result in a drive in tumour progression, unlike loss of 
BRCA1 or BRCA2, which resulted in widespread peritoneal disease. Therefore, BRCA 
status seems to play an important role in progression to metastatic disease, despite it 
being less frequently altered compared to TP53 (Perets et al., 2013). Since 
approximately half of HGSC cases harbour defective HR repair, further work will need 
to be carried out to investigate the driving ability of components of HR in 
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tumourigenesis and progression to metastatic disease. Doing so will enable improved 
screening methods and therapeutic approaches for EOC patients, as well as provide a 
greater understanding of the pathogenesis of epithelial derived ovarian tumours.  
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1.4 Aims and objectives 
Hyperactivation of the PI3K/Akt pathway has been identified in numerous cancers, and 
approximately 45% of high grade serous ovarian tumours exhibit altered components in 
this pathway. Therefore, further investigation of components of this pathway in ovarian 
cancer may reveal a greater understanding of the tumour biology of this disease. The 
establishment of INPP4B as an important component of tumourigenesis and cancer 
progression has solidified over the last few years due to accumulating evidence being 
found across a range of cancer tissue types. In addition, LOH of INPP4B was identified 
in 40% of ovarian cancer patients. Thus, further exploration of the function of INPP4B 
and its biomarker potential may benefit a large patient population in the stratification of 
effective treatment regimes. The discovery of defective HR repair in approximately half 
of high grade serous tumours has introduced a myriad of therapeutic strategies that 
specifically target this repair deficiency in the clinical setting. The aim of this 
investigation is to therefore understand the role of INPP4B in DNA repair and examine 
whether loss of INPP4B expression can be therapeutically exploited with already 
established clinical treatments in the context of ovarian cancer. I will investigate the 
bioinformatics analysis of the identification of a ‘BRCAness’ signature identified in 
INPP4B-deficient MCF-10A human mammary epithelial cells. Furthermore, I will 
endeavour to establish and explore the biological function of INPP4B in the context of 
DNA repair in ovarian cancer cells using INPP4B knockdown cell pools. Finally, I will 
investigate the effect of INPP4B loss in conjunction with DNA repair inhibitor 
treatment, both in vitro and in vivo.  
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CHAPTER 2. Materials and methods 
2.1 General materials and methods 
The methods in this subsection represent standard tissue culture, infections, 
microbiology and molecular biology procedures. 
 
2.1.1 Tissue culture 
2.1.1.1 Cell line, maintenance, storage and retrieval 
The cell lines used for experiments were human mammary epithelial cells, MCF-10A, 
human epithelial ovarian cancer cell lines Ovca429 and Ovca433, and human 
embryonic kidney (HEK) 293T cells. MCF-10A cells were maintained in DMEM/F12 
media (Invitrogen, UK) with 5% horse serum (Invitrogen, UK), 20 ng/ml epidermal 
growth factor (EGF, Peprotech, UK), 0.5 µg/ml hydrocortisone (Sigma-Aldrich, UK), 
100 ng/ml cholera toxin (Sigma-Aldrich, UK), 10 µg/ml insulin (Sigma-Aldrich, UK) 
and 2 mM L-glutamine (Sigma-Aldrich, UK).  Ovca429 and Ovca433 cell lines were 
maintained in RPMI1640 media (Sigma-Aldrich, UK) with 10% foetal calf serum (FCS, 
Sigma-Aldrich, UK) and 2 mM L-glutamine. HEK 293T cells were maintained in 
DMEM media supplemented with sodium pyruvate (Lonza, UK) with 10% FCS and 2 
mM L-glutamine. INPP4Bfl/fl MEFs were cultured in DMEM with 10% FCS, 5 mg/ml 
glutamine, 5 mg/ml penicillin streptomycin (Sigma-Aldrich, UK) and 1:1000 beta-
mercaptoethanol (Sigma-Aldrich, UK). Knockdown derived cell lines were selected for 
in appropriate media containing 2 µg/ml puromycin (Invivogen, UK).  
 
Cells were grown in either 100 mm2 or 150 mm2 tissue culture plates (BD Falcon, UK), 
depending on the number of cells required. Cells were incubated in a humidity-saturated 
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(95%) incubators (Forma Scientific, UK) at 37°C with 5% CO2. On average cells were 
passaged three times a week, at a confluency of 80 – 90%. The cell media was aspirated 
from the plates and the cells washed with 10 ml sterile 1 X phosphate buffered saline 
(PBS, 80 g NaCl, 2.2 g KCl, 9.9 g Na2HPO4.2H2O. 2.0 g K2HPO4  were added to 2 L of 
distilled water to make a 10 X stock and the pH adjusted to pH 7.4). The PBS was 
aspirated and the cells detached by the addition of 2 ml 0.05% Trypsin-
Ethylenediaminetetraacetic acid (Trypsin-EDTA, Invitrogen, UK) and incubated at 
37°C. 6 ml of growth media were added to the plate to deactivate the trypsin and the 
cells were transferred to a Falcon tube where they were thoroughly resuspended to get a 
single cell suspension. The cells were centrifuged at 300 g at room temperature for 5 
min (Eppendorf, UK), and the supernatant was aspirated. The cell pellet was 
resuspended in growth media and transferred to a new plate at a maintenance ratio of 
1:6 for 293T cells and 1:8 for the Ovca429, Ovca433 and MCF-10A cell lines. 
 
Cells to be frozen were grown to a confluency of 90% before being trypsinised, pelleted 
by centrifugation and resuspended in 1 ml Bambanker serum-free freezing medium 
(Lymphotec Inc., Japan) per 100 mm2 plate of cells. Cells were transferred into a 
cryovial and slowly frozen in a Nalgene freezing container (Sigma-Aldrich, UK) at -
80°C. Cells were retrieved by thawing the cells briefly in a 37°C waterbath, adding 6 ml 
growth medium to the cells, and pelleting the cells by centrifugation. The supernatant 
was aspirated and cells resuspended in regular growth media, seeded in plates and left to 
attach overnight in the incubator at 37°C. The next morning growth media in plates was 
exchanged to remove dead cells. 
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2.1.1.2 Cell counting 
Cells were counted using the Vi-CELL cell viability analyser (Beckman Coulter, UK). 1 
ml of cell suspension was placed in holding vessels designed specifically for the 
machine. Cells were counted by the trypan blue dye exclusion method and the cell count 
and cell viability was noted.  
 
2.1.1.3 Plasmids 
Knockdown cell pools were generated by using pSM2 shRNA hairpins against Renilla 
luciferase, INPP4B, PTEN and BRCA1 (figure 2.1, OpenBiosystems, UK). shRNA 
hairpin-expressing retroviral vector Renilla luciferase (MSCV-U6miR30-PIGdeltaRI-
FF2), and PTEN (MSCV-U6miR30-PIGdeltaRI) were generous gifts from Dr. Steven 
Elledge (Harvard University, Boston, MA). Specific shRNA-hairpins directed against 
human INPP4B (RHS1764-9399376, sequence: TGCTGTTGACAGTGAGCG 
ACGTTGGCATTTCCGATTTAAATAGTGAAGCCACAGATGTATTTAAATCGGA
AATGCCAACGGTGCCTACTGCCTCGGA) and human BRCA1 (RHS4430-
98708636, sequence: 
TGCTGTTGACAGTGAGCGCGGCATGAATATTTCATATCTATAGTGAAGCCAC
AGATGTATAGATATGAAATATTCATGCCATGCCTACTGCCTCGGA) were 
obtained from Open Biosystems. pEAK FLAG-INPP4B, pcDNA3.1(+) FLAG-ATR, 
and pMT123 HA-Ubiquitin plasmids were used for protein overexpression studies and 
pcDNA3.1+ FLAG-EMPTY plasmids were used as the vector control . pEAK FLAG-
INPP4B and pcDNA3.1+ FLAG-EMPTY were generous gifts from Dr. Robin Ketteler 
(MRC Laboratory for Molecular Cell Biology, UK) (figure 2.2). pMT123 HA-
Ubiquitin, pENTR1A and pGEX-KG were generous gifts from Dr Pablo Rodriguez-
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Viciano (UCL, UK) (figure 2.3). Finally, pcDNA3.1+ FLAG-ATR was kindly given by 
Dr Steve Jackson (Gurdon Institute, UK). 
 
 
Figure 2.1. Plasmid for knockdown studies: pSM2 plasmid map. The pSM2 vector 
backbone was used for the expressing Renilla luciferase, INPP4B, PTEN and BRCA1 
shRNA constructs. The plasmid contains an ampicillin bacterial selection element and a 
puromycin and zeomycin mammalian selection elements. Image source: Thermo 
Scientific Open Biosystems Expression Arrest GIPZ Lentiviral shRNAmi technical 
manual (http://www.thermo.com/eThermo/CMA/PDFs/Various/File_8305.pdf) 
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Figure 2.2. Plasmid for overexpression studies: pEAK and pcDNA3.1(+) plasmid 
maps.  pEAK vector backbone containing a FLAG and INPP4B insert and 
pcDNA3.1(+) plasmid map. These vectors were used for protein overexpression studies. 
The plasmids contain an ampicillin bacterial selection element. Image source: (pEAK, 
http://www.addgene.org/24324/; pcDNA3.1(+), http://www.invitrogen.com)  
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Figure 2.3. Plasmid for GST studies: pENTR1A and pGEX-KG plasmid maps.  
pENTR1A entry vector containing a ccdB gene and carrying a kanamycin bacterial 
selection element; pGEX-KG vector containing a Glutathione S-transferase (GST) tag 
and an ampicillin bacterial selection marker used as a destination vector for bacterial 
protein amplification and isolation. Image source: (pENTR1A,  
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http://www.invitrogen.com; pGEX-KG, http://www.addgene.org/vector-
database/2890/)  
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2.1.1.4 Cell transfections for virus production 
Viral stocks were generated using 293T cells and linear polyethylenimine (PEI, 
Polysciences Inc., UK) as a transfection agent. PEI granules were dissolved in distilled 
water to make a 1 mg/ml working stock, neutralised to pH 7.0, sterile filtered using a 
0.22 µm filter (Corning Incorporated, UK) and 10 ml aliquots stored at -80°C. 2 x106 
293T cells were seeded in a 100 mm plate and incubated at 37°C overnight. The 
plasmid DNA components were combined in a 1.5 ml microcentrifuge tube with the 
appropriate shRNA hairpin, viral gag-pol, and viral env plasmid DNA at a ratio of 
4:3:1, totalling 15 µg DNA per 100 mm plate. 300 µl of DMEM serum-free media was 
added to the DNA and PEI was added at a DNA:PEI ratio of 1:6 ( 60 µg per 100 mm2 
plate). The microcentrifuge tube was immediately vortexed for 10 s and the solution 
incubated at room temperature for 15 mins to allow for DNA-PEI complexes to form. 
After the 15 mins incubation, the DNA-PEI complex solution was pipetted drop by drop 
onto the plate of 293T cells containing freshly replenished growth media. The cells 
were incubated at 37°C overnight and 24 hrs later, and the media was aspirated and 
replaced with 5 ml of growth media to concentrate the virus. 24 hrs later, the viral 
supernatant was collected, filtered using a 0.45 µm filter (Corning Incorporated, UK) 
and stored at -80°C until further use or used fresh to transduce cells. The cells were 
replenished with 5 ml of growth media and the viral supernatant collected as explained 
above 48 and 72 hrs after transduction.  
 
2.1.1.5 Infection of cells with virus 
Infection of the cell lines used from this study was based on the protocol defined by 
Debnath et al. (Debnath et al., 2003). Stable cell lines were generated by incubation of 
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40% confluent attached cells in 4.5 ml viral supernatant containing 10 µg/ml polybrene 
for 4 hrs. 10 ml of the appropriate cell line growth media was added to the virus 
supernatant and allowed to incubate overnight at 37°C. The next day, the virus and 
media mixture was aspirated and replaced with 10 ml of regular growth media. The 
following day the cells were subjected to selection by the addition of growth media 
containing 2 µg/ml puromycin (Invivogen, UK). The selection media was changed on a 
daily basis until only selected cells remained, which took approximately 3 days. The 
stable knockdown cell line was then maintained as described in section 2.1.1.1. 
 
2.1.1.6 Transient transfections 
6 x106 293T cells were seeded in 150 mm plates and grown overnight at 37°C. The 
293T cells were replenished with fresh growth media, then cells were transfected with 
the 25 µg of the desired DNA plasmid and 100 µg of PEI. The DNA and PEI were 
added in DMEM serum free media, allowed to incubate for 15 min before being added 
onto the 293T cells. The cells were left to incubate for 48 hrs at 37°C. Cells were 
trypsinised, pelleted, and washed in ice-cold, sterile 1 X PBS before being lysed in 1 X 
cell signalling lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 
1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 
1 mM sodium orthovanadate, 1 µg/ml leupeptin) containing 1 X protease inhibitor 
(Roche, UK) and 1µM dithiothreitol (DTT, Sigma-Aldrich, UK). From this point 
forward, all experiments were carried out on ice or at 4°C. Cells were incubated on ice 
for 10 min, vortexed frequently, and centrifuged at 16,000 g at 4°C for 20 min. The 
protein lysate supernatant was extracted and placed in a new 2 ml microcentrifuge tube. 
The input lysates were quantified and stored as described in section 2.1.3.2. 
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2.1.2 Cloning  
2.1.2.1 Preparation of Luria-Bertani (LB) broth and agar plates 
20 g of Luria-Bertani (LB) broth powder (Sigma-Aldrich, UK) was resuspended in 1 L 
distilled water and autoclaved at 121°C for 15 min to sterilise. The LB broth was sealed 
and stored at room temperature until further use. Preparation of agar plates was 
conducted by autoclaving 8 g of agar (Fisher Scientific, UK) in 400 ml of LB broth, as 
described above. The agar was left to cool, antibiotics ampicillin or kanamycin added to 
the broth and mixed thoroughly in 100 mg/ml and 50 mg/ml concentrations, 
respectively, and poured into petri dishes (BD Falcon, UK), adhering to typical 
microbiology aseptic techniques. Once the agar solidified, the agar plates were inverted 
and stored in a sealed bag at 4°C until further use.  
 
2.1.2.2 Plasmid transformation, inoculation, plasmid DNA isolation and DNA 
quantification 
250 µl of DH5α competent cells at a efficiency of ~1 X 106 cfu/µg were thawed on ice 
for 15 min. 1 µg of the DNA required to be subcloned was added to the competent cells, 
thoroughly mixed by pipetting, and incubated on ice for 30 min. The tube was placed in 
a 42°C water bath for 30 s and then placed on ice for further 2 min. The transformation 
reaction was diluted by the addition of 1 ml of LB broth and incubated at 37°C in a 
shaker rotating at 220 rpm for 60 min. 200 µl of the cell transformation mixture was 
plated and spread on LB agar plates containing the appropriate antibiotic, and incubated 
inverted overnight at 37°C. Single colonies were picked using a sterile pipette tip and 
placed in flask of 200 ml LB broth with antibiotics. The culture was incubated at 37°C 
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in a shaker rotating at 220 rpm for 12 – 16 hrs. Plasmid DNA was isolated and purified 
using the NucleoBond® Xtra Midi kit (Macherey-Nagel, Germany) according to the 
protocol supplemented by the NucleoBond® Xtra Midi kit. Plasmid DNA was 
resuspended in distilled water, quantified with the Nanodrop 1000 spectrophotometer 
(Thermo Scientific, UK) and stored at -20°C until further use. 
 
2.1.2.3 Sequencing  
DNA sequencing was performed by the UCL sequencing technology facility. Plasmid 
DNA was resuspended in deionised water and 10µl of either 100 ng/µl plasmid DNA or 
1 ng/µl per 100 bp PCR product was submitted for sequencing. 6 µl of sequence 
primers were provided at a concentration of 5pmol/µl. 
 
2.1.3 Western blot 
2.1.3.1 Total protein extraction  
Cells were trypsinised, pelleted, and washed in ice-cold 1 X PBS before being lysed in 
1 X cell signalling lysis buffer (see section 2.1.1.6. for recipe). Cells were incubated on 
ice for 10 min, vortexed frequently, and centrifuged at 16,000 g at 4°C for 20 min. The 
protein lysate supernatant was extracted and placed in a new microcentrifuge tube, and 
stored at -80°C.  
 
2.1.3.2 Protein quantification  
Protein concentration was quantified by adding 2 µl of protein lysate to 1 ml of 
Bradford reagent (Biorad, UK). The solution was vortexed briefly and the absorbance 
was measured using a spectrophotometer at 595 nm. A cuvette containing 1 ml 
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Bradford reagent and 2 µl of lysis buffer was used as a blank. Varying concentrations of 
bovine serum albumin (BSA, Sigma-Aldrich, UK) was used to calculate absolute 
protein concentrations. 25 µg of protein was mixed with 6 X laemmli sample buffer 
(12% sodium dodecyl sulphate (SDS, Sigma-Aldrich, UK), 6% bromophenol blue 
(Sigma-Aldrich, UK), 47% glycerol (Sigma-Aldrich, UK), 60 mM Tris pH 6.8, 600 mM 
DTT, 2.1 ml deionised water), denatured at 100°C for 5 min in the Accublock Digital 
Drybath (Labnet International Inc., USA) and stored at -80°C until ready for 
immunoblotting. 
 
2.1.3.3 Casting gels 
Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) were cast using the Mini-
PROTEAN® Tetra Handcast Systems (Biorad, UK). 1.0 mm and 1.5 mm glass plates 
along with 10 well combs (Biorad, UK) were used to form the gels were used 
containing 30% acrylamide (National Diagnostics, UK), 1.0 M Tris pH 6.8, 1.5 M Tris 
pH 8.8, 10% SDS, 10% ammonium persulphate (APS, Sigma-Aldrich, UK), and 
Tetramethylethylenediamine (TEMED, Sigma-Aldrich, UK). The detailed composition 
of the stacking and resolving gel is listed in Table 2.1. 6% gels were used to detect 
ATM, ATR and BRCA1. 8% gels were used to detect INPP4B, PTEN, AKT 1/2, and 
ERK 1/2.  
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Table 2.1 SDS-PAGE gel composition 
 
Stacking SDS-PAGE 
(ml) 
Resolving SDS-PAGE  
(ml) 
 5%  6% 8% 
Deionised water 3.400 Deionised water 10.600 9.300 
30% Acrylamide 0.840 30% Acrylamide 4.000 
 
5.300 
1.0M Tris pH 6.8 0.630 1.5M Tris pH 8.8 5.000 5.000 
10% SDS 0.050 10% SDS 0.200 0.200 
10% APS 0.050 10% APS 0.200 0.200 
TEMED 0.005 TEMED 0.016 0.012 
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2.1.3.4 Gel Electrophoresis and Transfer 
Protein lysates were thawed and pipetted into the wells of casted SDS-PAGE contained 
in a Mini-PROTEAN Tetra cell (Biorad, UK) filled with 1 X running buffer (250 mM 
Tris base, 1.9 M glycine, 0.1% SDS, deionised water up to 2 L were used to make a 10 
X stock and stored at room temperature). The gel composition varied between 5% and 
8% acrylamide, depending on the size of protein detected. Prosieve quadcolour protein 
marker (Lonza, UK) was used to determine protein size. The SDS-PAGE was 
electrophoresed at 4°C with an initial voltage of 45V, then 90V once the protein had 
entered the resolving gel. The gel was transferred onto a nitrocellulose membrane (Pall 
Corporation, USA) and transferred in 1 X transfer buffer (250 mM Tris base, 1.9M 
glycine, 0.05% SDS, 20% methanol (Sigma-Aldrich, UK) deionised water up to 2 L 
were used to make a 10 X stock and stored at room temperature) at 65V for 120 min at 
4°C.  
 
2.1.3.5 Protein detection 
The proteins contained in the nitrocellulose membrane was stained with Ponceau S 
solution (Sigma-Aldrich, UK), then blocked with 5% skimmed milk (Sigma-Aldrich, 
UK) in 1 X Tris-buffered saline (TBS) (made from a 10 X stock containing 200 mM 
Tris base, 1.4 M sodium chloride and deionised water, pH 7.6) containing 0.1% Tween-
20 (Sigma-Aldrich, UK) (TBST) for 30 min. The blots were then incubated with the 
appropriate primary antibodies (Table 2.2) overnight at 4°C in 1 X TBS containing 
0.05% sodium azide (Sigma-Aldrich, UK) and 5% BSA. The BRCA1 primary antibody 
was diluted in 1 X TBS containing 0.05% sodium azide and 5% skimmed milk powder 
(Sigma-Aldrich, UK). The next day, the blots were washed three times in 1 X TBS 
containing 0.1% Tween20 (TBST, Sigma-Aldrich, UK) for 10 min per wash and probed 
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with the appropriate secondary antibody listed in Table 2.2. (α-rabbit-HRP, α-mouse-
HRP: Cell Signaling, UK; α-goat-HRP, Santa Cruz Biotechnology Inc.,UK) at a 
dilution of 1:10000 for 1 hr at room temperature. The blots were washed a further three 
times in 1 X TBST for 10 min per wash. Protein expression levels were detected by 
incubation of the blots in Lumminata Forte western HRP substrate (Millipore, UK) for 5 
min, followed by detection by film. 
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Table 2.2. Immunoblotting primary antibody dilutions and secondary antibody 
species specification 
Primary 
Antibody 
Primary 
antibody 
dilution 
Primary antibody 
Supplier 
Secondary 
antibody 
species 
Predicted 
Molecular 
Weight (kDa) 
ATM 1:5000 07-1286, Millipore, UK rabbit 350 
ATR 1:10,000 A300-138A, Bethyl Laboratories, UK rabbit 
300 
BRCA1 1:500 sc-642, Santa Cruz, UK rabbit 220 
INPP4B 1:1000 
#8450, Cell Signaling, 
UK 
rabbit 
110 
PTEN 1:1000 
sc-6817-R, Santa Cruz, 
UK rabbit 
55 
Akt, 1/2 1:1000 
sc-1619, Santa Cruz, 
UK goat 
55 
Erk 1/2 1:1000 
#4695, Cell Signaling, 
UK rabbit 
42, 44 
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2.2 Chapter 3 materials and methods 
The methods below represent all the methods used in chapter 3 (‘Establishment of a 
DNA repair defect in ovarian cancer cells’). 
 
2.2.1 Microarray 
The microarray and bioinformatics analyses were conducted by Dr. George Pouligiannis 
(Harvard University, USA) and the methods used are described here for completeness 
of study. The MCF-10A human mammary epithelial cell line was infected with a 
retroviral shRNA against either INPP4B or Renilla luciferase vector control and each 
microarray experiment was performed in triplicate. Total RNA samples were isolated 
using the RNeasy mini kit (Qiagen, UK) and hybridised according to the standard 
protocol for Affymetrix U133 Plus 2.0 arrays at the Beth Israel Deaconess Medical 
Centre Genomics and Proteomics Core (USA). Data pre-processing and quality control 
were performed in R (http://www.r-project.org/) and Bioconductor. Prior to any 
statistical computation, data were normalised using the gc-Robust Multi-array Average 
algorithm. The differentially expressed genes were computed by an empirical Bayes 
shrinkage of the standard errors toward a common value approach embedded within the 
Limma package (Smyth, 2004). P – values were adjusted for multiple comparison using 
the false discovery rate approach implemented by Benjamini & Hochberg (Klipper-
Aurbach et al., 1995).  
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2.2.2 RT-PCR 
2.2.2.1 RNA extraction 
Purification and isolation of RNA from cells was performed with the RNeasy Mini kit 
(Qiagen, UK) using the supplemented protocol.  
 
2.2.2.2 DNase I digestion 
Extracted RNA was digested with DNase I (Thermo Scientific, UK). 20 µg RNA, 20 µl 
10 X reaction buffer, 20 U RNase-free DNase I and deionised water was added into a 
microcentrifuge tube and incubated at 37°C for 30 min. 20 µl of 50 mM EDTA was 
added to the solution and further incubated at 65°C in a heatblock for 10 min. The final 
concentration of the RNA was diluted to 100 ng/µl and the RNA was stored at -20°C. 
The resulting digested RNA was used as a template for reverse transcription. 
 
2.2.2.3 cDNA reverse transcription 
Single-stranded cDNA was obtained from the DNase I digested RNA by reverse 
transcription using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, UK), adhering the supplemented protocol. The cDNA was stored at -20°C 
until further use. 
 
2.2.2.4 qPCR 
Real-time polymerase chain reaction (qPCR) was conducted using the Maxima SYBT 
Green/ROX qPCR Master Mix (2X) (Thermo Scientific, UK) according to the 
supplemented protocol. 1 µl of cDNA template and 200 ng of primer were used for the 
qPCR reaction mix composition. The reaction was run according to the following 
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conditions: 1 cycle of 10 min initial denaturation at 95°C; 40 cycles of 15 sec 
denaturation at 95°C and 30 sec annealing/extension at 60°C. Primers used are listed in 
table 2.3. 
Table 2.3. Primers used for qPCR 
  
Amplicon 
Size Sequence (Forward/Reverse) Tm°  Location 
ANKRD35 150 GCAGGCGTGCGATCTATCAT 62.5 1429-1448 
    GCTGTCGTTGTCTGAGATGTTC 61.2 1578-1557 
CA2 92 ATCACTGGGGGTACGGCAA 58.8 19 - 41 
  TGTATGAGTGTCGATGTCAACAG 58.9 111 - 89 
MPDZ 108 TGTCCAGCTAGTTATTGCCAGA 58.5 645 - 666 
  GTGAACCGGATTAGAGTGAGC 59.8 753 - 755 
TFPI 110 AGCCTTTTTGAATTTCACGGTCC 58.9 619 - 641 
  GCGGCATTTCCCAATGACT 56.7 729 - 711 
C5ORF13 118 GTCTGGGTCAGTCAAGAACCA 61.3 127-147 
    AGGCAGCGTTTGTCTCATCG 62.8 244-225 
β-actin 250 CATGTACGTTGCTATCCAGGC 60.8 393-413 
    CTCCTTAATGTCACGCACGAT 60.2 642-622 
CA12 100 ATCTTAAAGGAACAGCCTTCCAG 58.9 46 - 68 
  GACGGGTACTTCTTGGACCA 59.4 146 - 127 
SPARC 104 AGCACCCCATTGACGGGTA 58.8 719 - 737 
  GGTCACAGGTCTCGAAAAAGC 59.8 823 - 803 
GALNT7 137 GGTTCATCTTACGCAGTTTGCT 58.4 17 - 39 
  GCATGGGGTCATTGACATCTC 59.8 154 - 134 
NTN4 119 GAGTAGCTGGAGTGAGTTCCC 61.3 65-85 
    GTACAGTTCGGTAGCATTCTGAC 60.7 183-161 
GPC1 118 CCCTGCCCTGACTATTGCC 62.1 799-817 
    CCCAGAACTTGTCGGTGATGA 61.7 916-896 
CAMK2N1 67 GAGCAAGCGGGTTGTTATTGA 60.9 156-176 
    TGCCTTGTCGGTCATATTTTTCA 60.5 222-200 
TMEM98 151 GAAGACTGGATCGAAGATGCC 60.2 241-261 
    CCACAATGATGTCGCTGACAC 61.6 391-371 
INPP4B 156 CCCTGACATTTGTGCTCCTT 64.0 1802-1821 
  GGAAGCCTGGGTCATACAGA 64.0 1957-1938 
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2.2.3 Comet assay 
2.2.3.1 Preparation of samples for dose response curves and DNA repair curves 
175,000 cells per well were seeded in a 6-well plate (BD Falcon, UK) and allowed to 
adhere overnight at 37°C. The cells were trypisised and resuspended with growth media 
to a final volume of 2.5x104 cells per ml. For dose response experiments, the cells were 
irradiated with 15, 25 and 30 Gy X-ray using the A.G.O. HS 321 kV X-ray system.  For 
the establishment of DNA repair curves, the cells were irradiated with 30 Gy X-ray. 
Untreated samples were kept on ice. The cells were allowed to recover 0, 15, 30, 45, 60 
and 90 mins after irradiation at 37°C. At the specified time points, the cells were 
centrifuged at 300 g for 5 mins, media aspirated and cells thoroughly resuspended in 
freezing media containing FBS with 10% DMSO. The cells were frozen at -80°C for a 
minimum of 24 hrs.  
 
2.2.3.2 Electrophoresis and staining 
Cells were prepared as indicated above. All of the following steps were carried out on 
ice. Frozen cells were thawed and resuspended into a cell suspension of 2.5x104 cells 
per ml in growth media. Cells were resuspended in 1 ml of molten 1% low-gelling-
temperature agarose type VII (Sigma Aldrich, UK) and pipetted onto duplicate slides 
pre-coated with 1% type 1-A agarose (Sigma-Aldrich, UK). The cells were lysed in 
lysis buffer (100 mM disodium EDTA, 2.5 M sodium chloride, 10 mM pH 10.5 Tris-
HCl) containing 1% triton X-100 on ice for 1 hr in the dark. Under dark conditions, the 
cells were then washed in distilled water every 15 min for 1 hr, incubated in ice-cold 
alkali buffer (50 mM sodium hydroxide, 1 mM pH 12.5 disodium EDTA) for 45 min 
and then electrophoresed for 25 min at 18V (0.6 V/cm), 250 mA. The slides were rinsed 
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once in neutralising buffer (0.5 M Tris-HCl, pH 7.5), once in 1 X PBS and left to dry 
overnight. The following day the slides were rehydrated with distilled water, stained 
with 2.5 µg/ml propidium iodide solution (Sigma- Aldrich, UK), rinsed again in 
distilled water and placed at 37°C until dry.  
 
2.2.3.3 Data analysis 
The comets were visualised by a Nikon inverted microscope with a super high pressure 
mercury lamp using a 580 nm dichromic mirror, 510 – 560 nm excitation filter and 590 
barrier filter for propidium iodide staining. Measurements were taken by the KOMET 
version 6.0 software from Andor Technology.  In total, 50 cells per sample (25 cells per 
slide) were analysed. Experiments were conducted independently three times in 
duplicates.   
 
2.2.4 Immunofluorescence assay 
2.2.4.1 Cell seeding and genotoxic treatment 
2.5 x 104 and 3.5 x 104 of Ovca429 and Ovca433 knockdown cell pools, respectively, 
were seeded in 8 well chamber slides (PAA Laboratories Ltd., UK) and grown 
overnight at 37°C. The cells were then exposed to genotoxic stress under the following 
conditions: 2 Gy x-ray irradiation for γH2AX and 53BP1 detection; 10 Gy x-ray 
irradiation for RAD51 and BRCA1 foci detection; 1 hr incubation of 1 µM etoposide 
(Sigma-Aldrich, UK) for γH2AX and 10 µM etoposide for 53BP1 and RAD51 foci 
formation.  
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2.2.4.2 Foci detection 
After treatment, the cells were incubated at 37°C to allow for DNA repair and the cells 
fixed at the following time points after DNA damage exposure: 0 hr, 30 min, 60 min, 
180 min, 4 hrs, 8 hrs, 24 hrs, 48 hrs and 72 hrs. The cells were fixed in 4% 
paraformaldehyde (Alfa Aesar, UK) for 10 min, permeabilised for 10 min in 0.5% 
Triton X-100, and blocked in 10% normal goat serum (Invitrogen, UK) for 1 hr at room 
temperature. The slides were incubated with the appropriate primary antibody (Table 
2.4) overnight at 4°C on a rotator, washed three time with 1 X PBS containing 0.1% 
Tween-20 (PBST) for 10 min each, and incubated with Alexa Fluor 488-conjugated 
goat α-rabbit or α-mouse secondary antibody (Invitrogen, UK) for 1 hr at room 
temperature in the dark. From this point forward, all methods were conducted in the 
dark. Cells were washed twice in 1 X PBST and once in 1 X PBS  for 10 min each and 
mounted using EverBrite Mounting Medium with DAPI (Biotium, UK). Fluorescence 
images were captured with inverted microscope Zeiss Axio Observer Z1 (Zeiss) and 
visualised using AxioVision 4.8.2.0 software. At least images of 50 cells per condition 
were captured and foci counted manually by eye. Experiments were conducted 
independently three times. The antibodies used for immunofluorescence studies are 
listed in table 2.4. 
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Table 2.4. Immunofluorescence antibody dilutions 
Primary 
Antibody 
Primary 
antibody 
dilution 
Primary antibody 
Supplier 
Secondary 
Antibody 
Secondary 
antibody 
dilution 
53BP1 1:500 #4937, Cell Signaling, UK rabbit 1:1000 
BRCA1 1:500 sc-642, Santa Cruz, UK rabbit 1:1000 
H2AX 1:500 05-636, Millipore, UK mouse 1:1000 
RAD51 1:500 sc-8349, Santa Cruz, UK rabbit 1:1000 
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2.2.5 Cell cycle analysis 
2.2.5.1 Treatment conditions 
Ovca433 parental and knockdown cell lines were seeded at a cell density of 5.0 x 104 
cells per 100 mm plate, respectively, and allowed to adhere overnight at 37°C. To 
assess basal levels of cell cycle progression, cells were serum starved by the addition of 
RPMI media containing 2 mM L-glutamine and left to incubate for a further 18 hrs, 
before being replenished with growth media containing 10% FBS.  
 
2.2.5.2 Sample Fixation  
Cells were trypsinised, counted and 1x106 cells were centrifuged at 300 x g for 5 min, 
washed in 1 X PBS, further centrifuged at 300 x g for 5 min and resuspended in 50 µl of 
1 X PBS. The resuspended cells were added drop-wise into 1 ml 70% absolute ethanol 
while being vortexed at a medium speed. The cells were frozen at -20°C for a minimum 
of 3 hrs prior to staining.  
 
2.2.5.3 Staining and analysis  
The cells were thoroughly resuspended and 200 µl of ethanol-fixed cells were added to 
a 12 x 75 mm polystyrene tube (BD Biosciences, UK). The cells were centrifuged at 
300 x g for 5 min, washed in 500 µl 1 X PBS, further centrifuged at 300 x g for 5 min, 
and resuspended in 200 µl of staining solution (7.5 µg/ml propidium iodide, 20 µg/ml 
RNase A (Sigma-Aldrich, UK), 0.01% Triton-X, 0.05% sodium azide, stored in the 
dark at 4°C). The cells were incubated for 30 min in the dark at room temperature 
before being analysed on the Muse Cell Analyser (Millipore, UK). The gate settings 
were adjusted as depicted in figure 2.4.  
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Figure 2.4. Example of gate settings for the MUSE cell sample analyser. Propidium 
iodide, staining of nuclear cellular content distinguish cells at different stages of the cell 
cycle, which differ in DNA content. Resting cells (G0/G1) contain two copies of each 
chromosome. As cells begin cycling, they synthesise chromosomal DNA (S phase). 
Fluorescence intensity from the DNA intercalating dye, propidium iodide, increases 
until all chromosomal DNA has doubled (G2/M phase). At this state, the G2/M cells 
fluoresce with twice the intensity of the G0/G1 population. The G2/M cells eventually 
divide into two cells. The assay thus utilises the differential staining of cells based on 
DNA content. Image source: http://www.emdmillipore.com/GB/en/product/Muse®-
Cell-Cycle-Assay-Kit,MM_NF-MCH100106#overview 
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2.3 Chapter 4 materials and methods 
The methods below represent all the methods used in chapter 4 (‘Biological function of 
INPP4B’). 
 
2.3.1 Immunoprecipitation 
293T cells were transiently transfected with 25µg pcDNA3-FLAG empty vector or 
peak-FLAG-INPP4B vector, as described in section 2.1.1.6. The lysates were incubated 
with 10 µl anti-FLAG M2 beads (Sigma-Aldrich, UK) for 2 hrs on a rotator at 4°C. The 
beads were spun down at 5000 rpm at 4°C for 1 min, then allowed to settle for 2 min on 
ice. The supernatant was carefully removed, ensuring no beads are removed. The beads 
were washed by the addition of 1 ml ice cold 1 X TBST, the closed microcentrifuge 
tube inverted several times, and centrifuged at 2,300 x g at 4°C for 1 min. This washing 
procedure was repeated twice in 1 X TBST and once in 1 X TBS. After removing the 
supernatant from the last wash, the immunoprecipitated complexes were eluted from the 
beads by the addition of 8 µl 5 X sample buffer. The beads in sample buffer was 
vortexed briefly, incubated at 95°C for 5 min and centrifuged at 16,000 x g for 2 min at 
room temperature. The immunoprecipitated complexes were analysed in a 5% 
acrylamide SDS-PAGE by immunoblotting, as described in section 2.1.3. Primary 
antibodies used were as follows: α-BRCA1, α-ATR, α-ATM, α-INPP4B, α-PTEN (see 
table 2.2. for dilutions and supplier). 
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2.3.2 MEF experiments 
INPP4Bfl/fl MEFs were infected with Adenovirus Cre recombinase (1x103pfu/ml, 
1x104pfu/ml, 1x105pfu/ml, 1x106pfu/ml Ad5CMVCre-eGFP, Gene Transfer Vector 
Core, University of Iowa, USA) overnight. 10 ml of the appropriate cell line growth 
media was added to the virus supernatant and allowed to incubate overnight at 37°C. 
The next day, the virus and media mixture was aspirated and replaced with 10 ml of 
regular growth media. Protein quantification was conducted following the protocol in 
section 2.1.3. Primary antibodies used were as follows: α-BRCA1, α-ATR, α-ATM, α-
INPP4B (see table 2.2. for dilutions and supplier). 
 
2.3.3 GST pull down assay 
2.3.3.1 Generation of INPP4B fragments and preparation of entry and expression 
vectors 
Fragments of INPP4B were generated by using pEAK FLAG-INPP4B as a template, as 
shown in figure 2.5. Primers (Eurofins MWG Operon, Germany) are listed in table 2.5. 
Polymerase chain reactions (PCR) were conducted using the Novagen KOD Hot Start 
DNA Polymerase (Millipore, UK) in a TProfessional Basic Gradient Thermocycler 
(Biometra, Germany). A high fidelity polymerase was used to ensure amplification the 
correct DNA sequences. 100 ng of pEAK INPP4B template and 200 ng of primer were 
used for the PCR reaction mix composition, along with the reaction components and 
volumes listed in the manufacturer’s supplemented protocol, for a total reaction volume 
of 50 µl. The reaction was run according to the following conditions to generate the 
middle INPP4B fragment: 1 cycle of 2 min polymerase activation at 95°C; 30 cycles of 
20 sec denaturation at 95°C, 30 sec annealing at 63°C and 2 min extension at 70°C; 1 
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cycle of 3 min of final extension at 70°C. Due to the differing annealing temperatures of 
the primer pairs, for the N-terminal and C-terminal INPP4B fragments, the PCR 
reaction was conducted in a multi-step gradient fashion as follows: 1 cycle of 2 min 
polymerase activation at 95°C; 30 cycles of 20 sec denaturation at 95°C, 30 sec 
annealing at 53 - 67°C, with 2 cycles conducted per temperature every 2 degrees, and 2 
min extension at 70°C; 1 cycle of 3 min of final extension at 70°C. The PCR product 
was stored at 4°C until further use. The pENTR1A entry vector and the pGEX-KG 
expression vector were generous gifts from Dr Pablo Rodriguez (UCL, UK). Isolation 
and purification of the DNA plasmids were obtained as described in section 2.1.2.2.  
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Table 2.5. Primers used for amplifying INPP4B fragments 
Primer Sequence (5’ à  3’)  Tm° 
INPP4B_1_aa_S 
sense primer CCGTCGACATGGAAATTAAAGAG 58.9 
INPP4B_460_aa_AS 
antisense primer 
 
AAGCGGCCGCGGCATGTACAAAAAG 66.3 
INPP4B_460_aa_S 
sense primer CCGTCGACATGGAAAAAACAGAG 60.6 
INPP4B_925_aa_AS 
antisense primer 
 
AAGCGGCCGCTTAGGTGTCAGC 65.8 
INPP4B_200_aa_AS 
antisense primer 
 
AAGCGGCCGCATCTGTGGTGAT 64.0 
INPP4B_200_aa_S 
sense primer 
 
CCGTCGACATGGTACAGGGACAA 64.2 
INPP4B_760_aa_AS 
antisense primer 
 
AAGCGGCCGCAAACCTTTCAGC 64.0 
INPP4B_760_aa_S 
sense primer 
 
CCGTCGACATGGGAGATGTCTCT 64.2 
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Figure 2.5. INPP4B fragments. pEAK FLAG-INPP4B was used as a template to 
generate three different INPP4B fragments by PCR: N-terminus fragment constituting 1 
– 460 aa of INPP4B; Middle fragment constituting 200 – 760 aa of INPP4B; C-terminus 
fragment constituting 460 – 925 aa of INPP4B. 
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2.3.3.2 Cloning of INPP4B fragments into pENTR1A entry vector 
The PCR product and digested entry vector were purified using the Nucleospin Extract 
II kit (Macherey Nagel, Germany) according to the supplemented protocol. The purified 
PCR product was then digested using restriction enzymes Sal I and Not I (New England 
Biolabs, UK) with the following reaction constituents: 200 µl purified PCR product, 2 
µl Sal I (100,000 U/ml), 2 µl Not I (50,000 U/ml), 21 µl distilled H2O, 25 µl 10X 
restriction enzyme buffer 3.1 (New England Biolabs, UK). The reaction mixture was 
gently mixed and incubated overnight in a 37°C waterbath. The digested products were 
subjected to electrophoresis at 70V in a 1% agarose gel (1% w/v agarose (Sigma-
Aldrich, UK), 1 X Tris Acetate EDTA (TAE) buffer (40 mM Tris-base, 20 mM glacial 
acetic acid (VWR Chemicals, UK), 1mM EDTA) alongside the peqGOLD 1kb DNA 
ladder (Peqlab, UK). Once the product was sufficiently run out, the bands were 
visualised on a UVIvue BTX 20M 312nm Transilluminator (Uvitec, UK), excised at the 
correct molecular weight and the gel purified using the Nucleospin Extract II kit 
(Macherey Nagel, Germany), according to the manufacturer’s protocol. Similarly, the 
pENTR1A vectors were digested as follows: 10 µg DNA plasmid, 2 µl Sal I, 2 µl Not I, 
and the appropriate amount of distilled H2O and 10X restriction enzyme buffer 3.1 
(New England Biolabs, UK) to a total volume of 50 µl. As above, the digested product 
was electrophoresed at 70V in a 1% agarose gel, excised, purified, and stored at -20°C 
until further use. The sticky ends of the INPP4B fragments and pENTR1A vector 
formed, as a result of the restriction enzymes used, were ligated with T4 DNA ligase 
(New England Biolabs, UK) using 1 µg INPP4B fragment PCR product, 10 µg 
pENTR1A vector, 1 µl T4 ligase (400,000 U/ml), 5 µl 10X T4 DNA ligase reaction 
buffer and distilled water to a total volume of 50 µl. The reaction mix was gentle mixed 
by swirling, incubated at room temperature for an hr and concentrated using the 
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Vacufuge basic concentrator (Eppendorf, UK) to reduce the volume to approximately 
20 µl. 10 µl of the concentrated ligation mixture was added into 50 µl gold efficiency α-
select competent cells (Bioline, UK), and transformed as described in section 2.1.2. 
using LB-kanamycin agar plates. Positive colonies were selected and inoculated in a 
bacteria culture, the DNA isolated and purified, and checked for correct insertion size 
by digestion and visualisation on a 1% agarose gel.  
 
2.3.3.3 LR recombination reaction 
The INPP4B fragments inserted in the pENTR1A entry vector was transferred to 
destination vector pGEX-KG using the Gateway LR Clonase II Enzyme Mix 
(Invitrogen, UK) to catalyse the reaction. The reaction was set up with 400 ng entry 
clone, 300 ng destination vector, 4 µl 5 X clonase reaction buffer and Tris-EDTA (TE) 
buffer pH 8.0 up to a volume of 16 µl, and carried out according to the manufacturer’s 
supplemented protocol. The LR reaction was transformed as described in section 2.1.2.2 
and plated on LB-ampicillin agar plates to select for the ampicillin-resistant pGEX-KG 
plasmids. Positive colonies were selected and cloned, the DNA isolated and purified, 
and checked for correct insertion size by digestion and visualisation on a 1% agarose 
gel. 
 
2.3.3.4 Purification of GST-tagged recombinant proteins 
The colonies with the correct insertion size was transformed in E. Coli BL21 (Promega, 
UK) for maximal GST-tagged protein expression. The positive colonies were selected, 
inoculated in a 20 ml LB-ampicillin pre-culture and grown overnight in a 37°C 
incubated shaker. 5 ml of the densely grown culture were added to 200 ml ampicillin 
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LB-broth per fragment, and grown in the 37°C shaken until the culture reached an 
OD600 of 0.6 – 1.0. Desired GST protein expression was induced adding 0.1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Scientific, UK) and cultured 
for an additional 3 hrs at 37°C in the shaker. The bacteria were pelleted by 
centrifugation at 3500 x g for 10 min at 4°C, resuspended in ice-cold PBS lysis buffer 
(1% Triton-X and protease inhibitors from Roche tablets in 1 x PBS), at a volume of 4 
ml PBS lysis buffer per 200 ml bacteria culture. The bacterial suspension was sonicated 
on ice with 3-5 cycles of 10 sec sonication, followed by 10 sec rest. The sonicated 
lysate was pelleted again by centrifugation at 12,000 x g for 15 min at 4°C and the 
supernatant transferred to a fresh 15 ml falcon on ice.  
 
2.3.3.5 Pull down of GST-tagged proteins 
Glutathione Sepharose Fast Flow (GE Healthcare Life Sciences, UK) beads were 
precleared overnight on a rotator at 4°C in 5% skimmed milk in PBS lysis buffer; the 
beads were washed once in PBS lysis buffer and stored in a 1:1 slurry with PBS lysis 
buffer. Per 1 ml lysate used for each INPP4B fragment 250 µl of 1:1 sepharose bead 
slurry was added, and the beads were incubated at 4°C on a rotator for 2 hrs. A negative 
control was included by incubating the sepharose beads in PBS lysis buffer containing 
5% skimmed milk. The lysate was centrifuged at 750 x g for 1 min at 4°C to pellet the 
beads, supernatant removed and beads washed once in 1 ml ice cold PBS lysis buffer, 
centrifuged again to pellet the beads, and incubated with FLAG-ATR lysate for 30 min 
at 4°C on a rotator (293T cells were transiently transfected with 25 µg pcDNA3.1 
FLAG-ATR vector and lysed as described in section 2.1.1.6). The FLAG-ATR lysate 
was removed by centrifugation, and the beads washed three times in ice cold PBS lysis 
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buffer, before being eluted in 40 µl of 6 X sample buffer. Immunoblotting was carried 
out as described in section 2.1.3. Antibody detecting ATR (Bethyl Laboratories, UK; 
1:10,000 primary antibody dilution) was used to detect interaction of ATR with GST-
tagged INPP4B fragments. Input lanes were also detected and  represents 1% of protein 
lysates in pulldown assays. 
 159 
2.4 Chapter 5 materials and methods 
The methods below represent all the methods used in chapter 5 (‘Treatment of INPP4B 
deficiency with DNA repair inhibitors’). 
 
2.4.1 Drug handling and storage 
10 mg of olaparib (KU-0059436, Selleck Chemicals, UK) was resuspended in DMSO to 
a stock concentration of 10 mM. Etoposide (Sigma-Aldrich, UK) was resuspended in 
DMSO to a stock concentration of 50 mM. Chk 1 inhibitors (LY2603618 and 
LY2940930, Eli Lilly, UK) was resuspended in DMSO to a stock concentration of 10 
mM. Cisplatin (Teva UK Limited, UK) was generously provided by Dr. Victoria 
Spanswick (UCL, UK) in a 3.3 mM aqueous solution. Cisplatin was stored in the dark 
at room temperature. The remaining drugs were stored in 50 µl aliquots and stored at -
20°C. 
 
2.4.2 Cell proliferation assay 
3000 and 4000 cells per well of Ovca429 and Ovca433 knockdown cell pools, 
respectively, were seeded in triplicates per condition in a 96-well plate (BD Falcon, 
UK) and grown overnight at 37°C. The cells were treated with drugs diluted in growth 
media in a range of concentrations as follows: Olaparib – 1 µM, 5 µM, 10 µM, 25 µM, 
50 µM and 100 µM; LY2603618 – 250 nM, 500 nM, 750 nM, 1 µM, 5 µM, 10 µM and 
25 µM; LY2940930 – 50 nM, 100 nM, 500 nM, 500 nM, 1 µM, 5 µM, 10 µM and 
50µM. DMSO was used as a control. 24 hrs after seeding the cells, the cells were 
treated with drugs for 72 hrs. AlamarBlue (Thermo Scientific, UK) was used as a cell 
viability indicator to indirectly measure cell proliferation (metabolic readout). It uses 
 160 
the natural reducing power of living cells to convert resazurin to the fluorescent 
molecule, resorufin. Resazurin is a nontoxic, cell permeable compound that is blue in 
color and virtually nonfluorescent.  Upon entering cells, resazurin is reduced to 
resorufin, which produces very bright red fluorescence. Viable cells continuously 
convert resazurin to resorufin, thereby generating a quantitative measure of viability—
and cytotoxicity. Fluorescence was measured by a spectrophotometer at an excitation 
wavelength of 590 nm and emission wavelength of 560 nm between 3 – 6 hrs after the 
addition of AlamarBlue.  
 
2.4.3 Clonogenic survival assay 
1000 cells per well were seeded in triplicates in a 6-well plate (BD Falcon, UK) and 
grown overnight at 37°C. Experiments were conducted using single agent treatments 
and double agent treatments. Dual drug treatment of cisplatin and olaparib was 
administered by adding 10 µM cisplatin on day 1 for 2 hrs, followed by continuous 1 
µM olaparib treatment for 6 days. Cisplatin was removed by aspirating the media 
containing the drug, and washing the cells with fresh media before pipetting the media 
containing olaparib into the wells. Continuous treatment of olaparib was replenished 
every 48 hrs with fresh drug and media. DMSO was used as a control. The cells were 
grown until colonies of 50 or more cells were established. The cells were washed with 1 
X PBS and fixed and stained with 1 X PBS containing 6% Glutaraldehyde (Sigma-
Aldrich, UK) and 0.5% Crystal Violet (Sigma-Aldrich, UK) for 2 hrs at room 
temperature. The dye was removed and the cells were washed with deionised water and 
left to dry overnight. The number colonies were counted manually by eye. Experiments 
were conducted independently three times in triplicates. 
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2.4.4 Xenograft experiments 
The xenograft experiments were conducted by Dr. Christina Gewinner (UCL, UK). 
Ovca429 shRNA-Renilla luciferase and Ovca429 shRNA-INPP4B expressing cells 
were injected subcutaneously in female NOD/SCID mice (1x107 cells/animal, n=8 each 
cell pool). Tumours were grown until a 50 to 60mm3 tumour volume was reached, then 
animals were treated with 50mg/kg olaparib daily consecutively for 5 days followed by 
two days break for two weeks. Tumour occurrence and size as well as animal weight 
and health were evaluated. All animal studies were approved by the UCL Biological 
Services Ethical Review Committee and licensed under UK Home Office regulations 
and the Guidance for the Operation of Animals (Scientific Procedures) Act 1986 (Home 
Office, London, UK). Project licence number PPL 70/7134. 
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CHAPTER 3. Establishment of a DNA repair defect in ovarian 
cancer cells 
3.1 Introduction 
Aberrant DNA repair processing and/or dysfunctional cell cycle checkpoint results in a 
predisposition to developing cancer, as well as altered responses to anti-cancer 
therapies, namely DNA-damaging chemotherapy and radiotherapy. The loss of function 
of a DNA repair pathway may result in increased activation of other pathways as a 
compensatory mechanism, and can cause resistance to DNA-damaging therapies. 
Inhibitors of these pathways may re-sensitise tumours to these treatments. Conversely, 
tumours that harbour dysfunctional DNA repair mechanisms may benefit from targeted 
therapies against the faulty pathway, which render the DNA damage irreparable by way 
of synthetic lethality. Establishing DNA repair defects to identify alternate DNA repair 
pathways for therapeutic exploitation may therefore result in clinical benefit for patients 
harbouring these defects. 
 
Loss of INPP4B is associated with tumourigenesis, radio-resistance, aggressive cancer 
sub-types and poor survival in a wide variety of tissue types. Reduced INPP4B 
expression has been found across a variety of ovarian cancer subtype, mostly in ovarian 
serous and endometrioid adenocarcinomas, as depicted in figure 3.1-3.2.  
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Figure 3.1. INPP4B expression across various ovarian cancer subtypes (‘Hendrix 
Ovarian’ dataset). Image source: www.oncomine.com depicting data from Hendrix et 
al. (Hendrix et al., 2006)  
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Figure 3.2. INPP4B expression across various ovarian cancer subtypes (‘Tothill 
Ovarian’ dataset). Image source: www.oncomine.com depicting data from Tothill et 
al. (Tothill et al., 2008) 
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However, validation of INPP4B in the context of DDR is yet to be reported in more 
detail in scientific literature. In order to further investigate and identify novel roles 
associated with loss of INPP4B, a microarray analysis was performed by Dr. George 
Pouligiannis (Harvard University, USA, current address: Institute for Cancer Research 
(ICR), London) and Dr. Christina Gewinner (UCL, UK). Stable knockdown cell pools 
expressing RNA hairpins against INPP4B or Renilla luciferase as a control were used to 
compare differential gene expression using the Affymetrix Human Genome U133 (HG-
133) Plus array (Affymetrix, USA; appendix 1). Upon microarray analysis, BRCA1-
mutant and poor survival gene signatures revealed in INPP4B deficient MCF-10A cells 
by microarray analysis. The full bioinformatics analysis of the microarray studies can be 
found in appendix 1 – 7. 
 
Since BRCA1 mutations are a common occurrence in ovarian cancers, validation of the 
BRCA1 gene signature was conducted to assess the validity of the microarray findings. 
Data from each significant hit on the gene signature was collected from the microarray 
database, the protein functions researched and the hybridisation location for each probe 
was obtained. The primers used for qPCR experiments were selected from an 
established primer database (PrimerBank; http://pga.mgh.harvard.edu/primerbank/) 
such that they generated similar amplicon sizes, when available. To note, the hairpins 
used for this experiment were thoroughly tested for specificity and off-target effects 
(Gewinner et al., 2009; Westbrook et al., 2005). Knockdown cell pools of the MCF-10A 
cells were independently generated, and RNA carefully extracted. The RNA prepared 
for the microarray analysis was prepared in triplicates comprising sample preparations 
from two differently established knockdown cell pools and different RNA preparations. 
In addition to validation by qPCR, the microarray data were compared to a 60 gene 
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BRCAness gene signature defined by Konstantinopoulos et al. (Konstantinopoulos et 
al., 2010) to assess the gene signature by an alternative method. 
 
The presence of a DNA-repair defect in the context of female-related cancers has great 
clinical implications due to the prevalence of BRCA1/2 mutations found in breast and 
ovarian cancers. With respect to ovarian tumours, BRCA1/BRCA2 germline mutations 
represent up to 15% of high grade serous ovarian carcinomas (HGSC), and mounting 
evidence is pointing to a larger proportion of patients whose tumour biology reflects the 
‘BRCAness’ phenotype. The ‘BRCAness’ phenotype has been defined by Chalasani et 
al. to be the phenotype of deficient BRCA function (Chalasani and Livingston, 2013). 
Muggia et al. further defines ‘BRCAness’ to include sporadic mutations and epigenetic 
alterations of the BRCA genes themselves, as well as other genes that contribute to a 
functionally deficient BRCA phenotype (Muggia and Safra, 2014).  5 – 31% of sporadic 
epithelial ovarian cancers (EOCs) exhibit dysfunctional BRCA1 through BRCA1 
promoter methylation (Baldwin et al., 2000; Esteller et al., 2000; Geisler et al., 2002). 
Amplification of EMSY, an inhibitor of BRCA2, was found amplified in 17% of 
sporadic ovarian tumours (Hughes-Davies et al., 2003). Defects in HR have been 
identified in up to 50% of EOC (CGARN, 2011), representing a large proportion of 
ovarian cancer patients which may benefit from treatment with therapies that target 
DNA repair.  
 
Given the prevalence of ‘BRCAness’ found in ovarian tumours, in conjunction with the 
DNA repair defect identified in the microarray data upon loss of INPP4B, further 
investigations were carried out to examine the role of INPP4B in the context of DNA 
repair in ovarian cancer. For the assessment of DNA repair integrity and DNA damage 
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response (DDR) in relation to INPP4B loss, key experiments were conducted using 
comet assays and immunofluorescence assays. Comet assays, also known as single cell 
gel electrophoresis, is a tool to measure DNA damage in an individual cell. Initially 
developed by Ostling and Johanson in 1984 (Ostling and Johanson, 1984), and further 
modified a few years later by Singh et al. (Singh et al., 1988), the assay has the ability 
to identify broken DNA fragments through a series of procedures that involve lysis of 
agarose-embedded cells, gel electrophoresis, staining and microscopic analysis 
(described in detail in section 2.3.1). Lysis of the cells results in the removal of cellular 
membranes and release of soluble cell components, resulting in bare nucleoids 
remaining in the gel. The application of an electric field allows the migration of broken 
fragments of DNA, and damaged nucleoids can be visualised by propidium iodide 
staining. The resulting images can be divided into two parts: comet heads representing 
the intact DNA of a nucleiod, and comet tails representing broken fragments and 
damaged DNA “trailing” behind (figure 3.3). The olive tail moment is a measure of 
numerically assessing DNA damage by measuring percentage tail DNA and tail length 
and taking the product of these two values (Olive et al., 1990). Immunofluoresence 
assays were also conducted to assess the response of critical DNA repair proteins upon 
genotoxic stress. γH2AX has been commonly used as a marker of DSB through 
immunofluorescence assays that enable the visualisation and quantification of foci in 
individual cells (Kuo and Yang, 2008). RAD51 and 53BP1 are important DNA repair 
proteins involved in DSB repair in HR and NHEJ, respectively. In addition, cell cycle 
progression was investigated in INPP4B-deficient cells. DNA lesions activate 
checkpoint pathways that regulate specific DNA-repair mechanisms. The PI3K/Akt 
pathway has been implicated in the G1/S transition; Akt prevents cyclin D1 degradation 
 168 
by regulating the activity of GSK3 (Diehl et al., 1998) and can negatively influence the 
expression of the CDK-inhibitor p27/kip1 protein (Shin et al., 2002).  
 
 
Figure 3.3. Comet head and comet tail images. The left image represents two 
nucleoids possessing no comet tails. The right image represents two nucleoids which 
possess a comet tail surrounding a comet head. The olive tail moment is calculated by 
multiplying the percentage tail DNA with the comet tail length. Cells used were 
Ovca433 (left image: unirradiated; right image: irradiated with 30 Gy X-ray) using the 
method details in 2.3.1. 
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A panel of ovarian cancer cell lines were obtained and characterised by assessing the 
protein expression levels of components of the PI3K/Akt pathway (INPP4B, PTEN and 
phospho-Serine 473 Akt), as well as activation of MAPK and mTOR pathways through 
phosphorylated p42/44 MAP kinases (phospho-p42/44) and phosphorylated ribosomal 
S6 (phospho-S6), respectively (figure 3.4). The characterisation of these cell lines was 
conducted by Dr. Christina Gewinner (UCL, UK). The PI3K/Akt pathway activation 
observed in the cell lines reflects the mutation/loss status of critical components in this 
pathway (PTEN or INPP4B loss, as well as PIK3CA mutations). From the ovarian 
cancer panel, epithelial cell lines Ovca429 and Ovca433 were selected for comparative 
experiments due to their robust protein expression of INPP4B and rapid growth rate. 
Knockdown cell pools of these cell lines were generated using shRNA hairpins directed 
against INPP4B and Renilla luciferase as a control (figure 3.5). Knockdown cell pools 
containing a heterogeneous population of cells that possess varying knockdown levels 
were purposely used to reflect tumour heterogeneity. Since knockdown of INPP4B 
diluted over time due to clonal selection shift, the cell pools were frequently re-derived 
and monitored for knockdown efficiency to guarantee reliability of experimental data.  
In general, a knockdown of 50% and more of reduced protein expression was generated 
for each knockdown cell pool generated. INPP4B knockdown in this study was 
achieved with the same retroviral hairpin directed against INPP4B as used in a study 
conducted by Gewinner et al. (Gewinner et al. 2009), where knockdown efficiency of 
60% in two-dimensional studies pointed to a tumour suppressor function of INPP4B as 
well as a strong haploinsufficiency function of INPP4B. Furthermore, analyses of allelic 
loss of INPP4B in the cBioPortal for Cancer Genomics (MSKCC) and in collaboration 
with Dr. Andrea Richardson at Harvard University (Gewinner et al. 2009) resulted in 
only heterozygous loss of INPP4B in human epithelial tumours. Finally, Cre-
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recombinase treatment of INPP4Bfl/fl MEFs causing homozygous allelic deletion of 
INPP4B resulted in non-viability of these ‘floxed’ MEFs in long-term culture, 
suggesting that homozygous loss of INPP4B may be disadvantageous for cells and cells 
with haploinsufficiency have a growth advantage. 
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Figure 3.4. Characterisation of ovarian cancer cell lines. Immunoblotting of several 
ovarian cancer cell lines was performed to investigate protein expression levels and 
pathway activation of various components of the PI3K/Akt pathway and MAPK 
pathway. Protein expression levels of INPP4B, PTEN, pS473-Akt, total Akt, phosphor-
p42/44, total p42/44 and pS6 were detected in ovarian cancer cell lines A2780, 
OAW42, Igrov1, Ovca429, Ovca433, Hoc7, Ovcar3, Skov3, Hey. In addition, PIK3CA, 
Trp53, and BRCA1 mutation status are summarised. Cell line profiling was conducted 
by Dr. Christina Gewinner (UCL, UK).  
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Figure 3.5. INPP4B knockdown of Ovca429 and Ovca433 cells. (A) Representative 
immunoblots displaying the knockdown efficiency of Ovca429 and Ovca433 cells using 
shRNA hairpins directed against INPP4B (110 kDa) and Renilla luciferase. Total Akt 
protein expression was used as a loading control. The knockdown effect was regularly 
monitored every two weeks. The doublet signal seen here is likely to be due to various 
post-translational modifications of the INPP4B protein such as acetylation or 
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phosphorylation, as suggested by Cell Signaling Inc.. The immunoblot for downstream 
phosphoSer473 Akt activation due to INPP4B knockdown can be found in figure 4.1. 
(B) The quantification of the protein levels revealed an INPP4B knockdown of 52% and 
51% in Ovca429 and Ovca433 INPP4B knockdown cells pools, respectively. Semi-
quantitative analysis was conducted using ImageJ. Quantification is representative of 
three independent experiments using three different knockdown cell pools. 
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3.2 Results 
3.2.1 Validation of BRCA1 mutant gene signature  
For this study, the set of 37 genes that encompass the BRCA1 mutant gene signature 
obtained from the microarray analysis was validated by qPCR (appendix 4). Appendix 5 
lists individual microarray probe data of the genes that make up the BRCA1 mutant 
gene signature. Knockdown cell pools were independently generated using MCF-10A 
cells and shRNA hairpins against INPP4B or Renilla luciferase (figure 3.6B). 12 genes 
that were clearly over- or under-expressed in the microarray gene signature heat map 
were analysed by qPCR and relative gene expression was determined against expression 
of a housekeeping gene, β-actin, using the ΔΔCq method (Livak and Schmittgen, 2001) 
(appendix 6). The primers used were obtained from PrimerBank, which have been 
extensively tested for PCR specificity and efficiency (Spandidos et al., 2010; Wang and 
Seed, 2003; Wang et al., 2012). All of the 12 genes positively correlated with the 
microarray differential expression direction, as shown in figure 3.6A. The shRNA 
targeting INPP4B resulted in a 79% reduction in INPP4B mRNA expression. 
Interestingly, MCF-10A BRCA1 knockdown cell pools also harboured reduced INPP4B 
expression levels by 73% compared to the Renilla luciferase control (Figure 3.6B). In 
addition to validation by qPCR, the microarray data were compared to a 60 gene 
BRCAness gene signature defined by Konstantinopoulos et al. (Konstantinopoulos et 
al., 2010). 71% of the differentially expressed genes from the microarray data set 
correlated to the gene expression found in the 60 gene BRCAness signature (Figure 
3.6C). A comprehensive list of differential gene expression between the two data sets is 
shown in appendix 7.  
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Figure 3.6. qPCR and microarray gene log (2) fold change comparison. (A) 12 
genes were selected from the 37 BRCA1 mutant gene signature gene set and relative 
differential gene expression was quantified in MCF-10A INPP4B knockdown cell pools 
compared to the Renilla luciferase control. The gene expression log (2) fold change 
obtained from qPCR was compared to the log (2) fold change identified in the 
microarray data set. The qPCR results positively correlate with the microarray gene 
B	 C	
A	
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expression values. (B) Knockdown efficiency of INPP4B in the MCF-10A shRNA 
INPP4B cell pools was relatively quantified against MCF-10A shRNA Renilla 
luciferase control. INPP4B mRNA expression was reduced by 79% in the INPP4B 
knockdown cell pools. Expression levels of INPP4B were also assessed in the BRCA1 
knockdown cell pools and found to be reduced by of 73%. (C) The 60 gene BRCAness 
gene signature defined by Konstantinopoulos et al. was compared to the MCF-10A 
shRNA-INPP4B microarray data set (Konstantinopoulos et al., 2010). 71% of the 
differentially expressed genes from the MCF-10A shRNA INPP4B microarray data 
exhibited full correlation with the 60 gene signature weight, with respect to gene 
expression.  
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3.2.2 Loss of INPP4B results in a DNA repair defect in Ovca429 cells upon comet 
assay analysis 
Ovca429 and Ovca433 shRNA Renilla luciferase cells were subjected to 16.2, 24.3, 
32.4 Gy of X-ray irradiation to obtain dose response curves (figure 3.7), to define the 
appropriate level of DNA damage that would be sufficiently repairable. The olive tail 
moment is a measure of DNA damage that takes into account the tail length of the 
comet and the fraction of total DNA in the tail. The multiplication of these two factors 
gives rise to a numerical figure that assesses the extent of DNA damage of an individual 
cell. Both Ovca429 and Ovca433 knockdown cell pools exhibited olive tail moments 
above seven at 32.4 Gy irradiation, exhibiting a tail DNA percentage of 45.32% and 
48.56%, respectively. Comet assays were also conducted to measure DNA repair. Cells 
were incubated at 37°C 15, 30, 45 and 60 min after irradiation, and the olive tail 
moment was plotted for each time point generating a DNA repair curve. A relative 
DNA repair curve was plotted, Upon 30 Gy X-ray radiation, Ovca429 shRNA INPP4B 
cells exhibited increased DNA damage 15 min post-irradiation, with an olive tail 
moment percentages of 3.67 compared to 2.31 and a p – value of 3 x 10-5 (figure 3.8A.). 
30 min and 60 min post-irradiation, the shRNA INPP4B expressing cell pools compared 
to the control cells exhibited significantly different olive tail moment of 1.63 and 1.23, 
and 1.52 and 1.04, respectively, with a p – value of 0.04 and 0.05, respectively. Images 
from the analysis revealed a significantly enhanced comet tail in the INPP4B 
knockdown cell compared to the control 15 min, 30 min and 60 min after irradiation 
(figure 3.8B). DNA repair assays conducted with Ova433 knockdown cell pools treated 
with 35 Gy X-ray radiation revealed no difference in olive tail moment between the 
shRNA INPP4B and shRNA Renilla luciferase expressing cell pools (figure 3.8A).   
 178 
 
 
 
Figure 3.7. Comet assay dose response in Ovca429 and Ovca433 cells. Ovca429 and 
Ovca433 shRNA Renilla luciferase expressing cell pools were irradiated with 16.2, 24.3 
and 32.4 Gy X-ray radiation and the respective olive tail moment plotted to form a dose 
response curve. Experiments were conducted independently three times. Error bars 
represent the standard deviation.   
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Figure 3.8. Ovca429 and Ovca433 DNA repair curves upon X-ray radiation. (A) 
Ovca429 and Ocva433 knockdown cell pools were treated with 30 and 35 Gy 
irradiation, respectively, and cells were left to repair at 37°C for 15, 30, 45 and 60 min 
after irradiation. Ovca429 shRNA INPP4B cells exhibited impaired DNA repair 
compared to the knockdown control. The p-values for conditions at 15 min, 30 min and 
60 min are 3 x 10-5, 0.04 and 0.05, respectively. Ovca433 shRNA INPP4B cells showed 
no significant differences in DNA repair compared to the control. In total 50 cells per 
sample (25 cells per slide) were analysed per experiment. Experiments were conducted 
independently three times. Error bars represent standard deviation and the t-test was 
used for statistical analysis (p-value of *≤0.05, ***≤0.0005). (B) Images capturing the 
comet tails of Ovca429 shRNA INPP4B cells and shRNA Renilla luciferase control 0, 
15 and 90 min after irradiation.  
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3.2.3 Loss of INPP4B results in γH2AX foci retention upon treatment with 
etoposide in Ovca429 and Ovca433 knockdown cell pools 
Immunofluorescence assays were conducted to investigate the effect loss of INPP4B 
has on the DNA damage response by quantification of γH2AX and RAD51 foci 
formation. Etoposide treatment was first optimised to determine the concentration to use 
in experiments (figure 3.9). Treatment of Ovca429 shRNA INPP4B expressing cell 
pools with 1 µM etoposide resulted in γH2AX foci retention compared to control cell 
pools (figure 3.10). For example, 30 min after treatment, INPP4B knockdown nuclei 
contained a mean value of 20.9 foci per nucleus compared to 16.2 foci in the control 
nuclei (p = 0.001); 60 min after treatment, INPP4B knockdown nuclei contained a mean 
value of 17.7 foci per nucleus compared to 14.3 foci in the control nuclei (p = 0.01); 
180 min after treatment, nuclei from the Ovca429 shRNA INPP4B knockdown cell 
pools maintained a mean foci value of 14.8 compared to 11.7 foci in the control cells (p 
value = 0.005). Furthermore, the untreated INPP4B knockdown cell pools contained 
significantly increased mean foci per nucleus compared to the knockdown controls, and 
carried a mean value of 9.4 γH2AX foci per nucleus compared to 4.9 foci (p = 4 x 10-7). 
Ovca433 shRNA INPP4B knockdown cell pools harboured a significant increase in 
γH2AX foci retention 180 min after treatment with 14.3 foci per nucleus compared to 
9.9 foci per nucleus in the knockdown control cells (p = 9 x 10-5) as depicted in figure 
3.11. There was no statistical difference between the two knockdown cell pools in the 
untreated cells upon analysis, nor 0, 30, and 60 min after etoposide treatment.  
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Figure 3.9. Optimisation of etoposide treatment. Ovca429 cells were treated for 1 hr 
with either DMSO, 1 µM or 10 µM etoposide. The rows of the figure represent staining 
of α-H2AX antibody, DAPI, and merged (DAPI and α-H2AX antibody) from top to 
bottom, respectively. The cells were washed, fixed and probed with the γH2AX 
antibody.  
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Figure 3.10. INPP4B knockdown in Ovca429 cells results in γH2AX foci retention 
upon etoposide treatment. (A) After treatment with 1 µM etoposide, Ovca429 
knockdown cell pools were fixed 0, 30, 60 and 180 min after treatment. Ovca429 
shRNA INPP4B expressing cell pools retained more foci per nucleus untreated, as well 
as 30, 60 and 180 min after treatment compared to the knockdown control. The p-value 
for untreated conditions and conditions at 30 min, 60 min and 180 min were 4 x 10-7, 
0.001, 0.01 and 0.005, respectively. The foci distribution graph on the right represents 
four foci groups categorised into number of nuclei containing 15 or more foci, 5 – 10 
foci, 0 – 5 foci, and 0 foci. The sample size was a minimum of 30 cells and the t-test 
was used for statistical analysis (p-value of **≤0.005, ***≤0.0005). Foci were manually 
by eye. Experiment were conducted independently three times.  (B) Image comparison 
of γH2AX foci formation in Ovca429 INPP4B and control knockdown cell pools. The 
B	
 185 
rows of the figure represent staining of α-H2AX antibody, DAPI, and merged (DAPI 
and α-H2AX antibody) from top to bottom, respectively.  
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Figure 3.11. INPP4B knockdown in Ovca433 cells results in γH2AX foci retention 
upon etoposide treatment. (A) After treatment with 1 µM etoposide, Ovca433 
knockdown cell pools were fixed 0, 30, 60 and 180 min after treatment. Ovca429 
INPP4B knockdown cell pools retained more foci 180 min after treatment compared to 
the knockdown control. The p-value conditions at 180 min was 9x10-5. The sample size 
was a minimum of 30 cells and the t-test was used for statistical analysis (p-value of 
*≤0.05). Foci were manually by eye. Experiment were conducted independently three 
times. (B) Image comparison of γH2AX foci formation in Ovca433 INPP4B and control 
knockdown cell pools. The rows of the figure represent staining of α-H2AX antibody, 
DAPI, and merged (DAPI and α-H2AX antibody) from top to bottom, respectively.   
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3.2.4 Loss of INPP4B results in RAD51 and 53BP1 foci retention upon treatment 
with etoposide in Ovca429 knockdown cell pools 
Similarly, immunofluorescence assays that detected foci formation of DSB repair 
protein RAD51 also found aberrant foci formation in Ovca429 INPP4B knockdown cell 
pools compared to the controls (figure 3.12).  Cells were treated with 10 µM etoposide 
and incubated at 37°C 6, 12 and 24 hrs after treatment. Cells harbouring an INPP4B 
knockdown displayed increased mean RAD51 foci per nucleus quantities of 9.7 12 hrs 
after treatment compared to 7.1 foci per nucleus observed in the control cells (p = 1.4 x 
10-7). 24 hrs after treatment, while RAD51 mean foci quantities remained at 6.7 foci per 
nucleus in the control cells, shRNA INPP4B cells displayed significantly increased foci 
quantities of 13.81 foci per nucleus (p =1.2 x 10-16). In untreated cells, the two 
knockdown cell pools also exhibited statistical differences in the mean foci value with 
shRNA INPP4B cells harbouring a mean foci value of 2.7 compared to 3.4 in the 
control (p = 0.002).  
 
Detection of 53BP1 in Ocva429 knockdown cell pools resulted in significant statistical 
differences at 6 and 12 hrs after 10 µM etoposide treatment, as well as in the untreated 
samples (figure 3.13). shRNA INPP4B knockdown cells possessed a mean foci value of 
20.6 compared to 18.1 (p = 0.008) 6 hrs after treatment and 12 hrs after treatment. Cells 
with reduced INPP4B expression had a mean foci value of 23.1 compared to 18.4 (p = 
0.00005) in the control cells. In the untreated samples, cells with less INPP4B contained 
a mean of 10.5 foci per nucleus, compared to 8.8 foci per nucleus in the control cells (p 
= 0.01).  
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Figure 3.12. INPP4B knockdown in Ovca429 cells results in RAD51 foci retention 
upon etoposide treatment. (A) Upon treatment with 10 µM etoposide, RAD51 foci 
were quantified in Ovca429 knockdown cell pools 6, 12, and 24 hrs after treatment. 
Ovca429 INPP4B knockdown cell pools displayed RAD51 foci retention 12 and 24 hrs 
after treatment compared to the knockdown control. The p-value for the untreated 
condition and conditions at 12 hrs and 24 hrs were 0.002, 1.4x10-7 and 1.2x10-16, 
respectively. The foci distribution graph reveals an increase in the number of nuclei 
containing more than 15 foci per nucleus at the same time points in INPP4B knockdown 
cells compared to the control. The sample size was a minimum of 50 cells and the t-test 
was used for statistical analysis (p-value of **≤0.005, ***≤0.0005). Foci were manually 
by eye. Experiments were conducted independently three times. (B) Image comparison 
of RAD51 foci formation in Ovca429 shRNA INPP4B and shRNA Renilla luciferase 
expressing cell pools. Here only the single-stained images are seen rather than the 
merged image for clearer observation of the foci. 
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Figure 3.13. INPP4B knockdown in Ovca429 cells results in 53BP1 foci retention 
upon etoposide treatment. (A) Upon treatment with 10 µM etoposide, 53BP1 foci 
were quantified in Ovca429 knockdown cell pools 6 and 12 hrs after treatment. 
Ovca429 INPP4B knockdown cell pools displayed RAD51 foci retention across all time 
points after treatment compared to the knockdown control. The sample size was a 
minimum of 50 cells and the t-test was used for statistical analysis (p-value of *≤0.05, 
**≤0.005, ***≤0.0005). Foci were manually by eye. Experiments were conducted 
independently three times. (B) Image comparison of 53BP1 foci formation in Ovca429 
shRNA INPP4B and shRNA Renilla luciferase expressing cell pools. The rows of the 
figure represent staining of α-53BP1 antibody, DAPI, and merged (DAPI and α-53BP1 
antibody) from top to bottom, respectively.   
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3.2.5 Loss of INPP4B results in RAD51 foci retention upon irradiation in 
Ovca433 knockdown cell pools 
Ovca433 knockdown cell pools were irradiated with 15 Gy X-ray radiation and 
incubated at 37°C for 24, 30 and 48 hrs after DNA damage. shRNA-INPP4B expressing 
cells displayed increased RAD51 foci formation 24 hrs after irradiation, harbouring a 
mean foci per nucleus value of 7.1 compared to 5.9 in the control cells (figure 3.14.; p = 
0.0004). 48 hrs after treatment, the mean foci difference between the two knockdown 
cell pools was more apparent, with shRNA INPP4B cells possessing a mean of 7.0 foci 
per nucleus compared to 4.5 foci in the control knockdown cells (p =0.01).  
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Figure 3.14. INPP4B knockdown in Ovca433 cells results in RAD51 foci retention 
upon irradiation. (A) Upon irradiation with 15 Gy X-ray RAD51 foci were quantified 
in Ovca433 knockdown cell pools 24, 30, and 48 hrs after treatment. Ovca433 INPP4B 
knockdown cell pools displayed RAD51 foci retention 24 and 48 hrs after treatment 
compared to the knockdown control, as well as in the untreated samples. The sample 
size was a minimum of 50 cells and the t-test was used for statistical analysis (p-value 
of *≤0.05, **≤0.005, ***≤0.0005). Foci were manually by eye. Experiments were 
conducted independently three times. (B) Image comparison of RAD51 foci formation 
in Ovca433 INPP4B and Renilla luciferase knockdown cell pools.   
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3.2.6 Loss of INPP4B in Ovca429 and Ovca433 cancer cell lines has no impact on 
BRCA1 foci formation upon irradiation  
Plo et al. demonstrated that activated Akt1 repressed HR through cytoplasmic retention 
of BRCA1 and Rad51 resulting in a BRCA1-deficient phenotype in breast cancer (Plo 
et al., 2008a). Therefore, Ovca429 and Ovca433 knockdown cell lines were investigated 
for BRCA1 foci formation upon IR. Ovca429 and Ovca433 knockdown cell pools were 
irradiated with 2 Gy X-ray and incubated at 37°C for 7 and 24 hrs after radiation. Loss 
of INPP4B had no effect on BRCA1 foci formation in both ovarian cancer knockdown 
cell pools (figure 3.15– 3.16).  
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Figure 3.15. BRCA1 foci formation in Ovca429 knockdown cell pools. (A) Upon 
treatment with 2 Gy X-ray radiation, BRCA1 foci were quantified in Ovca429 Renilla 
luciferase (control) and INPP4B knockdown cell pools 7, and 24 hrs after treatment. No 
differences in mean foci values were detected between the knockdown cell pools.  The 
sample size was a minimum of 50 cells and the t-test was used for statistical analysis (p-
value of *≤0.05, **≤0.005, ***≤0.0005). Foci were counted by using Cell Profiler and 
the experiment was conducted independently three times. (B) Image comparison of 
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BRCA1 foci formation in Ovca429 INPP4B and Renilla luciferase knockdown cell 
pools.  
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Figure 3.16. BRCA1 foci formation in Ovca433 knockdown cell pools. (A) Upon 
treatment with 2 Gy X-ray radiation, BRCA1 foci were quantified in Ovca433 Renilla 
luciferase (control) and INPP4B knockdown cell pools 7 and 24 hrs after treatment. No 
differences in mean foci values were detected between the knockdown cell pools.  The 
sample size was a minimum of 50 cells and the t-test was used for statistical analysis (p-
value of *≤0.05, **≤0.005, ***≤0.0005). Foci were counted by using Cell Profiler and 
the experiment was conducted independently three times. (B) Image comparison of 
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BRCA1 foci formation in Ovca433 shRNA INPP4B and shRNA Renilla luciferase 
knockdown cell pools.  
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3.2.7 INPP4B-deficient Ovca433 knockdown cell pools undergo aberrant cell 
cycle progression 
The PI3K/Akt pathway has been implicated in regulation of cell cycle progression, and 
hence the cell cycle progression in relation to INPP4B loss was investigated. Ovca433 
knockdown cell pools containing shRNA-INPP4B and shRNA-Renilla luciferase were 
subjected to cell cycle analyses using the Muse Cell Analyser machine (Milllpore, UK). 
Unchallenged Ovca433 knockdown cell pools were serum starved for 18 hrs to 
synchronise the cells and after replenishment of serum-containing media, the cells were 
fixed at various time points to track cell cycle progression. Cells were fixed at 0, 6, 12, 
18, 24, 27, 30 hrs after serum starvation resulted in good analytical distribution of time 
points to examine cell cycle progression. The experiments revealed that loss of INPP4B 
in Ovca433 cells results in aberrant cell cycle progression compared to the knockdown 
control (figure 3.18). Unchallenged Ovca433 INPP4B-deficient cells displayed aberrant 
cell cycle progression compared to the knockdown control counterparts 24 hrs after 
serum replenishment (p = 0.006). Representative images of the primary data are 
depicted in figure 3.17. Cell cycle analysis of Ovca429 knockdown cell pools 
containing shRNA-INPP4B and shRNA-Renilla luciferase were not conducted due to 
time constraints.  
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Figure 3.17. Cell cycle analysis of Ovca433 knockdown cell pool upon serum 
starvation. Ovca433 knockdown cell pools were serum starved for 18 hrs, fixed at the 
indicated time points and cell cycle stage analysed using the Muse Cell Analyzer. 
Experiments were conducted independently three times. The depicted graphs are 
representative primary data for one experiment used to assess cell cycle progression.  
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Figure 3.18. Cell cycle progression of Ovca433 knockdown cell pool upon serum 
starvation. Ovca433 knockdown cell pools were serum starved for 18 hrs, fixed at the 
indicated time points and cell cycle stage analyzed using the Muse Cell Analyzer. 
Unchallenged Ovca433 INPP4B-deficient cells displayed aberrant cell cycle 
progression compared to the knockdown control counterparts 24 hrs after serum 
replenishment (p = 0.006). One sample was used per condition. The t-test was used for 
statistical analysis and experiments were conducted independently three times. The 
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depicted graph is the average of all three experiments and representing the outcome of 
all three experiments.   
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3.3 Discussion 
The tumour biology of ovarian cancer has been frequently associated with genetic 
alterations in components of DNA repair, the most well established genes being 
BRCA1/2. However, recent studies have revealed that women possess ‘BRCAness’ in 
up to a third of all ovarian cancers, as well harbour HR deficiency in almost half of 
ovarian carcinomas. Thus, investigation of INPP4B in the context of DNA repair in 
ovarian cancer could shed new light on its role in DDR, and its therapeutic relevance.  
 
Microarray analyses comparing MCF-10A shRNA-INPP4B with MCF-10A shRNA 
Renilla luciferase expressing cell pool gene expression revealed two novel gene 
signature associations: ‘poor survival’ and ‘BRCA1-mutant’ gene signatures (appendix 
4). These two gene sets have never previously been associated with knockdown of 
INPP4B in human mammary epithelial cells. The prevalence of BRCA1 mutations 
within breast and ovarian cancer highlighted the importance of this finding, and 
consequently further analysis was conducted to verify the BRCA1-mutant signature 
through validation of the microarray results. The 37 gene-set that makes up this gene 
signature consists of a collection of transcription factors, proteases and ligases and 
protein kinases that are differentially expressed when BRCA1 is mutated, as defined by 
the KEGG pathway database. The microarray analysis revealed differential log(2) fold 
changes ranging from -3.78 to 4.00 (appendix 5). From the 37 gene set, 12 of the genes 
were selected for relative quantification via qPCR: NTN4, GPC1, CAMK2N1, CA2, 
MPDZ, TFPI, CA12, SPARC, TMEM98, GALNT7, C5ORF13, ANKRD35. These 
genes encode proteins involved in transcription regulation (ANKRD25), neural function 
(C5ORF13, MPDZ), glycosylation (GALNT7), extracellular matrix synthesis and cell 
shape change (SPARC), respiration (CA2, CA12), blood coagulation (TFPI), cell 
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growth (CAMK2N1) and cell migration/adhesion/proliferation/apoptosis (NTN4). 
While eight of the genes examined by qPCR exhibited similar differential gene 
expression (in direction and magnitude) to the microarray results, the qPCR gene 
expression values for genes CA2, TFPI, TMEM98 and SPARC were much lower 
compared to the log(2) fold changes found in the microarray analysis. While qPCR is a 
commonly used validation tool for confirming microarray results, data from these two 
methods of analyses often result in disagreement. Within the individual techniques 
themselves, they possess inherent pitfalls that may significantly influence the data 
obtained. The multiple sources of variability in microarray analysis include differences 
in arrays, dye labelling, efficiency in reverse transcription and hybridisation. Likewise, 
qPCR generated data also has several sources of error, namely amplification biases, 
exponential amplification of errors, mispriming, formation of primer dimers and the 
changing efficiency of qPCR at later cycles.  High quality RNA is essential for accurate 
results, as gene expression can be affected by contaminating factors, salts, alcohols, 
phenols, all of which can affect the reverse transcriptases, and consequently RNA 
amplification in both methods. It should be noted that the MCF-10A knockdown cell 
pools derived for the microarray experiments and the ones used for qPCR were 
independently generated, and consequently, further adds to biological variances that 
contribute to discrepancies found between qPCR generated data and microarray data 
(Etienne et al., 2004).  
 
Another explanation for the variability of results lies in the primer selection and 
microarray probe complementation. These probes have DNA oligomer sequences that 
target several splice variants of individual genes. Multiple probes for the same gene can 
target differing combinations of the gene splice variants and consequently the resulting 
 207 
log(2) fold change can also be vastly different. An example of this includes the gene 
TFPI, which has four probes exhibiting log(2) fold changes of 0.68, 1.88, 4.00 and 3.64. 
These log(2) fold changes represent hybridisation of the probes for the following 
transcript variants (TV), respectively: TV2, TVX2; TV1, TVX1 – 3; TV1, TVX1, 
TVX2, TVX4; TVX1 – 4. Each of these probes target differing combinations of splice 
variants, and consequently the log(2) fold changes that arise are also different in 
magnitude. Furthermore, Etienee et al. reported that an increase in distance between the 
location of the PCR primers and the microarray probe on a given gene results in a 
decrease in correlation between the two methods (Etienne et al., 2004), which would 
also contribute to the discrepancies observed in the validation of the gene signature. 
Nevertheless, the gene expression trends obtained by qPCR echoed those found in the 
microarray data. 
 
Down-regulation of INPP4B in MCF-10A shRNA BRCA1 cells was an interesting and 
novel finding; however, due to lab constraints this observation was not further 
investigated. While more experiments are required to further elucidate the relationship 
between INPP4B loss and BRCA1 loss in these cells, the results suggest that INPP4B 
may play a role in DNA damage repair in human mammary epithelial cells, in 
agreement with the finding of the BRCA1-mutant gene signature found in INPP4B 
deficient MCF-10A cells.  
 
To further confirm that INPP4B loss in MCF-10A cells results in a BRCA1 mutant gene 
signature, the obtained microarray data were compared to a gene expression profile of 
BRCAness defined by Konstantinopoulos et al. that correlates with responsiveness to 
chemotherapy and with outcome in patients with epithelial ovarian cancer (EOC) 
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(Konstantinopoulos et al., 2010). A publicly available microarray data set containing 
tumour expression data from 61 EOC patients with either sporadic disease or BRCA1/2 
germline mutations was used to derive the 60 gene signature into two clusters, BRCA-
like (BL) and non-BRCA-like (NBL), of which the gene set was able to distinguish BL 
from NBL with 94% accuracy. Appendix 7 compares this ‘BRCAness’ signature with 
the MCF-10A shRNA INPP4B microarray data, and the summary of the data is 
depicted in Figure 3.6C. 71% of the differentially expressed genes found in the MCF-
10A shRNA-INPP4B microarray data correlated with the gene expression change found 
in the BRCAness profile. 22 genes that were part of the ‘BRCAness’ signature were not 
differentially expressed in the microarray and therefore not included in this analysis. 
The two microarray datasets were derived from differing tissue types, as well as 
between malignant and non-malignant cells, which could explain why the correlation 
between the two datasets was not stronger. However, the comparison marks an 
important transition from investigating the DNA damage defect in mammary epithelial 
cells to ovarian cancer cells, which is the tissue type of interest for this study, and it is 
encouraging to observe significant correlation despite some biological differences 
between the two datasets. 
 
In order to investigate DNA repair in individual cells, comet assays were conducted in 
both Ovca429 and Ovca433 knockdown cell pools to assess the repair of damage DNA 
over time after exposure to X-ray radiation. Ovca429 knockdown cell pools revealed a 
delay in DNA repair in cells harbouring decreased INPP4B expression compared to the 
shRNA Renilla luciferase control cells upon irradiation. Ionising radiation (IR) strand 
breaks primarily occur through reaction of reactive oxygen species (ROS) with the 
hydrogen radical on the surface areas of the DNA backbone (Balasubramanian et al., 
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1998) and IR produces SSBs at a rate 20 times more than DSBs (Bradley and Kohn, 
1979). With regards to both cell lines, the cells displayed a heterogeneous response to 
the DNA damage, with some cells possessing greater tail moments upon IR, and others, 
smaller tail moments. In experiments conducted using Ovca429 knockdown cell pools, 
the olive tail moments of both the shRNA INPP4B cells and the control cells were 
statistically different 15, 30 and 60 min after irradiation; However for the latter two time 
points, the olive tail moments were below 2, in which the cells visually did not possess 
a comet tail, and hence were assumed not to possess a large level of DNA damage. 15 
min after damage the shRNA INPP4B cells clearly displayed larger tail moments, with 
cells retaining a mean tail moment of 3.67 compared to 2.31 in the control cells, 
indicating that cells with decreased INPP4B expression exhibits a delay in DNA repair 
compared to cells with normal INPP4B expression. While the results indicate that loss 
of INPP4B indeed results in a DNA repair defect, the specifics of the DNA lesions or 
mechanisms involved that caused this delay could not be defined due to the broad 
nature of the assay conducted. Also, due to the alkaline nature of the protocol 
implemented, the comet assay detects all forms of strand breaks, SSBs and DSBs, as 
well as alkali-labile lesions. The neutral comet assay, which was originally developed to 
detect primarily DSBs independent of SSBs (Olive and Banath, 2006), was not 
conducted due to the unreliable results of the protocol at hand. More extensive comet 
assays could be conducted to detect specific kinds of DNA damage, such as base 
damage, and interstrand cross-link, as follow up experiments. Finally, is important to 
note that the comet assay detects the rejoining of strand breaks and does not provide 
information on the fidelity of the repair (Olive et al., 1994). However, the results did 
provide a good indication that INPP4B plays a role in timely DNA repair and merited 
further investigation. 
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The Ovca433 shRNA INPP4B cells, on the other hand, did not display an aberration of 
DNA repair. This can be explained potentially by the biological differences between the 
two ovarian cancer cell lines. For example, the Ovca429 cell line carries a PI3KCA 
mutation that is not found in the Ovca433 cell line. The oncogenic nature of the 
constitutively active catalytic subunit of class IA PI3K in Ovca429 cell lines could aid 
in the sensitivity of the cells towards inefficient repair of DNA damage upon 
concomitant loss of INPP4B. Ovca433 cell lines may possess amplified repair 
mechanisms that dilute the effect of INPP4B knockdown, and therefore no DNA repair 
was observed in this particular cell line. To note, the disparity between the magnitude of 
the DNA damage induced by IR between the two cell lines analysed was a result of 
human error, a miscalculation of the intended dose imposed due to routine recalibration 
of the dosimeter.  
 
To further investigate the DNA repair delay found upon comet assay analysis, detection 
of γH2AX, RAD51, and 53BP1 was conducted in Ovca429 knockdown cell pools to 
examine whether loss of INPP4B had an effect on the individual cell’s immediate 
response to DNA damage, as well as the integrity of HR and NHEJ repair in situ. 
Etoposide was used to introduce strand breaks in the cells for these experiments. While 
conducting the experiment with IR would allow for a more comparative study of DNA 
repair in these cells with the results of the comet assays, due to laboratory limitations, 
etoposide was used as an alternative agent for DNA damage. Etoposide induces DNA 
damage by the inhibition of topoisomerase II (TOP2), an important enzyme that 
introduces transient DSBs and re-ligates them during DNA replication (TOP2α) and 
transcription (TOP2β) to relieve torsional stress. Etoposide has very low affinity for 
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intact DNA, but can readily insert into the DNA cleavage site formed by the TOP2 
enzyme as it interacts with the DNA, preventing TOP2 from re-ligating the cleavage 
site (Wu et al., 2011). Hence, treatment of cells with etoposide results in DSB 
formation, although etoposide is also capable of generating SSBs (Bromberg et al., 
2003).  
 
Ovca429 shRNA INPP4B expressing cells were subjected to etoposide treatment for 1 
hr to introduce strand breaks, and after the cells were washed thoroughly to remove the 
drug and foci were quantified to evaluate response to DNA damage over time. Without 
any DNA damage imposed, γH2AX foci were found significantly increased in Ovca429 
shRNA INPP4B cells that were treated with DMSO only, and held a mean foci per 
nucleus value of 9.4, almost twice that of the control value, which is indicative of 
shRNA INPP4B expressing cells harbouring more genomic instability than their control 
knockdown counterparts. Interestingly, immediately after DNA damage was induced, 
both knockdown cells exhibited similar levels of damage, despite the increased mean 
foci per nucleus shRNA INPP4B cells retained in the control conditions. Thereafter, 
γH2AX mean foci values were significantly higher in shRNA INPP4B cells 30, 60 and 
180 min after DNA damage compared to the control cells. Of note, the cells responded 
to the treatment in a heterogeneous manner. Ovca433 cells responded similarly, with the 
shINPP4B cells also retaining γH2AX 180 min after DNA damage. Akin to the γH2AX 
results, 53BP1 foci were found increased in Ovca429 shRNA INPP4B cells 6 and 12 
hrs after treatment with 10 µM etoposide compared to the control cells, as well as 
DMSO treated conditions. The observations of the similarity in trend of 53BP1 foci 
formation to the γH2AX foci formation in shRNA INPP4B expressing cells are in line 
with evidence that 53BP1 accumulation at the DSBs is dependent on γH2AX formation 
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(Mallette et al., 2012). Treatment of Ovca429 knockdown cell pools with 10 µM 
etoposide and subsequent analysis of cells during DNA repair revealed a persistence of 
RAD51 foci 12 and 24 hrs after DNA damage in shRNA INPP4B cells compared to the 
control cells. Interestingly, 24 hrs after damage cells with reduced INPP4B expression 
displayed mean foci per nucleus values almost twice that of the control cells (13.81 vs 
6.69, p = 1.21x10-16), suggesting an increase in the number of DSBs generated after the 
initial genetic insult. Treatment of Ovca433 knockdown cell pools by IR also revealed 
similar findings of RAD51 persistence in cells with loss of INPP4B. While loss of 
BRCA1 function was shown to result in suppressed RAD51 foci formation, loss of ATR 
was linked to increased RAD51 foci formation in conjunction with increased γH2AX 
foci (Banath et al.; Chanoux et al., 2009). The experiments that address the relationship 
between INPP4B and ATR will be discussed in the next chapter. The above 
experiments clearly show that INPP4B regulates efficient DNA repair, including 
RAD51 related repair. Given that RAD51 is a crucial protein involved in homology-
mediated pairing and strand exchange in HR, it can be proposed that loss of INPP4B is 
involved in regulation of HR repair efficiency. Finally, as aforementioned, Plo et al. 
demonstrated that activated Akt1 repressed HR through cytoplasmic retention of 
BRCA1 and Rad51 resulting in a BRCA1-deficient phenotype in breast cancer (Plo et 
al., 2008a). Thus, both Ovca429 and Ovca433 knockdown cell lines were investigated 
for BRCA1 foci formation upon IR. Knocking down INPP4B in both cell lines did not 
result in cytoplasmic retention of BRCA1 nor an aberration of BRCA1 foci formation, 
suggesting a different mechanism of defective DNA repair in INPP4B deficient cells.  
 
Cell cycle studies were conducted to investigate if INPP4B loss impacted cell cycle 
progression. INPP4B-deficient Ovca433 cells resulted in a decrease in cell population 
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24 hrs after serum starvation in the S/G2/M phase (62.4%) compared to the control cells 
(70.2%) (p=0.006) indicating a faster progression through the cell cycle. While a further 
time point analysis between 18 hrs and 24 hrs is needed to conclude the meaning of this 
statistical difference, it was not conducted due to practical scheduling difficulties fixing 
the cells over a 30 hrs period. It is likely that INPP4B-deficiency results in an 
acceleration of cell cycle progression due to hyperactivation of the PI3K/Akt pathway. 
Another possibility is that loss of INPP4B may result in defective cell cycle 
checkpoints, since the cells displayed faster progression through the cell cycle. 
Investigating G1, S and G2 cell cycle control by flow cytometry in the context of 
INPP4B loss may provide more insight if there is any cell cycle checkpoint aberration. 
It would be of interest to investigate if DNA damage affects cell cycle progression in 
INPP4B-deficient cells. Affected cell cycle stages, if any, would give an indication as to 
which cell cycle specific proteins may also be affected by the loss of INPP4B. 
Additional cell cycles studies for INPP4B-deficient Ovca429 cells were not conducted 
due to time constraints. 
 
Due to time restraint the DNA repair defect in Ovca429/Ovca433 INPP4B knockdown 
cell pools was not further investigated. Flow cytometry analysis could have been 
conducted to assess in which cell cycle does γH2AX, 53BP1 and RAD51 foci form in 
shRNA INPP4B cells relative to the control cells. GFP assays could have also been 
carried out to measure HR and NHEJ integrity specifically (Gunn and Stark, 2012). 
However, the evidence accumulated from the series of experiments conducted suggests 
that loss of INPP4B indeed leads to a DNA repair defect in the Ovca429 ovarian cancer 
cell line. While mechanisms for this defect have yet to be established, it is clear that 
INPP4B plays a role in HR efficiency and ovarian cancer patients harbouring a loss of 
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INPP4B may benefit from therapies that promote the use of DNA repair inhibitors in 
the context of synthetic lethality.  
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CHAPTER 4. Biological function of INPP4B 
4.1 Introduction 
One of the approaches in personalising cancer treatment is through stratification of 
DNA damage response (DDR) proteins based on their status, and subsequent 
implementation of appropriate therapies that exploit the defective DNA repair pathway. 
In the previous chapter a BRCA1-mutant gene signature was identified in INPP4B-
deficient human mammary epithelial cells via microarray analysis, and then a DNA 
repair deficiency was confirmed in INPP4B-deficient ovarian cancer knockdown cells. 
Further investigation of INPP4B in the context of DNA repair would provide not only a 
more in depth understanding of the function of INPP4B, but also potentially widen the 
selection of therapeutic agents that would be effective in treating INPP4B-deficient 
tumours. Thus far, no studies have examined the mechanism of INPP4B and its role in 
DDR. Having established the cellular phenotypes associated with loss of INPP4B, 
further experiments were conducted to determine the molecular mechanisms that may 
result in the observed DNA repair defect. The cell systems were switched from the 
ovarian cancer cell lines to human embryonic kidney 293T cells due to its enhance 
transfection efficiency, which is needed for overexpression studies conducted to 
investigate interacting partners of INPP4B. Immunoblotting was conducted to 
investigate the loss of INPP4B in relation to the expression of other DDR proteins in 
MCF-10A cells, ovarian cancer cell lines, as well as in mouse embryonic fibroblasts 
(MEFs) containing loxP-flanked INPP4B. Potential phosphorylation sites of INPP4B as 
a substrate of ATR/ATM were also assessed. In addition, cell cycle studies were carried 
out to observe any aberration in cell cycle progression due to INPP4B loss. Finally, the 
interacting domain of INPP4B was determined using GST-pull down assays (Harper 
and Speicher; Katzen, 2007).  
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Results 
4.1.1 Reduced ATR expression observed in INPP4B deficient Ovca429 
knockdown cells. 
Previous experiments revealed a DNA repair defect in INPP4B deficient breast and 
ovarian models. Supporting this finding, a reduction of INPP4B protein in MCF-10A 
shRNA-BRCA1 expressing cells was observed in immunoblots (figure 4.1A). In 
addition, reduced ATR protein levels were found in Ovca429 INPP4B knockdown cell 
pools compared to controls. No changes in BRCA1 protein expression were detected in 
Ovca429 and Ocva433 shRNA INPP4B knockdown cell lines relative to the control 
(figure 4.1B). These findings provide novel evidence that loss of INPP4B results in an 
aberration in DNA repair through reduced levels of key DNA protein, ATR, while 
BRCA1 protein levels remain unchanged. PhosphoSer473 Akt levels upon INPP4B 
knockdown were found significantly increased upon serum stimulation in Ovca433 cells 
in experiments conducted by Dr. Christina Gewinner, indicating that depletion of 
INPP4B is sufficient for increased lipid dependent signalling. Upon EGFR/Her2 
inhibitor Erlotinib and Lapatinib treatment of Ovca433 shRNA-INPP4B cell pools show 
reduced/absent phosphoSer473 Akt (figure 4.1C).  
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Figure 4.1. Immunoblots detecting ATR and BRCA1 protein expression in various 
cell lines. (A) A reduction of ATR and INPP4B protein expression was found in 
Ovca429 shRNA INPP4B and MCF-10A shRNA BRCA1 cells relative to the shRNA 
Renilla luciferase control, respectively. (B) No changes in BRCA1 protein expression 
were detected in Ovca429 and Ocva433 INPP4B knockdown cell lines were detected 
relative to the control. Immunoblotting was conducted independently three times. (C) 
Experiments conducted by Dr. Christina Gewinner revealed an increase of 
phosphoSer473 Akt levels upon INPP4B knockdown and serum stimulation in Ovca433 
cells. In addition, Ovca433 cell pools were treated with the inhibition of the EGFR/Her2 
pathway inhibitors Erlotinib and Lapatinib to study the effects of EGFR signalling in 
the context of INPP4B knockdown in Ovca433 cells. Erlotinib and Lapatinib treatment 
of Ovca433 shRNA-INPP4B cell pools show reduced/absent phosphoSer473 Akt. This 
experiment was conducted independently three times.  
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4.1.2 Loss of INPP4B in mouse embryonic fibroblasts results in concomitant loss 
of BRCA1, ATR and ATM protein levels 
The experiments in this subsection were conducted by Dr. Christina Gewinner (UCL, 
UK). Floxed INPP4B (INPP4Bfl/fl) MEFs were obtained from Prof. Takehiko Sasaki, 
(Akita University, Japan). INPP4B expression was ablated in INPP4Bfl/fl MEFs through 
infection with adenovirus Cre recombinase (Ad5Cre) and immortalised with shRNA 
against p53. Western blot analysis of dose-dependent Ad5Cre infection efficiency in 
INPP4Bfl/fl shRNA-p53 MEFs resulted in loss of INPP4B greater than 50% 72 hrs post – 
infection (figure 4.2). Investigation of BRCA1, ATR and ATM protein levels revealed 
concomitant loss of BRCA1, ATR and ATM proteins. While modest downregulation of 
INPP4B protein expression resulted in reduced BRCA1 and ATM protein expression, a 
greater INPP4B protein level reduction was required to downregulate ATR protein 
levels. To control for a potential Ad5Cre off-target effect INPP4B, BRCA1, ATR and 
ATM protein levels of infected wildtype MEFs were compared to INPP4Bfl/fl MEFs, 
however no changes in protein levels were detected in wild-type MEFs confirming the 
specificity of the observation described above (figure 4.3).  These results suggest a key 
role for INPP4B in the stability three major DDR proteins BRCA1, ATM and ATR 
either on a protein level or mRNA level in transcription or translation.  
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Figure 4.2. INPP4Bfl/fl MEFs results in loss of ATM, ATR and BRCA1 protein 
expression with increasing concentrations of adenovirus Cre recombinase. (A) 
Immunoblots depicting increasing loss of INPP4B in conjunction with loss of ATR, 
ATM and BRCA1 protein expression. “U” represents the untreated MEFs. (B) 
Quantification of protein expression of INPP4B, ATR, ATM and BRCA1 relative to 
p42/44 loading control. Semi-quantitative analysis was conducted using ImageJ. 
Experiments were conducted independently three times by Dr. Christina Gewinner 
(UCL, UK).  
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Figure 4.3. No off-target effects were observed in wild-type MEFs upon 
administration of adenovirus Cre recombinase. Infection of wild-type MEFs (wt 
MEFs) with adenovirus Cre recombinase did not result in changes in protein levels of 
ATM, ATR, BRCA1, and INPP4B, as depicted on the immunoblots. Experiments were 
conducted independently three times by Dr. Christina Gewinner (UCL, UK). 
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4.1.3 INPP4B, BRCA1, and ATR interact in a protein complex 
Since loss of INPP4B in MEFs resulted in loss of key ATM, ATR and BRCA1, protein-
protein interaction of INPP4B and the aforementioned DNA repair proteins was 
investigated to see if the loss was due to protein-protein interaction. 293T cells 
expressing Flag-tagged INPP4B (Flag-INPP4B) or empty Flag vector (control) were 
lysed and Flag-INPP4B protein complexes immunoprecipitated. Western blot analysis 
revealed specific interaction of INPP4B with ATR and BRCA1, but not with ATM or 
PTEN (figure 4.4). Interestingly, increased protein levels of BRCA1 in cell lysates 
overexpressing Flag-INPP4B was observed compared to control lysates. GST-pull 
down experiments using bacterial overexpressed GST-tagged fragments of N-terminal 
(aa1-460), middle (aa200-760) or C-terminal (aa460-924) INPP4B fragments (depicted 
in figure 4.5A) and Flag-tagged ATR or BRCA1 overexpressed in 293T cells revealed 
specific interactions of ATR and BRCA1 with the N-terminal and middle fragment of 
INPP4B but not with the C-terminal fragment in immunoblots (figure 4.5B). For these 
experiments it is important to note that the control used in this experiment consisted of 
sephorose beads incubated in FLAG-tagged lysates, rather than a GST-empty vector 
control. GST pull-down studies were conducted as published previously (Harper and 
Speicher; Katzen, 2007). 
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Figure 4.4. INPP4B forms a protein complex with endogenous ATR and BRCA1. 
293T cells were transfected with pcDNA3/FLAG empty (indicated by Ø sign) or 
pEAK/FLAG-INPP4B (indicated by + sign) using PEI (9002-98-6, Polyscience). 48 hrs 
post – transfection cells were lysed and lysates incubated with anti-FLAG M2 beads. 
Input lanes represent 1% of protein lysates. Experiments were conducted independently 
three times.  
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Figure 4.5. 293T cells overexpressing Flag-tagged ATR or BRCA1 revealed 
interactions of ATR and BRCA1 with the N-terminal and middle fragment of 
INPP4B but not with the C-terminal fragment. (A) GST-tagged fragments of N-
terminal (aa1-460), middle (aa200-760) or C-terminal (aa460-924) were generated as 
depicted in the diagram. The aa1-460 N-terminal fragment contains the C2-domain of 
INPP4B, the aa200-760 middle fragment contains a NERF2 domain and the aa460-924 
C-terminal domain contains the phosphatase domain of INPP4B. (B) GST-fusion 
constructs were used to ‘fish’ in extracts from 293T cells transfected with pcDNA3.1 
FLAG-ATR. Each INPP4B fragment was incubated with precleared Glutathione 
A	
B	
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Sepharose Fast Flow (GE Healthcare Life Sciences, UK) slurry for 2 hrs, then after 
washing the beads were incubated with the ATR-lysate for 30 min. Immunoblotting was 
carried out as described in section 2.1.3. Antibody detecting ATR (Bethyl Laboratories, 
UK; 1:10,000 primary antibody dilution) was used to detect interaction of ATR with 
GST-tagged INPP4B fragments. Input lanes were also detected and  represent 1% of 
protein lysates in pulldown assays. GST assays revealed BRCA1 and ATR interacting 
with the N-terminal and middle fragment of INPP4B, but not with the C-terminal 
fragment. Input lanes represent 1% of protein lysates. Experiments were conducted 
independently three times (UCL, UK). In these experiments, only empty agarose beads 
incubated with FLAG-tagged lysates were used as a control, rather than using a GST- 
empty vector control. 
  
 226 
4.2 Discussion 
We have shown in previous experiments a DNA repair defect in INPP4B-deficient 
ovarian cancer cell lines – Upon etoposide treatment INPP4B-deficient cells revealed an 
increase and retention of γH2AX, RAD51 and 53BP1 foci relative to controls 
indicating abnormal DNA repair and dysfunctional HR. Further experiments were 
carried out to investigate association of INPP4B with key DDR protein players and 
elucidate a mechanism that would explain the observed DNA defect. 
 
Detection of DDR proteins in Ovca429 and Ovca433 unchallenged knockdown cell 
pools revealed a link between INPP4B and DDR protein expression levels. Specifically, 
MCF-10A cell pools containing BRCA1 knockdown possessed reduced INPP4B 
protein expression compared to the control knockdown cell pools. In addition, shRNA-
INPP4B expressing Ovca429 cell pools harboured reduced ATR protein expression 
compared to the mock-knockdown controls. BRCA1 expression levels in ovca429 and 
ovca433 shRNA-INPP4B cell pools remained unchanged compared to the control. 
Depletion of INPP4B resulted in increased S473 phospho-Akt expression, revealing that 
loss of INPP4B is sufficient in increasing lipid-dependent signalling. 
 
Experiments conducted in INPP4B deficient MEFs revealed concomitant loss of ATR, 
ATM and BRCA1 protein expression. Interestingly, increasing loss of INPP4B resulted 
in increasing loss of ATM, ATR and BRCA1, suggestive of a function of INPP4B 
protein in the expression-dependent stability of these critical DDR proteins. In order to 
address the mechanisms underlying the regulation of protein levels of ATR, ATM and 
BRCA1 proteins upon loss of INPP4B, protein-protein interaction in 293T cells 
overexpressing INPP4B were studied. While investigation of endogenous proteins 
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avoids any artificial effects of affinity tags or overexpression, endogenous protein-
protein interaction was not conducted due to the unavailability of INPP4B antibody that 
functions effectively in immunoprecipitation experiments. In addition, the ovarian 
cancer cell lines used in this study could not be efficiently transfected and were 
consequently not used for overexpression studies. Instead, 293T cells were used for 
these experiments due to excellent transfection protein expression efficiency of the cell 
line. Immunoprecipitation studies revealed that 293T cells overexpressing INPP4B 
revealed an interaction of INPP4B with BRCA1 and ATR. Surprisingly, ATM was not 
found to interact with INPP4B, suggestive of different molecular mechanism that 
manifest with changing protein levels of INPP4B.  
 
The protein section in which INPP4B interacts with ATR and BRCA1 was also 
investigated. INPP4B domains were cloned into bacterial GST overexpression plasmids 
and GST-tagged INPP4B fragments representing the N-, middle- and C-terminal 
sections of INPP4B were bacterially expressed and isolated. Protein-protein interactions 
of these bacterially expressed and isolated INPP4B fragments with BRCA1 and ATR 
were investigated in GST-pull down assays. The N-terminal region of INPP4B (aa1-
460) and the middle region (aa200-760) of INPP4B were identified to be predominantly 
necessary for interaction with ATR and BRCA1. Further refining of the interacting 
domain could be investigated by cloning the overlapping region of the N- and middle 
fragment, isolating these fragments and assess interaction with BRCA1 and ATR in 
GST-pull down assays. It is worthy to note that in the GST pull-down assays, the 
control used consisted of sepharose beads incubated in FLAG-tagged lysates, and 
therefore does not take rule out possible sticky interaction of the FLAG-tagged 
ATR/BRCA1 with the GST-tag itself. However, given that three of the GST-tagged 
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INPP4B fragments resulted in varying levels of ATR and BRCA1 binding, it is likely 
that the effects are authentic.  
 
 
Other questions that arise from the data obtained include investigating the exact 
mechanism of the interaction of INPP4B with BRCA1 and ATR. The protein 
interactions observed do not give a clear indication of whether or not INPP4B interacts 
directly or indirectly with BRCA1 and ATR. In order to determine if INPP4B interacts 
directly with BRCA1 and ATR, a yeast two-hybrid screening assay could be conducted. 
Yeast cells would be transfected with two plasmids consisting of INPP4B and ATR, 
coupled to the DNA-binding domain of a yeast transcription factor, like Gal4, and a 
cDNA fragment containing the activation domain on the transcription factor, 
respectively. If INPP4B and ATR interact directly, the DNA-binding domain and the 
activating domain would be in close proximity to each other resulting in the 
transcription activation of the reporter gene. It would also be worthy to investigate and 
identify other proteins that INPP4B may indirectly or directly be interacting with in a 
complex with ATR and BRCA1 by affinity purification of tagged INPP4B, followed by 
mass spectrometry (the same could be done with BRCA1). Also, subcellular 
localisation of INPP4B could be also determined using relevant lysis buffers to isolate 
nuclear proteins from cytoplasmic proteins and membrane proteins. Due to time 
constraints, however, the proposed experiments were not carried out. However, the 
novel interaction identified between INPP4B and ATR/BRCA1 shows that INPP4B 
plays a crucial role in modulating the stability of key players of the DDR pathway and 
may indicate a potential protein function of INPP4B. INPP4B deficiency in the context 
of ovarian cancer therapies that engage in the principle of synthetic lethality should 
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therefore be assessed to investigate the potential role of INPP4B as a biomarker of 
ovarian cancer treatment. 
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CHAPTER 5. Treatment of INPP4B deficient cells with DNA 
repair inhibitors 
5.1 Introduction 
Inhibition of DNA repair in cancer cells used to enhance the cytotoxicity of 
chemotherapies has been subjected to extensive scientific research over the last few 
decades. Amongst the numerous drugs that target critical DNA repair proteins as anti-
cancer treatment, the most developed DNA repair inhibitors to date are the PARP 
inhibitors. There are currently nine PARP inhibitors in clinical development to treat a 
variety of cancer types that potentiate the effects of chemotherapy and radiation, as well 
as exploiting synthetic lethality in tumours with defective homologous recombination 
(HR) repair (PARP inhibitor trials in BRCA-mutated ovarian cancers, table 5.1; PARP 
inhibitor trials in sporadic ovarian cancers, table 5.2). The most promising results thus 
far stem from single-agent treatment of BRCA1/2-mutant breast and ovarian cancers in 
the clinic (Audeh et al., 2010; Fong et al., 2010; Tutt et al., 2010). BRCA1/2 play an 
important role in HR and a substantial body of evidence describes ovarian tumours with 
aberrant HR function: up to 15% of ovarian cancers harbour BRCA1/2-mutations and up 
to 30% of sporadic ovarian cancers exhibit methylation of the BRCA1 promoter 
(Baldwin et al., 2000; Catteau et al., 1999; Chan et al., 2002b; Esteller et al., 2000). 
Molecular aberrations were also investigated in 489 high grade serous ovarian 
carcinomas and approximately 50% of these samples harboured defective homologous 
recombination (CGARN, 2011), representing a larger proportion of patients than those 
currently being stratified for PARP inhibitor treatment. Novel predictive biomarkers are 
therefore required to accurately select patients who would benefit from PARP inhibitor 
treatment. Previous chapters have revealed a DNA repair defect in INPP4B deficient 
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ovarian cancer cells in response to genotoxic stress. In addition, INPP4B was found to 
interact with BRCA1 and ATR in overexpression studies. Since, INPP4B loss has been 
identified in 40% of ovarian tumours, the significance of INPP4B has great clinical 
implication, and therefore, the effect of INPP4B loss on tumour cell responses to the 
PARP inhibitor olaparib (Astrazeneca, UK) were assessed. INPP4B deficiency was also 
assessed in the context of other DNA damage response (DDR) protein inhibitors to 
screen for potential synthetic lethal interactions.  
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Table 5.1. PARP inhibitor trials in BRCA1/2-mutated ovarian cancers. Table 
source: (Burgess and Puhalla, 2014) 
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BC, breast cancer; OC, ovarian cancer; ORR, objective response rate; PR, partial 
response; SD, stable disease; recur, recurrent; BRCAwt, BRCA-wild type; HGS, high-
grade serous; TNBC, triple negative breast cancer; PRef, platinum-refractory; PRes, 
platinum-resistant; PFS, progression free survival; OS, overall survival; CR, complete 
response; met, metastatic; unresect, unresectable; EOC, epithelial ovarian cancer; 
PSens, platinum-sensitive; BLBC, basal-like breast cancer. 
 234 
Table 5.2. PARP inhibit trials in sporadic ovarian cancers. Table source: (Burgess 
and Puhalla, 2014) 
 
recur, recurrent; BRCAmut , mutated BRCA; OC, ovarian cancer; BC, breast cancer; 
BRCAwt , BRCA-wild type; HGS, high-grade serous; TNBC, triple negative breast 
can- cer; CR, complete response; PR, partial response; SD, stable disease; PSens, 
platinum-sensitive; PFS, progression free survival; OS, overall survival; ORR, objective 
response rate; EOC, epithelial ovarian cancer; BLBC, basal-like breast cancer; met, 
metastatic; unresect, unresectable.  
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5.2 Results 
5.2.1 Loss of INPP4B results in increased sensitivity towards olaparib 
Cell proliferation assays were conducted to assess the effect of INPP4B loss in the 
context of PARP inhibitor treatment of ovarian cancer cells. Cells were treated 
continuously for 72 hrs with increasing concentrations of olaparib (dose-response) and 
cell viability assessed with a metabolic readout measured using Alamarblue. Ovca429 
shRNA INPP4B cell pools displayed a dose-dependent and significantly increased 
sensitivity upon olaparib treatment compared to controls (figure 5.1). Treatment with 
100 µM olaparib resulted in 38% reduction in growth in INPP4B deficient Ovca429 
cells compared to 61% in the control cells (p = 0.02). Ovca433 knockdown cell pools 
were also assessed, however the shRNA INPP4B cells did not display as great a 
difference in olaparib sensitivity compared to the control. 
 
The observed olaparib sensitivity in Ovca429 and Ovca433 INPP4B knockdown cell 
pools was also assessed in cell lines with varying endogenous expression levels of 
INPP4B or PTEN (experiments performed by Dr. Christina Gewinner). Cell 
proliferation assays were conducted in A2780 (INPP4B− / −, PTEN− / −), Ovcar3 
(INPP4B− / −, PTEN+/+), and Ovca433 (INPP4B +/+, PTEN +/+) ovarian cancer cell 
lines in the same manner as previous experiments (see figure 3.4 for cell line protein 
expression). A2780 (INPP4B− / −, PTEN− / −) demonstrated the highest olaparib 
sensitivity followed by the INPP4B-negative Ovcar3 (INPP4B− / −, PTEN+/+). 
Ovca433 cells (INPP4B+/+, PTEN+/+) displayed greatest olaparib resistance (figure 
5.2) Additional PTEN loss in INPP4B- deficient Ovcar3 cells resulted in additive 
olaparib sensitivity similar to the A2780 cell line (INPP4B− / −, PTEN− / −). PTEN 
knockdown in Ovcar3 cells resulted in additive olaparib sensitivity similar to the A2780 
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cell line (INPP4B− / −, PTEN− / −). In rescue experiments re-expression of Flag-tagged 
INPP4B in the INPP4B-deficient Igrov-1 cell line resulted in a 2-fold increase in 
olaparib resistance in cell proliferation assays (figure 5.2B) 
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Figure 5.1. Dose response curve of olaparib treated Ovca429 and Ocva433 
knockdown cell pools. Cell proliferation assays were conducted in Ovca429 
knockdown cell pools subjected to 72 hrs continuous treatment of olaparib in increasing 
concentrations. Ovca429 shRNA INPP4B cell pools displayed a dose-dependent and 
significantly increased sensitivity upon olaparib treatment compared to controls. P-
values for conditions at 1 µM, 5 µM, 10 µM and 100 µM were 0.027, 0.019, 0.039 and 
0.026, respectively. IC50 for shRNA INPP4B cell pool is 61 µM, calculated using a 
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best-fit curve on Microsoft Excel. Ovca433 shRNA INPP4B cell pools also displayed 
increased sensitivity towards olaparib. P-values for  conditions at 5 µM, 10 µM, 25 µM 
and 50 µM were 0.004, 5.79x10-5, 0.026 and 1.54x10-4, respectively. Experiments were 
conducted independently three times, in triplicates. Error bars indicate standard 
deviation. The t-test was used for statistical analysis (p-value of *≤0.05, **≤0.005, 
***≤0.0005). 
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Figure 5.2. INPP4B loss in various ovarian cancer cell lines results in sensitivity 
towards PARP inhibitor treatment in vitro. (A) Cell proliferation assays were 
conducted in ovarian cancer cell line A2780 (INPP4B-/-, PTEN-/-), and these cells 
A	
B	
p= 0.004 
p= 0.02 
p= 0.02 
p= 0.009 
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demonstrated highest olaparib sensitivity followed by the INPP4B-negative Ovcar3 
(INPP4B-/-, PTEN+/+). Ovca433 cells (INPP4B+/+, PTEN+/+) displayed greatest olaparib 
resistance. Additional PTEN loss in INPP4B-deficient Ovcar3 cells resulted in additive 
olaparib sensitivity similar to the A2780 cell line (INPP4B-/-, PTEN-/-). PTEN 
knockdown in Ovcar3 cells resulted in additive olaparib sensitivity similar to the A2780 
cell line (INPP4B-/-, PTEN-/-). Experiment was conducted independently three times, in 
triplicate by Dr. Christina Gewinner (UCL, UK). Error bars represent standard 
deviation. The t-test was used for statistical analysis (p-value of *≤0.05, **≤0.005; P 
values for Ovca433  cells at conditions of 5 µM and 10 µM were 0.019 and 0.009, 
respectively. P-values for Ovca3 cells at conditions of 2.5 µM and 5 µM were 0.004 and 
0.018, respectively). (B) Olaparib dose response curve of Igrov-1 cells (INPP4B-/-, 
PTEN+/+) expressing Flag-INPP4B or empty vector control. Percent growth is displayed. 
Experiment was conducted independently three times, in triplicate by Dr. Christina 
Gewinner (UCL, UK). P-values for conditions at 2.5 µM and 5 µM were 0.04 and 0.01, 
respectively. Error bars indicate standard deviation. The t-test was used for statistical 
analysis (p-value of *≤0.05). 
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5.2.2 Loss of INPP4B results in increase in cisplatin sensitivity and dual 
treatment of INPP4B-deficient cells with cisplatin and olaparib results in an 
additive effect 
Clonogenic assays were conducted to assess the effectiveness of olaparib on the 
survival and proliferation of INPP4B-deficient cells under cisplatin-only, olaparib-only 
or dual treatment conditions (figure 5.3). Dual-treated cells were continuously treated 
with 1 µM olaparib for 6 days preceded by a single dose of 10 µM cisplatin on day 1. 
Ovca429 INPP4B knockdown cells showed significantly greater inhibition of 
clonogenic growth to single agent cisplatin or olaparib compared to controls. 
Combination treatment resulted in an additive effect, with significantly greater 
inhibition of growth in Ovca429 INPP4B knockdown pools compared to controls.  
Clonogenic assays in Ovca433 cells were attempted, but the cells were unable to grow 
into succinct colonies that could be accurately counted, hence experiments with this cell 
line were not continued. The t-test was used for statistical analysis (p-value of *≤0.05, 
**≤0.005, ***≤0.0005). 
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Figure 5.3. Clonogenic assays of Ovca429 knockdown cell pools using cisplatin 
alone or in combination with continuous olaparib treatment. Cells were treated with 
10 µM cisplatin for 1 hr, continuously treated with 1 µM olaparib, or subjected to dual 
treatment of both cisplatin and olaparib. Single agent and dual agent treatments resulted 
in an additive and synergistic effect, respectively. Percent inhibition clonogenic growth 
is displayed. P-values for conditions between cisplatin treatments, cisplatin + dual 
treatment and olaparib + dual treatment were 0.006, 0.020 and 0.007, respectively. 
Experiments with all treatments pooled in one experiment were conducted 
independently three times, in triplicate. Error bars represent standard deviation. The t-
test was used for statistical analysis (p-value of *≤0.05). 
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5.2.3 INPP4B knockdown in Ovca429 cells sensitises tumour growth to olaparib 
in vivo 
Assessment of olaparib sensitivity in vivo was conducted by Dr. Christina Gewinner 
(UCL, UK). Ovca429 shRNA INPP4B or control cells were injected into nude mice 
subcutaneously and animals bearing established tumours were injected daily with either 
50 mg/kg olaparib or DMSO. The mice were sacrificed two weeks post – treatment and 
their tumour burden quantified (figure 5.4). As expected, INPP4B deficient tumours 
were larger than tumours containing shRNA-Renilla luciferase cells with control 
treatment. Post-treatment, shRNA INPP4B tumours treated with olaparib revealed a 
significant reduction in tumour burden compared to control treated tumours, which 
further support the in vitro findings that loss of INPP4B results in enhanced sensitivity 
to olaparib treatment.  
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Figure 5.4. INPP4B knockdown in Ovca429 sensitises tumour growth to PARP 
inhibitor treatment in vivo. (A) Nude mice were injected subcutaneously with 
Ovca429 INPP4B or Renilla luciferase knockdown cells. Tumour bearing animals were 
injected daily with olaparib or DMSO. Quantification of tumour volume is shown (error 
A	
B	
C	
Ovca429		
knockdown	 cell	
pools	
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bars represent SD.). (B) Waterfall plot of tumour volume compared to treatment start. 
Xenograft experiments and quantification analysis were conducted by Dr. Christina 
Gewinner (UCL, UK). (C) Western blots of Ovca429 knockdown cells pools used for 
the in vivo experiments. 
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5.2.4 Treatment of INPP4B deficient Ovca429 knockdown cells with Chk1 
inhibitor LY2940930 results in resistance in cell proliferation assays 
The interaction of INPP4B with ATR identified in previous experiments led to the 
rationale of investigating other compounds that inhibit substrates of ATR, such as Chk1, 
to assess for synthetic lethal effects. Cell proliferation assays using two Chk1 inhibitors, 
LY2940930 and LY2603618 (Eli Lilly, USA), were conducted in Ovca429 and 
Ovca433 knockdown cell pools to investigate potential synthetic lethal interaction. Cells 
were treated continuously for 72 hrs with increasing concentrations of the inhibitors 
(dose-response curve), and cell viability via metabolic readout was measured. Upon 
treatment, INPP4B-deficient ovca429 cells exhibited reduced sensitivity towards 
LY2940930 compared to the control. Compared to the control, shRNA INPP4B cells 
revealed a 107% growth increase vs. 98% (p = 0.038), 102% vs 83% (p = 0.0040, 60% 
vs 41% (p = 0.051), and 32% vs 25% (p = 0.014). On the other hand, treatment of 
Ovca433 shRNA INPP4B cells with LY2940930 resulted in no significant difference 
compared to the control (figure 5.5). Investigation of LY2603618 in both Ovca429 and 
Ovca433 knockdown cell pools resulted in no statistical difference between INPP4B-
deficient knockdown cell pools and the mock knockdown control (figure 5.6). Further 
investigation of LY2603618 treated Ovca429 shRNA INPP4B cells in clonogenic 
assays revealed no statistical difference between the cells and the controls (figure 5.7), 
although the trend was for INPP4B knockdown Ovca433 cells to be more sensitive; the 
opposite of that was observed in Ovcax429 cells with LY2940930. 
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Figure 5.5. Ovca429 and Ovca433 knockdown cell pool dose response curves upon 
LY2940930 treatment. Ovca429 and ovca433 knockdown cell pools were 
continuously treated with varying concentrations of Chk1 inhibitors LY2940930 and 
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metabolic activity was measured 72 hrs post-treatment. Ovca429 shRNA INPP4B cells 
displayed decreased growth inhibition upon LY2940930 treatment compared to the 
controls. P-values for conditions at 1 µM, 5µM and 50 µM were 0.038, 0.004 and 
0.014, respectively. Experiments with Ovca433 INPP4B deficient cells displayed no 
statistical difference and mock knockdown control. All experiments were conducted 
independently three times, in triplicates. Error bars represent standard deviation. The t-
test was used for statistical analysis (p-value of *≤0.05, **≤0.005).  
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Figure 5.6. Ovca429 and Ovca433 knockdown cell pool dose response curves upon 
LY2603618 treatment. Ovca429 and ovca433 knockdown cell pools were 
continuously treated with varying concentrations of Chk1 inhibitors LY2603618 and 
metabolic activity was measured 72 hrs post-treatment. No statistic difference was 
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observed between the INPP4B deficient cells and mock knockdown control. All 
experiments were conducted independently three times, in triplicates. Error bars 
represent standard deviation. The t-test was used for statistical analysis.  
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Figure 5.7. LY2940930 treated Ovca429 cells possessing shRNA INPP4B resulted 
in no statistical difference in clonogenic growth compared to the controls. 1,000 
Ovca429 knockdown cells were seeded per well in a 6-well dish and attached cells were 
treated with 1 nM, 2.5 nM and 5 nM LY2940930 every other day for 6 days, then 
stained and counted. No statistical difference was seen between INPP4B-deficient and 
control Ovca429 cells. Experiment was conducted independently three times, in 
triplicates. Error bars represent standard deviation. The t-test was used for statistical 
analysis.  
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5.3 Discussion 
Previous experiments have revealed a protein-protein interaction between INPP4B and 
ATR, and loss of INPP4B resulted in diminished protein expression of ATR in mouse 
embryonic fibroblast models. One of the key substrates of ATR is the serine threonine 
checkpoint kinase Chk1. Chk1 plays a central role in normal DNA replication, mitosis, 
and cytokinesis. Inhibition of Chk1 in the absence of DNA damage can cause impaired 
DNA replication, loss of DNA damage checkpoints, premature entry into mitosis, and 
cell death (Bucher and Britten, 2008; Thompson and Eastman, 2013). The effect of 
INPP4B knockdown on Chk1 inhibitors was investigated to screen for potential 
synthetic lethal interaction. For the experiments, two potent small molecule inhibitors of 
Chk1 were used, LY2940930 (also known as LY2606368) and LY2603618, which 
inhibit Chk1/2 and Chk1, respectively (Eli Lilly, UK). Both compounds are currently 
being assessed in phase I clinical trials for advanced cancers (NCT01115790, 2010; 
NCT01341457, 2011). Cell proliferation assays of LY2940930 treated Ovca433 cell 
pools did not result in any statistical difference between shRNA INPP4B cells and the 
control. Similarly, no statistical difference was found in cell proliferation assays 
conducted in both Ovca429 and Ovca433 knockdown cell pools. Downregulation of 
ATR and ATM protein levels due to INPP4B loss may contribute to decreased 
activation of Chk1 and Chk2, and hence, loss of sensitivity towards Chk1/2 inhibitors. 
On the other hand, Ovca429 shRNA-INPP4B cells displayed reduced sensitivity 
towards LY2940930 treatment compared to the controls in cell proliferation assays. The 
precise mechanism for the observed reduced sensitivity was not deduced due to time 
constraints. However, a study conducted observed that oncogenic KRAS and dominant 
negative TP53 render BRCA2-depleted HEK293 cells resistant to Chk1 inhibition, 
which suggests that modulations in other pathways due to INPP4B loss may contribute 
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to the reduced sensitivity towards Chk1 inhibition (Hattori et al., 2011). Further 
experiments will need to be conducted to examine DDR pathway activation and 
phosphorylation status of relevant proteins in the context of INPP4B loss, which may 
provide insight into which pathways are involved in this reduced sensitivity.  
 
The effect of INPP4B loss and PARP inhibition was also investigated in this study. 
Identification of HR defects has gained traction in cancer therapy research due to their 
potential exploitation by PARP inhibitors, as well as by conventional treatment. Pre-
clinically, PARP inhibitors have shown efficacy not only in cells lacking BRCA1/2, but 
also in cells with other defective HR proteins, such as RAD51, ATR, ATM, Chk1, and 
FANCA or FANCC (Bryant et al., 2005; Farmer et al., 2005; McCabe et al., 2006), 
which provided the rational for assessing PARP inhibitors clinically in BRCA1/2-mutant 
tumours. The phase II trial data of PARP inhibitor olaparib in ovarian cancer patients 
that received treatment based on BRCA1/2 mutation status revealed a median 
improvement of 6.9 months in progression-free survival and an overall survival 
improvement of 3 months compared with placebo (Ledermann et al., 2012). While 10 – 
15% of ovarian tumours harbour germline mutations in BRCA1/2, there is a growing 
body of evidence that suggests additional mechanisms of BRCA1/2 dysfunction and 
HR-deficiency are involved in the pathogenesis of ovarian cancer (George et al., 2013; 
Turner et al., 2004; Weberpals et al., 2008). Therefore, there is a great need to identify 
patients who would benefit most from PARP inhibitor treatment and be included in 
these in clinical trials currently designed for BRCA-related cancers. Upon treatment 
with the PARP inhibitor olaparib, INPP4B deficient Ovca429 and Ovca433 ovarian 
cancer cells displayed a modest increase in sensitivity towards the drug compared to 
control cells in cell proliferation assays. In addition, studies in other ovarian serous 
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adenocarcinoma based cell lines (A2780, Ovcar-3), have also confirmed that loss of 
INPP4B is associated with olaparib sensitivity and re-expression of INPP4B in the 
INPP4B-deficient IGROV-1 endometrioid carcinoma cell line resulted in decreased 
olaparib sensitivity. Therefore, the integrity of INPP4B expression and its effect on 
olaparib sensitivity can be observed across a range of ovarian cancer cell lines and 
subtypes. However, it must be noted that the limitation of this study remains being 
unable to determine whether the two cell ovarian cancer cell lines represent either high 
grade or low grade serous ovarian carcinomas, two distinct diseases with differing 
molecular and clinical pathological profiles. Clonogenic growth assessment in Ocva429 
shRNA INPP4B cells revealed not only an increased sensitivity towards single agent 
treatment of olaparib, but interestingly, also a heightened sensitivity towards single 
agent cisplatin treatment. The sensitivity of INPP4B deficient cells towards cisplatin 
treatment mirrors the responsiveness of germline BRCA1/2-mutant ovarian tumours to 
platinum-based regimens, whereby the DNA damage induced by the platinum is more 
efficacious in cells harbouring DNA repair defects (Cass et al., 2003). In addition, dual 
treatment of both drugs resulted in an additive effect in INPP4B deficient cells 
compared to the controls. In vivo experiments in immunosuppressed mice further 
confirmed great sensitivity of INPP4B-deficient tumours towards olaparib compared to 
the control treatment.  
 
The clinical implications of using PARP inhibitors in cancer therapy have been 
promising, albeit not without adversity. Several clinical trials have provided greater 
insight into problems of drug toxicity and resistance. When used as monotherapy, 
PARP inhibitors are generally well tolerated with the most common side effects 
including fatigue, nausea, and vomiting; dose-limiting toxicities of cognitive 
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dysfunction and mood alterations have also been described (Audeh et al., 2010; Fong et 
al., 2009; Gelmon et al., 2011). PARP inhibitors combined with chemotherapy in 
BRCA-mutated ovarian malignancies, on the other hand, have resulted in 
myelosuppression with grade 3/4 adverse events (neutropenia (42%)), as well as 
thrombocytopenia (20%), and anaemia (13%) (Jung-min Lee, 2013). Combination 
therapies of PARP inhibitors and novel targeted agents have also been assessed. 
Cadiranib, an anti-angiogenic agent was used in conjunction with olaparib in recurrent 
epithelial ovarian cancers, and while the overall response rate was 44%, patients 
frequently experienced grade 3 or higher haematologic and non-haematologic toxicities 
(Liu et al., 2013). Further examination of drug combinations and toxicities will need to 
be conducted to implement effective treatment of patients with PARP inhibitors while 
keeping side effects at a minimum. 
 
Furthermore, the issue of drug resistance has pervaded the study of ovarian cancer, with 
the majority of patients likely to develop resistance against first line platinum therapy. 
The continuation of clinical trials exploring the effects of PARP inhibitors targeting 
BRCA-mutant tumours also highlights the need to address drug resistance in this 
context. While the phase II study led be Lederman et al. revealed a 40% response to 
olaparib in germline BRCA mutation carriers with breast or ovarian cancer, several 
mechanisms of resistance have been hypothesised to take account of the remainder of 
patients who do not respond to PARP inhibitor treatment. Amongst the numerous 
resistance mechanisms that have been proposed, secondary mutation of BRCA2 is the 
most well validated mechanism of PARP-inhibitor resistance. Two groups 
independently discovered that PARP inhibitor resistance came about due to mutation in 
the BRCA2 gene itself that resulted in the restoration of the opening reading frame for 
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BRCA2 was frequently observed in resistant tumour cell lines (Edwards et al., 2008; 
Sakai et al., 2008). Whether the secondary mutations are present before or arise during 
PARP-inhibitor therapy is currently unknown. It may be possible that rare resistant cells 
harbouring secondary mutations before treatment are selected by the PARP inhibitor 
treatment itself resulting in developed resistance. Additional studies are required to 
identify approaches that would result in more effective PARP inhibitor treatment, 
reduce de novo resistance to the drug, and provide alternative therapies to circumvent 
inherent or acquired resistance.  
 
Despite the toxicities and resistance encountered by these drugs in clinic, the relevance 
of INPP4B with respect to PARP inhibitors is one of great importance. Reliable 
biomarkers are currently needed to identify DDR defects to best select and stratify 
patients on the basis of the molecular phenotype of the tumour in order to improve 
therapeutic response, as well as reduce healthcare costs of administering drugs that are 
likely to have little effect. Additional studies are necessary to establish the level of 
INPP4B protein expression that would result in optimum sensitivity towards PARP 
inhibitor treatment. The mechanisms of PARP inhibitor sensitivity should also be firmly 
defined, which include assessing via immunoblotting the cellular response of various 
DDR proteins, as well as other players in major signalling pathways, since crosstalk 
between pathways is a common feature in drug response and resistance. Gaining a 
deeper understanding of these cellular changes would also provide further insight into 
potential synergistic effects with other clinical inhibitors.  Given that INPP4B loss has 
been found in 40% of ovarian cancer patients, the experiments conducted provide the 
rationale for establishing INPP4B as a biomarker of PARP inhibitor response, and 
consequently offers novel therapeutic options for a significant subset of patients. 
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CHAPTER 6. Final Discussion 
Current standard of care ovarian cancer treatment involves optimal cytoreductive 
surgery and adjuvant platinum- and taxane-based chemotherapy. While the majority of 
patients are initially responsive to treatment, over 70% develop disease recurrence and 
platinum-resistance, revealing an urgent need to develop alternative treatment options 
for these patients. 
 
The study of ovarian cancer and the lack of advancement in providing treatment options 
with better outcomes are in part due to the lack of appropriate models available in the 
laboratory setting. Conventional models have been limited to a set of relatively poorly 
characterised immortalised cell lines, to which the true origins of the cell lines have 
recently been called into question (Anglesio et al., 2013; Domcke et al., 2013). A study 
conducted by Domcke et al. found that 60% of all published research articles on high 
grade serous ovarian carcinomas (HGSC) are inaccurate representations of the disease, 
and the 12 most suitable ovarian cancer cell lines that best characterise HGSC were 
used in only 1% of publications (Domcke et al., 2013). In addition, the redefinition of 
ovarian cancer as a collective term for molecularly and aetiologically distinct diseases 
that share a common anatomical location, has also caused further confusion as to the 
origins of the cell lines on hand (Bast et al., 2009). The progress of establishing animal 
models that mimic ovarian cancer pathogenesis is also being redefined. Mouse models 
for endometrioid ovarian cancer subtype have been successfully implemented to 
identify the site of origin and disease pathogenesis of this particular subtype (Dinulescu 
et al., 2005; Wu et al., 2013; Wu et al., 2007). However, the development of accurate 
mouse models that recapitulate the early molecular alterations and disease progress of 
HGSC, have been slow to progress, likely due to previous models targeting the ovarian 
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surface epithelium as the site of origin. A recent study conducted by Perets et al. has 
challenged the traditional model of the ovaries being the site of carcinogenesis by 
demonstrating that HGSC can originate from the secretory cells of the fallopian tubes. 
By generating a de novo mouse model of HGSC that targets commonly altered HGSC 
genes specifically to secretory epithelial cells within the fallopian tube, they observed 
the development of precursor serous tubule intraepithelial carcinomas lesions, HGSC, 
and the progression to advanced stage disease, including ovarian and peritoneal 
metastases (Perets et al., 2013). More methodological studies are required to firstly re-
verify the origins of ovarian cancer cell lines that are currently available, and secondly 
to further evaluate the site origins of the different subtype of ovarian cancer to provide 
the appropriate cellular context for assessing therapeutic strategies more accurately. 
 
Using synthetic lethality as a basis for therapy in order to exploit inherent differences 
between cancer cells and normal cells provides an attractive opportunity to develop 
novel treatments for cancer that is tailored and highly selective. The best example of 
synthetic lethality use is PARP inhibitor treatment for ovarian tumours harbouring 
BRCA1/2 mutations. Given the promising results of several PARP inhibitors currently 
in phase III trails, identifying other genetic determinants of PARP inhibitor sensitivity 
may enhance treatment options for women with ovarian cancer. Identifying the 
relevance of a DNA repair defect due to INPP4B loss prevails in the context of ovarian 
cancer, where BRCA1 mutations, “BRCAness” and homologous recombination (HR) 
repair deficiency is common feature of ovarian tumours. The novel function of INPP4B 
in maintaining HR integrity identified in this study results in a therapeutic opportunity 
through the delivery of therapeutic strategies on this same basis of synthetic lethality. 
The effect of INPP4B loss resulting in increased sensitivity to the PARP inhibitor 
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olaparib in ovarian cancer cells and in xenograft models as evidenced from this study 
has great implications for using INPP4B as a novel biomarker of PARP inhibitor 
sensitivity in ovarian cancer. Current clinical trials that involve the use of PARP 
inhibitors as monotherapy or in conjunction with other treatments have previously 
enrolled patients primarily based on their BRCA status. Newer studies have also 
incorporated patient selection based on their disease subtype and platinum-sensitivity. 
Stratifying patients based on INPP4B expression may have a profound impact on the 
inclusion of more patients likely to benefit from PARP inhibitor treatment. Using the 
recently established revised ovarian cancer models and redefined cell lines, it would be 
profitable to investigate the effects of INPP4B on DNA repair in each of the five main 
subtypes of ovarian cancer, HGSC, LGSC, clear cell carcinoma, mucinous carcinoma 
and endometriod carcinoma, which would better appropriate relevant therapeutic 
strategies to patients based specifically on their disease subtype. From a clinical 
perspective, this study provides the rationale to investigate olaparib sensitivity in 
INPP4B-deficient serous ovarian tumours in phase 0 trials.  
 
This study also identified a potential mechanism for the DNA repair defect through the 
identification of protein-protein interaction of INPP4B with ATR and BRCA1 and 
provides a platform for further research to be conducted to construe the details of this 
mechanism and how it temporally and spatially relates in response to DNA damage, as 
well as in an unchallenged environment. In addition, elucidation of whether or not the 
function of INPP4B in this context is dependent on its catalytic activity or its protein 
function still needs to be defined. While INPP4B loss affected HR repair, assessing the 
function of INPP4B in other DNA repair pathways in detail may identify other DNA 
repair inhibitors that would also show therapeutic efficacy. It is of interest to note that 
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the experiments in this study were conducted in a variety of tissue types apart from the 
ovarian cell lines used, including human mammary cell line MCF-10A, where INPP4B 
loss and its tumour suppressor function was initially characterised, and INPP4B floxed 
mouse embryonic fibroblasts. Regardless of the cell lines used, the results across all 
experiments pointed to the involvement of INPP4B with a DNA repair defect. In 
addition, since INPP4B loss is found in various epithelial cancers, these observations 
raise further questions as to whether this DNA repair deficiency can be found in cancers 
of different tissue types, and whether or not the protein-protein interaction of INPP4B 
with ATR and BRCA1 is conserved. Speculation for INPP4B’s mechanism of action 
could be that INPP4B plays a role in the stability of ATR and BRCA1 in the context of 
proteosomal degradation; loss of INPP4B as a protein that interacts with ATR and 
BRCA1 directly or indirectly could lead to an acceleration of degradation of the DNA 
repair proteins, therefore resulting in a DNA repair defect.  The loss of INPP4B 
expression resulting in cisplatin sensitivity observed in this study merits in depth 
assessment within the ovarian cancer setting. Data obtained in collaboration with Dr. 
Andrew Feber (University College London, UK) have revealed that re-expression of 
INPP4B in bladder cancer patients resulted in developed resistance to platinum drugs, 
indicative of a role of INPP4B in platinum sensitivity in other cancer tissue types. This 
study investigated the loss of INPP4B and its effect on DNA repair and treatment 
strategies in ovarian cancer; however the effect of INPP4B loss and INPP4A levels 
were not addressed and potentially could in part compensate for INPP4B loss.  
 
In the last decade the establishment of targeted therapies in ovarian cancer treatment has 
reignited advances in developing effective treatment options for patients. In parallel 
with determining the clinical efficacy of the inhibitors, the establishment of predictive 
 261 
biomarkers are needed not only to enrich trials with more patients that would likely 
respond to the treatment, but also to provide a greater chance in furthering clinical 
development and ultimately achieving drug registration (Carden et al., 2010). Current 
models of identifying tumours with non-germline HR repair defects include 
immunohistochemistry (IHC) analysis of tissue microarrays (TMAs), gene expression 
profiling, and methylation-specific arrays, all of which have been reported to have 
varying degrees of predictive power (Ahluwalia et al., 2001; Jazaeri et al., 2002; 
Konstantinopoulos et al., 2010; Vollebergh et al., 2012). In addition to knowledge 
driven gene-based markers, other strategies for assessing HR integrity include the use of 
genomic instability as a general hallmark of HR deficiency through copy number 
aberration analysis by array comparative genomic hybridisation (aCGH), and the use of 
pharmacodynamics biomarkers as a readout of HR activity through the measurement of 
RAD51 foci following ex vivo DNA damage induction (Mukhopadhyay et al., 2010). A 
study conducted by the Cancer Genome Atlas Research Network identified HR 
deficiency in approximately 50% of HGSC and specifically found genetic mutations 
and epigenetic silencing in numerous HR genes, including BRCA1, BRCA2, EMSY, 
RAD51C, ATR, ATM, PALB2, and several FA genes (CGARN, 2011). This study 
provides the rationale for including INPP4B as a biomarker of HR deficiency that 
should be further investigated in preclinical and clinical settings.  
 
A comprehensive analysis of INPP4B overall gene expression in metastatic melanomas 
compared to primary melanomas was performed and significantly lower INPP4B 
expression was found in metastatic melanomas compared to primary lesions 
corroborating earlier findings that loss of INPP4B expression may modulate the 
metastatic potential of tumours (figure 6.1A) (Gewinner et al., 2009). Loss of INPP4B 
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expression was associated with poor overall survival in patients bearing ductal invasive 
breast carcinomas, as evidenced from earlier studies (figure 6.1B) (Gewinner et al., 
2009). Taken together, these findings point to a critical role of INPP4B in overall 
patient survival and metastatic disease. It will be profitable to address if INPP4B 
correlates with patient outcome in clinical trials using HR inhibitors and if it can be 
used as a prognostic marker in ovarian cancer as well. 
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Figure 6.1. INPP4B is lost in human tumours and metastases. (A) Box-plots 
indicating significantly overall lower INPP4B expression in metastatic compared to 
primary melanomas (overall INPP4B loss: 48.6%). (B) Ranked INPP4B expression in 
ductal invasive breast carcinomas (n=93) and Kaplan-Meier survival curves comparing 
disease-free survival between cases with the lowest (<50th percentile) vs. highest 
(>50th percentile) INPP4B expression (P= 0.0316, log-rank test). Bioinformatic 
analysis was conducted by Dr. George Pouligiannis (Harvard University, USA).   
A	
B	
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In addition, the relevance of INPP4B within the context of the PI3K/Akt pathway and 
ovarian cancer requires further investigation. In a comprehensive analysis of 93 primary 
ovarian tumours, aCGH analysis was used to identify copy number changes amongst 
nine canonical signalling pathways (PI3K/AKT/mTOR, MAPK, TGF-B, p38/MAPK, 
JNK, JAK/STAT, WNT/β-Catenin, and NFκB) and the PI3K/AKT/mTOR pathway was 
the most frequently altered cancer related pathway (Huang et al., 2011). Currently, 
clinical trials that are combining PI3K/Akt/mTOR inhibitors with other targeted 
therapies are enrolling patients for the study regardless of the PI3K/Akt pathway 
component status within their tumours. Identifying biomarkers that would accurately 
predict patient response through assessment of PI3K/Akt component integrity, and 
hence also identify the relevant subset of patients for enrolment may increase the 
efficacy of clinical trials. In breast and gynaecological malignancies, PI3KCA mutation 
and PTEN loss correlated with patient response to doxorubicin, bevacizumab, and 
temsirolimus (Moroney et al., 2011). Preliminary studies treating INPP4B-deficient 
ovarian cancer cells with dual PI3K/mTOR inhibitor NVP-BEZ235 (Novartis, 
Switzerland) resulted in increased sensitivity compared to the control treated cells. It 
would be of interest to see whether the incorporation of PARP inhibitors would be a 
synergistic treatment addition in this context.  
 
The limitations of this study from a therapeutic perspective revolve around the long-
term impact of PARP inhibition of ovarian tumours. While novel predictive markers are 
needed to accurately include patients likely to respond to PARP inhibitor treatments, 
current predictors of sensitivity and the one proposed in this study do not necessarily 
represent predictors of long lasting therapy sensitivity. Evidence of PARP inhibitor 
resistance has emerged, through resistance of secondary mutations of BRCA2, and also 
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resistance through loss of 53BP1 expression (Bouwman et al., 2010; Bunting et al., 
2012). Continuing research is required to provide a better framework of understanding 
the function of INPP4B in ovarian cancer as well as present potential therapeutic 
alternatives to circumvent arising drug resistance. Gaining greater insight into the 
regulation of INPP4B, defining the cytoplasmic and nuclear roles of the protein, and 
discerning how INPP4B contributes to other signalling pathways directly and indirectly 
will provide a more well-rounded understanding of the impact of INPP4B on ovarian 
cancer and how it can be best exploited therapeutically to provide a specific and long 
lasting benefit for patients.  
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CHAPTER 7. Appendix  
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Appendix 1. Qualitative analyses of the microarray experiments that were used to 
assess the transcriptional changes of MCF-10A shRNA INPP4B or Renilla 
luciferase expressing cell pools. (A) RNA degradation plots indicating the relative 
intensities of individual probes ordered from 5′ to 3′ averaged over all probe sets. 
(B) Scatter plots of the log – intensity values of the genes across all microarray 
experiments. (C) Unsupervised hierarchical clustering across the 54,675 gene probes 
that were included in the microarray platform indicating good clustering among the 
replicate samples. (D) Image plots of the arrays that were used in this experiment 
indicating no major artifacts. Analysis was performed by Dr. George Pouligiannis 
(Harvard University, USA). Experiments were conducted in triplicates (n = 6). Data 
pre-processing and quality control were performed in R (http://www.r-project.org/) and 
Bioconductor.  
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Appendix 2. Heatmap of the most significantly differentially expressed genes (adjusted 
P-value < 0.05) between Renilla luciferase and INPP4B knockdown MCF-10A cells. 
Red and blue bars represent high and low gene expression relative to the median 
expression, respectively. Cell preparation and bioinformatic analysis were conducted by 
Dr Christina Gewinner (UCL, UK) and Dr George Pouligiannis (Harvard University, 
USA). The differentially expressed genes were computed by an empirical Bayes 
shrinkage of the standard errors toward a common value approach embedded within the 
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Limma package (Smyth, 2004). P-values were adjusted for multiple comparisons using 
the false discovery rate approach implemented by Benjamini & Hochberg (Klipper-
Aurbach et al., 1995). 
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Appendix 3.  Biological processes and Kyoto encyclopaedia of genes and genomes 
(KEGG) pathways enriched in the genes associated with INPP4B knockdown. 
Gene ontology and pathway enrichment analysis was performed using a classical 
hypergeometric test and the gene ontologies or pathways with the highest negative 
log(10) P value were plotted. Bioinformatic analysis was conducted by Dr George 
Pouligiannis (Harvard University, USA). 
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Appendix 4. BRCA1-mutant and poor survival gene signatures revealed in 
INPP4B deficient MCF-10A cells by microarray analysis. (A) Heatmap highlighting 
differences of the differentially expressed genes in the poor survival gene set. Red and 
blue bars represent high and low gene expression relative to the median expression, 
respectively. (B) Heatmap highlighting coordinated differential expression of the 
BRCA_BRCA1_NEG gene signature in MCF-10A shRNA INPP4B knockdown cells. 
(C) Gene set enrichment analysis (GSEA) of the BRCA_BRCA1_NEG gene signature. 
Method was performed as described previously (Subramanian et al., 2005). 
Bioinformatic analysis was conducted by Dr George Pouligiannis (Harvard University, 
A	 B	
C	
 272 
USA). The differentially expressed genes were computed by an empirical Bayes 
shrinkage of the standard errors toward a common value approach embedded within the 
Limma package (Smyth, 2004). P – values were adjusted for multiple comparison using 
the false discovery rate approach implemented by Benjamini & Hochberg (Klipper-
Aurbach et al., 1995).   
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Appendix 5. BRCA1-mutant gene signature microarray data 
Gene name Probe ID 
Log (2) Fold 
Change P Value 
Adjusted  
P Value  
ACOX2 205364_at 1.48 1.62E-06 2.80E-04 
AHNAK 220016_at -0.62 6.19E-02 3.12E-01 
AHNAK 211986_at -0.33 1.23E-01 4.41E-01 
AHNAK 238855_at -0.05 6.97E-01 8.95E-01 
AHNAK 1563560_at -0.01 9.51E-01 9.85E-01 
AHNAK 235281_x_at -0.01 9.67E-01 9.89E-01 
ANKRD25 218418_s_at -1.21 2.02E-05 1.57E-03 
ANKRD25 221068_at -0.13 4.51E-01 7.70E-01 
ANKRD25 1569602_at -0.02 9.00E-01 9.70E-01 
BMPR2 1556075_at -0.17 1.93E-01 5.46E-01 
BMPR2 210214_s_at -0.05 7.54E-01 9.19E-01 
BMPR2 238516_at 0.00 9.90E-01 9.97E-01 
C5ORF13 201310_s_at -1.31 1.60E-04 6.54E-03 
C5ORF13 201309_x_at -0.72 8.48E-04 2.06E-02 
C5ORF13 230424_at -0.21 1.86E-01 5.36E-01 
C5ORF13 238411_x_at 0.17 2.45E-01 6.04E-01 
C5ORF13 238410_x_at -0.04 7.46E-01 9.16E-01 
C5ORF13 222344_at 0.04 7.49E-01 9.17E-01 
C5ORF21 212936_at 0.15 5.01E-01 8.01E-01 
C5ORF21 223882_at -0.08 5.87E-01 8.47E-01 
CA12 203963_at 1.35 9.84E-06 9.44E-04 
CA12 214164_x_at 1.13 2.36E-05 1.75E-03 
CA12 210735_s_at 1.19 4.87E-05 2.89E-03 
CA12 215867_x_at 1.15 5.35E-05 3.07E-03 
CA12 204508_s_at 1.19 7.45E-05 3.87E-03 
CA2 209301_at 2.80 2.96E-07 9.36E-05 
CAMK2N1 229163_at -1.79 4.57E-07 1.19E-04 
CAMK2N1 218309_at -1.61 3.00E-06 4.14E-04 
CAMK2N1 228302_x_at -1.34 1.99E-05 1.56E-03 
DKFZP686A01247 212328_at 0.51 2.16E-02 1.71E-01 
DKFZP686A01247 232457_at 0.14 3.19E-01 6.73E-01 
DKFZP686A01247 1569208_a_at 0.08 5.19E-01 8.10E-01 
DKFZP686A01247 212325_at 0.11 5.28E-01 8.15E-01 
DKFZP686A01247 1566248_at 0.08 5.41E-01 8.23E-01 
DKFZP686A01247 1566249_at -0.07 6.35E-01 8.68E-01 
DKFZP686A01247 244554_at -0.06 6.46E-01 8.73E-01 
DKFZP686A01247 241459_at 0.05 6.92E-01 8.93E-01 
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Gene name Probe ID 
Log (2) Fold 
Change P Value 
Adjusted  
P Value  
DKFZP686A01247 212327_at 0.07 7.31E-01 9.10E-01 
DKFZP761M1511 225355_at 0.43 1.98E-02 1.63E-01 
ENC1 201341_at -0.58 4.35E-02 2.56E-01 
ENC1 201340_s_at -0.66 6.03E-02 3.07E-01 
EPDR1 223253_at -3.78 6.71E-09 6.55E-06 
EPDR1 240297_at -0.26 8.05E-02 3.57E-01 
GALNT7 218313_s_at -0.74 2.11E-03 3.84E-02 
GALNT7 222587_s_at -0.47 4.60E-02 2.63E-01 
GLI3 227376_at 1.04 3.29E-04 1.08E-02 
GLI3 1569342_at -0.30 3.45E-02 2.25E-01 
GLI3 205201_at 0.35 3.46E-02 2.26E-01 
GPC1 202756_s_at -1.15 1.94E-05 1.53E-03 
GPC1 202755_s_at -0.79 8.06E-05 4.06E-03 
GPC1 214858_at 0.44 5.82E-02 3.01E-01 
HDGFRP3 209524_at -1.46 2.99E-02 2.08E-01 
HDGFRP3 228266_s_at 0.25 1.05E-01 4.09E-01 
HDGFRP3 221976_s_at -0.17 2.86E-01 6.45E-01 
HDGFRP3 209525_at -0.19 3.17E-01 6.71E-01 
HDGFRP3 209526_s_at 0.11 4.70E-01 7.83E-01 
HDGFRP3 216693_x_at 0.10 5.37E-01 8.20E-01 
HTRA1 201185_at 0.98 2.01E-03 3.71E-02 
ITGB5 214021_x_at -0.68 2.52E-04 8.99E-03 
ITGB5 201124_at 0.18 3.20E-01 6.73E-01 
ITGB5 214020_x_at -0.12 3.71E-01 7.16E-01 
ITGB5 201125_s_at 0.09 5.26E-01 8.14E-01 
KLF9 203542_s_at -1.29 4.69E-03 6.49E-02 
KLF9 203543_s_at -1.09 8.22E-03 9.42E-02 
KLF9 203541_s_at 0.27 7.50E-02 3.46E-01 
KLF9 230636_s_at -0.20 2.70E-01 6.30E-01 
KLF9 228474_s_at 0.00 9.86E-01 9.95E-01 
MAST4 225613_at 1.25 1.17E-04 5.21E-03 
MAST4 225611_at 1.06 6.00E-04 1.63E-02 
MAST4 40016_g_at 0.78 8.51E-04 2.06E-02 
MAST4 210958_s_at 0.58 1.04E-02 1.09E-01 
MAST4 243575_at 0.14 3.44E-01 6.94E-01 
MAST4 222348_at 0.10 6.15E-01 8.59E-01 
MAST4 1554652_s_at -0.03 8.57E-01 9.56E-01 
MEIS3P1 214077_x_at -0.50 6.17E-03 7.79E-02 
MPDZ 213306_at 1.80 2.08E-06 3.17E-04 
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Gene name Probe ID 
Log (2) Fold 
Change P Value 
Adjusted  
P Value  
MPDZ 205079_s_at 0.99 2.88E-05 2.02E-03 
NTN4 223315_at -2.03 3.75E-08 2.33E-05 
NTN4 234202_at 0.14 3.97E-01 7.35E-01 
PLCXD1 218951_s_at -0.48 6.86E-03 8.39E-02 
RNF43 218704_at 0.56 2.01E-03 3.71E-02 
RNF43 228828_at -0.23 1.89E-01 5.40E-01 
RNF43 239588_s_at 0.15 3.11E-01 6.66E-01 
RNF43 244226_s_at -0.10 4.20E-01 7.50E-01 
RNF43 228826_at -0.07 6.31E-01 8.67E-01 
RNF43 239589_at 0.05 7.26E-01 9.08E-01 
SPAG5 203145_at 0.10 6.99E-01 8.96E-01 
SPARC 200665_s_at 3.70 1.17E-10 4.87E-07 
STARD10 223103_at -0.79 4.08E-02 2.47E-01 
STARD10 232322_x_at -0.48 5.34E-02 2.86E-01 
STARD10 1557661_at 0.08 4.78E-01 7.87E-01 
STARD10 238911_at 0.04 7.99E-01 9.36E-01 
TFPI 210664_s_at 3.64 2.91E-10 9.34E-07 
TFPI 213258_at 4.00 3.31E-09 4.64E-06 
TFPI 209676_at 1.88 2.47E-04 8.89E-03 
TFPI 210665_at 0.68 1.18E-03 2.55E-02 
TMEM98 223170_at -1.14 3.92E-05 2.50E-03 
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Appendix 6. BRCA1 mutant microarray gene set used for microarray validation. 
Gene name 
Log (2) Fold 
Change 
Standard 
Deviation P Value 
Adjusted P 
Value 
ANKRD25 -1.21 	 2.02E-05 1.57E-03 C5ORF13 -1.02 0.42 5.04E-04 1.35E-02 
CA12 1.20 0.08 4.20E-05 2.51E-03 
CA2 2.80 	 2.96E-07 9.36E-05 CAMK2N1 -1.58 0.13 7.78E-06 6.96E-04 
GALNT7 -0.74 	 2.11E-03 3.84E-02 GPC1 -0.97 	 5.00E-05 2.80E-03 MPDZ 1.39 0.57 1.55E-05 1.17E-03 
NTN4 -2.03 	 3.75E-08 2.33E-05 SPARC 3.70 	 1.17E-10 4.87E-07 TFPI 2.55 1.55 3.56E-04 8.60E-03 
TMEM98 -1.14 	 3.92E-05 2.50E-03 
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Appendix 7. Konstantinopoulos et al. BRCAness gene profile comparison with the 
MCF-10A shRNA INPP4B microarray data set.  
Gene Symbol Weight BRCA1-mutant (Konstanopoulos et al.) 
Log-fold change in 
MCF-10A shRNA 
INPP4B 
microarray 
DAD1 0.10 N/A 
RAD21 0.17 1.09 	 	 0.69 LDHA 0.02 N/A 
SPARC 0.16 3.70 	 	 0.95 SKP1 0.14 0.17 
PPP1CC 0.02 N/A 
RAN 0.10 0.22 
USP9X -0.01 -0.31 
ECHS1 -0.05 0.58 
GNAI3 0.14 N/A 
HDAC1 -0.03 0.26 
LGMN -0.07 0.49 
CYR61 -0.05 -0.94 	 	 -1.01 SH3BGRL 0.07 0.60 
MGST3 -0.02 1.39 
RCN2 0.21 0.23 
SMC1A 0.03 0.40 	 	 0.36 BST2 0.21 2.96 
ENG 0.06 N/A 
SRGN -0.16 -2.75 	 	 -3.55 GBP1 0.08 -0.39 	 	 -0.20 UNC119B 0.14 0.22 
RGS1 -0.26 N/A 
CDC2 0.11 N/A 
SAT1 -0.04 -0.71 	 	 -0.40 	 	 -0.41 	 	 -0.27 GGH -0.02 -0.25 
GUCY1B3 0.02 0.67 	 	 0.45 WFDC2 0.07 N/A 
NMI 0.09 1.56 
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Gene Symbol Weight BRCA1-mutant (Konstanopoulos et al.) 
Log-fold change in 
MCF-10A 
shINPP4B 
microarray 
PRAME 0.03 N/A 
CCL4 -0.15 0.23 
MGST2 0.00 0.47 
MMP7 0.00 N/A 
SNCA -0.16 0.78 	 	 0.53 	 	 0.65 	 	 0.46 VTN -0.04 N/A 
ALPP -0.03 -0.67 
MTAP -0.05 0.38 	 	 0.22 IDUA 0.10 0.26 
SERPINF2 -0.01 0.37 
WAS -0.02 0.41 
CD1D -0.14 -0.25 
GFI1 -0.03 N/A 
P11 0.01 N/A 
SEMA3F 0.08 0.49 	 	 0.63 	 	 0.34 TNF -0.02 N/A 
ROS1 0.17 -0.24 	 	 -0.23 MADCAM1 -0.03 N/A 
PDIA4 0.16 N/A 
HMGN2 -0.02 -0.43 
HLA-B 0.10 1.48 	 	 1.27 	 	 1.48 TM9SF1 0.11 N/A 
CCDC93 -0.09 0.31 
APEX1 0.02 N/A 
VEGFA 0.06 0.32 	 	 0.20 POSTN 0.21 N/A 
PSTPIP1 -0.04 N/A 
PMS1 -0.06 N/A 
HLA-A 0.02 1.83 	 	 1.13 PCTP -0.05 0.92 
SEH1L 0.11 N/A 
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N/A represents genes present in the BRCAness gene profile but not in the MCF-10A 
shRNA INPP4B microarray data set, therefore no comparison of gene expression trends 
could be made. 
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